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Summary 
 
 
The aim of this study was to investigate the effect of MBV and Coley’s Toxin on dendritic 
cells in vitro. The dendritic cell system of antigen presenting cells is the initiator and 
modulator of the immune response. The principle function of the dendritic cells is to 
present antigens to resting naïve T lymphocytes: these cells are the only APCs that prime 
naïve T cells and only mature DCs can carry out this function.Previous studies done on 
dendritic cells showed that bacterial peptides can induce the maturation of dendritic cells. 
With the results of these studies in mind we hypothesized that these two vaccines will also 
induce the maturation of dendritic cells. 
 
Chapter 1 is a literature review on the immune system explaining the organs and cells of 
the immune system. Chapter 2 includes a full description of DCs, the MBV and Coley’s 
toxin. Also included in this chapter is a short explanation of the principle of the technique 
being used for the identification and maturation of both mDCs and pDCs, namely the 
technique of flow cytometry.  
 
Chapter 3 describes the method for the phenotypic identification of DCs: the subsets are 
distinguished by their absence of expression of several lineage markers for lymphocytes, 
monocytes and NK cells and the expression of CD11c (in the case of myeloid DCs) and 
CD123 (in the case of plasmacytoid DCs). The inclusion of HLA-DR in addition to the 
previous described markers allows the discrimination of CD123+ DCs from basophils. The 
assay requires three tubes per sample which enables quick analysis of these rare subsets 
with a small sample volume. This assay was applied to peripheral blood samples obtained 
from healthy individuals and individuals with cancer, HIV and HIV and TB co-infected 
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patients.  Our results showed that the maturation status of DCs in HIV and lymphoma were 
low but those measured in the case of HIV + TB patients were even higher than in the 
control group. 
 
Chapter 4 and 5 describe the in vitro activation and maturation status of DCs following 
their incubation with bacterial-derived products. Interactions between DCs and microbial 
pathogens are fundamental to the generation of innate and adaptive immune responses and 
upon contact with bacteria or bacterial components such as lipopolysaccharide (LPS), 
immature DCs undergo a maturation process that involves expression of costimulatory 
molecules, HLA molecules, and cytokines and chemokines, thus providing critical signals 
for lymphocyte development and differentiation. In this study, we investigated the 
response of human DCs to MBV and Coley’s Toxin. Previous studies showed DCs can be 
activated with killed Streptococcus pyogenes. With this study in mind it was hypothesized 
that the MBV and Coley’s Toxin used in this study might modulate DC maturation. The 
results of this study showed that the MBV and Coley’s toxin did induce the maturation of 
both pDCs and mDCs as measured by increased surface expression of costimulatory 
molecules such as CD80 and CD83.  
 
Chapter 6 presents the measurement of cytokines released after the PMBCs had been were 
incubated with Coley’s Toxin and Mixed Killed bacteria.  The BD™ Cytometric Bead 
Array (CBA) flex set was used for the simultaneous detection of multiple soluble analytes. 
The results indicated that both Coley’s Toxin and the MBV activated the DCs and 
subsequently induced TH1 as well as a TH2 responses in the T cells present in the cell 
cultures. 
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Finally, a general conclusion discussing the significance and implications of our results as 
well as possible future research required is discussed in Chapter 7. DCs are potent antigen 
presenting cells (APCs) which play a critical role in the regulation of the immune response. 
There is great interest in exploiting DCs to develop immunotherapies for cancer, chronic 
infections, immunodeficiency diseases and autoimmune diseases. 
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Opsomming   
Die doel van die studie was om die effek van ‘n gemengde bakteriële vaksiene en Coley se 
toksiene op dendritiese selle te toets in vitro. Die dendritiese sel sisteem speel ‘n 
belangrike rol in die modulering en reaksie van die immuun sisteem.Die hoof funksie van 
dendritiese selle is om antigene bloot te stel aan naïewe ongeaktiveerde T selle. Slegs 
volwasse dendritiese selle kan die T selle aktiveer. Vorige studies het bewys dat bakteriële 
peptiedes die veroudering van die dendritiese selle kan induseer. Met die resultate in 
gedagte het ons gehipotiseer dat die twee vaksienes ook die maturasie van dendritiese selle 
kan induseer. 
 
Hoofstuk 1 is ‘n literatuur studie wat handel oor die organe en selle van die immuun 
sisteem. Hoofstuk 2 gee n volle beskrywing van dendritiese selle, die gemengde bakteriële 
vaksiene en Coley se toksiene. Ingesluit in die hoofstuk is die beskrywing van die prinsiep 
van die tegniek, vloei sitometrie, wat gebruik word vir die identifikasie en veroudering 
status van die dendritiese selle. 
 
Hoofstuk 3 beskryf ‘n vloei sitometrie metode vir die fenotipiese identifikasie van 
dendritiese selle. Dendritiese sel tipes kan onderskei word deur die afwesigheid van sekere 
merkers vir limfosiete, monosiete en NK selle. Plasmasitoïede dendritiese selle druk 
CD123 uit en miloïede dendritiese selle druk CD11c uit. HLA DR is ook ingesluit saam 
met die bogenoemde merkers om die dendritiese selle te onderskei van basofiele.  
 
Vir elke toets word slegs drie buise geprosesseer en dus kan die subklasse vinning 
geanaliseer word. ŉ Klein volume bloed word benodig vir die toests. Perifêre bloed is 
gebruik vir die toets op bloed monsters van 10 gesonde individue en individue met kanker, 
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HIV en HIV en TB. Die resultate van die studie het getoon dat die maturasie status van die 
dendritiese selle in HIV en limfoom was, maar in die geval van HIV en TB pasïente was 
die maturasie status selfs hoër as die van die kontrole groep. 
  
Hoofstuk 4+5 beskryf die aktivering en maturasie status van die dendritiese selle na 
inkubasie met die bakteriële produkte. Interaksie tussen dendritiese selle en patogene speel 
‘n belangrike rol in die aktivering van die immuunstelsel. Wanneer dendritiese selle in 
aanraking kom met bakterieë of bakteriële komponente, matureer die dendritiese sel wat lei 
tot the uitdrukking van stimulerings molekules, HLA molekules end die uitskeiding van 
sitokiene. Die uitdrukking van die molekules lei tot limfosiet ontwikkeling en 
differensiasie. In die studie het ons gekyk na die reaksie van menslike dendritiese selle in 
die teenwoordigheid van die gemende bakteriële vaksiene en Coley se toksiene. Vorige 
studies het bewys dendritiese selle word geaktiveer deur Streptococcus pyogenes. Met die 
resultate in gedagte het ons gehipotetiseer dat die gemengde bakteriële vaksiene en Coley 
se toksiene ook die maturasie van dendritiese selle kan induseer. Die resultate van die 
studie het bewys dat die gemengde bakteriële vaksiene en Coley se toksiene die 
veroudering van beide pDCs en mDCs induseer. Die uitdrukking van verouderings merkers 
CD80 en CD83 is gemeet. 
  
Hoofstuk 6 beskryf ‘n vloei sitometrie metode om die sitokiene te meet wat afgeskei word 
nadat selle geinkubeer het in die teenwoordigheid van Coley se toksiene en die gemengde 
bakteriële vaksiene.Die BDTM CBA Flex set metode het dit moontlik gemaak om meer as 
een sitokiene te meet in net een buis  Die resultate het getoon dat albei die vaksienes ‘n 
TH1 en TH2 reaksie veroorsaak.  
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Laastens volg‘n algemene afleiding waar ons kyk na die toepassing en implikasies van die 
resultate asook toekomstige navorsings moontlikhede,word bespreek in Hoofstuk 7 
Dendritiese selle speel ‘n kritiese rol in die regulering van die immuun reaksie. Verdere 
studies kan nou gedoen word om dendritiese selle terapeuties toe te pas vir die behandeling 
van kanker, autoimmuniteit, immuun onderdrukkende siektes en kroniese siektes.  
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Chapter 1 
General introduction to the immune system 
1.1 Introduction 
The human body has natural barriers to prevent entry by microbes, but when these barriers 
are broken, pathogens can enter the body. The human body provides an ideal environment 
for many microbes and therefore they try to pass the skin barrier and enter. The immune 
system is a network of cells, tissues, and organs that have evolved to defend you against 
such "foreign" invasions. The innate immune system kicks in first and phagocytic white 
blood cells begin to attack the invading microbes within minutes. The microbes are killed 
by phagocytosis and other protein components including the complement components 
which facilitate the process of phagocytosis. Natural killer cells can detect certain virally 
infected cells and lyse them. The innate immune system is often sufficient to kill and 
destroy invading microbes. If this system fails to clear the infection then the adaptive or 
acquired immune response takes over (Janeway CA et al. 1996). The connection between 
the two systems is mediated by cytokines. 
At the heart of the immune response is the ability to distinguish between "self" and "non-
self". Every cell in the body carries the same set of distinctive surface proteins that 
distinguish you as "self". Normally the immune cells do not attack the body’s own tissues, 
which all carry the same pattern of self-markers. This set of unique markers on human cells 
is displayed on the major histocompatibility complex (MHC). There are two classes: MHC 
Class I proteins, which are present on all cells, and MHC Class II proteins, which are 
present on certain specialized cells. Any non-self substance capable of triggering an 
immune response is known as an antigen. An antigen can be a whole non-self cell, a 
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bacterium, a virus, an MHC marker protein or even a portion of a protein from a foreign 
organism. The distinctive markers on antigens that trigger an immune response are called 
epitopes. When tissues or cells from another individual enter your body carrying such 
antigenic non-self epitopes, your immune cells react. The immune cells recognize epitopes 
presented on the MHC when they distinguish between self and non-self. An MHC protein 
serves as a recognizable scaffold that presents pieces of a foreign protein (peptides) to 
immune cells.  
1.2 The arms of the immune system 
1.2.1. Innate (or natural) immunity 
Kabelitz D et al. (2007) explains that this part of the immune system is made up of several 
components: 
• Physical barriers are the first line of defense against infection. The mucous membranes 
and the skin provide a continuous surface  
• Physical or physico - chemical factors such as temperature, pH and oxygen tension limit 
microbial growth. In the stomach the acid environment combined with microbial normal 
flora inhibits gut infection 
• Invasion is also blocked by protein secretions, like lysozyme. Other factors like 
complement, interferons and molecules like C – reactive protein are important in 
protection against infection 
• Phagocytic cells are critical in the defense against bacterial and simple eukaryotic 
pathogens. Macrophages and polymorphonuclear leucocytes recognize bacterial and  
yeast cell walls through broadly specific receptors and this recognition is greatly 
enhanced by activated complement (opsonin) (Anderson KV,2000). 
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Complement 
The complement system has two pathways: the classical and the alternative pathway. Both 
pathways have a similar terminal sequence which creates the membrane attack complex 
(MAC).This enzyme complex punches a hole in various cell surfaces. Both pathways have 
by- products namely anaphylatoxins which contribute to an inflammatory response. The 
complement system consists of a series of about 25 proteins which are normally present in 
plasma in inactive form and become activated by classical or alternative pathways. The 
alternative pathway is triggered by a variety of substances, including bacterial 
polysaccharides.There is no formation of antigen-antibody complexes or the participation 
of C1, C4 or C2. In the absence of these complexes, there is a spontaneous conversion of 
C3 to C3b. In normal conditions the C3b binds to inhibitory proteins and sialic acid present 
on the surface of the body's own cells and the C3b is inactivated. However, bacteria and 
other foreign materials that may get into the body lack these proteins and have little or no 
sialic acid. The C3b binds a protein called Factor B forming a complex of C3b•Bb, which 
is a C3 convertase. The C3 convertase activates more C3. The C3b•Bb•C3b, which is a C5 
convertase, start the assembly of the membrane attack complex.  
The Classical pathway of the complement system helps to clear the body of antigen-
antibody complexes. Complement proteins (only activated C3a, C5a and C4a) cause blood 
vessels to become dilated and leaky, causing redness and swelling during an inflammatory 
response. Complement proteins circulate in the blood in an inactive form. The so-called 
"complement cascade" is set off when the first complement molecule, C1, binds to the 
antigen-antibody complex. The C4 and C2 are cleaved into C3 convertase. C3 convertase 
splits C3 into C3a and C3b. C3a is released and increases vascular permeability.C3b forms 
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a complex which splits C5 into C5a and C5b. C5a increases vascular permeability and is 
highly chemotactic to polymorphonuclear and mononuclear leucocytes. The end product is 
a cylindrical complex that punctures the cell membrane and by allowing fluids and 
molecules to flow in and out, dooms the target cell (Janeway CA et al. 1996). 
1.2.2. Adaptive immunity: 
The first encounter with an antigen is known as the primary response. Re- encounter with 
the same antigen causes a secondary response that is more rapid and powerful. The 
difference between the innate and the acquired immune system lies in the antigen 
specificity of lymphocytes. Lymphocytes express cell surface receptors that recognize 
discrete parts of the antigen known as antigenic epitopes (Barton GM et al. 2002). 
Adaptive immunity can be divided into two branches, the cellular or cell–mediated 
immune response and the humoral immune response. These two interconnected immune 
functions work together through finely tuned checks and balances to mount an appropriate 
defense.  
In response to bacterial invasion, B–cells of the humoral arm proliferate and produce large 
amounts of appropriate antibodies that flag invaders for elimination from the body. The 
cellular immune response employs specialized T–cells to recognize and destroy host cells 
showing signs of cancer or infection by viruses or parasites. The relative mobilization of 
each branch of the immune system depends on the specific disease or condition, and the 
nature of the response can be influenced by the pathogen itself and where it enters the body 
(Abbas et al. 2003). 
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1.3 Organs of the immune system: 
1.3.1 Primary lymphoid organs: 
Bone Marrow and Thymus: 
• Stem cells in bone marrow give rise to cells of all lineages produced by the bone 
marrow. 
• Cell lineages produced by the bone marrow:  
- Cells of innate immunity for example monocytes, macrophages, DCs  and 
granulocytes 
- Antigen specific cells or acquired immunity for example T cells, B cells and 
NK cells 
•  The thymus is a greyish organ located in the thoracic cavity just below the neck. The 
main function of the thymus is to develop immature T-cells into immunocompetent    
T-cells. Pre-T cells are produced in the bone marrow and transported to the thymus via 
the blood. The pre-T cells are then taken into the cortex of the thymus. Here, a series of 
molecular events take place allowing the cells to recognize certain antigens. Some of 
the cells recognize self-components, and these are eliminated by a process of negative 
selection. Those that fail the selection undergo apoptosis and those that live proceed to 
the medulla and eventually into the blood stream where they act upon foreign agents in 
the body.  
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1.3.2 Secondary immune organs: 
Spleen, lymph nodes and mucosa-associated lymphoid tissue (MALT):  
• The spleen is a flattened organ at the upper left of the abdomen. The white pulp in the 
spleen, provides lymphocytes and hence antibodies for the cellular and humoral 
specific immune defenses. 
• Small, bean-shaped lymph nodes sit along the lymphatic vessels, with clusters in the 
neck, armpits, abdomen and groin. Each lymph node contains specialized 
compartments where immune cells come together and encounter antigens. Immune 
cells and foreign particles enter the lymph nodes via incoming lymphatic vessels or 
tiny blood vessels. All lymphocytes exit lymph nodes through outgoing lymphatic 
vessels. Once in the bloodstream, they are transported to tissues throughout the body. 
Immune cells patrol everywhere for foreign antigens, then gradually drift back into the 
lymphatic system to begin the cycle all over again. 
• MALT includes nodules of immune- system tissue embedded in the mucosa of the 
digestive tract and the airways and lungs. These tissues include the tonsils, adenoids, 
appendix and Peyer’s patches of the intestine. MALT is specialized for production of 
IgA antibody which is secreted across mucosal surfaces.  
The organs of your immune system are connected with one another and with other organs 
of the body by a network of lymphatic vessels. Lymphocytes can travel throughout the 
body using the blood vessels. The cells can also travel through a system of lymphatic 
vessels that closely parallels the body's veins and arteries. Cells and fluids are exchanged 
between blood and lymphatic vessels, enabling the lymphatic system to monitor the body 
for invading microbes. The lymphatic vessels carry lymph, a clear fluid that flows through 
the body's tissues.  
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1.4 Cells of the immune system 
Cells destined to become immune cells arise in the bone marrow from stem cells. Some 
develop into myeloid progenitor cells while others become lymphoid progenitor cells. The 
myeloid progenitors develop into the cells that respond early and non-specifically to 
infection. Neutrophils engulf bacteria upon contact and send out warning signals. 
Monocytes turn into macrophages in body tissues and demolish foreign invaders.   
Granule-containing cells such as eosinophils attack parasites, while basophils release 
granules containing histamine and other allergy-related molecules. Lymphoid precursors 
develop into the small white blood cells called lymphocytes. Lymphocytes respond later in 
infection. They mount a more specialized attack after antigen-presenting cells such as DCs 
(or macrophages) display their catch in the form of antigen fragments (epitopes). The        
B cell turns into a plasma cell that produces and releases specific antibodies into the 
bloodstream. The T cells coordinate the entire immune response and eliminate the viruses 
hiding in the infected cells. 
1.4.1 B cells: 
B cells play a major role in the immune response to the presence of a foreign antigen.        
B cells fights foreign antigens by the production of antibodies and differentiate in the bone 
marrow from lymphoid stem cells. When an antigen-specific antibody on a B cell matches 
up with an antigen, a remarkable transformation occurs. The antigen binds to the antibody 
receptor, the B cell engulfs it, and allows phagocytes to digest and destroy the antigen 
completely. After a special helper T cell joins the action, the B cell becomes a large plasma 
cell factory that produces identical copies of specific antibody molecules. The plasma cells 
will disappear with time from the blood plasma, but a certain population of cells derived 
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from the original B cellswill be retained in a dormant state and allow a more rapid and 
effective immune response to occur if the same antigen appears again. These cells are 
called memory cells and are induced during immunization. They will be reactivated should 
the B cell come into contact with the identical antigen. 
Each antibody is made up of two identical heavy chains and two identical light chains, 
shaped to form a Y. The sections that make up the tips of the Y's arms vary greatly from 
one antibody to another; this is called the variable region. The variable region attaches to 
the specific antigen. The stem of the Y links the antibody to other participants in the 
immune defenses. This area is identical in all antibodies of the same class--for instance, all 
IgEs--and is called the constant region. This portion fixes complement and play a role in  
the binding of the antibody to receptors found on macrophages and various other cells. 
This leads to the start of a cascade that leads to more antibody production. Antibodies can 
cause toxic cells to clump together and cause agglutination so that they may be more 
effectively removed by the innate immune response. The clump of antibodies and toxic 
cells may become so large that it becomes insoluble, which also facilitates its removal 
(precipitation). The antibodies may actually neutralize and cover up the toxic portion of the 
foreign cell and are occasionally even able to directly attack and kill the toxic cell through 
a process called lysis. The actions listed above are all direct effects possible from antibody-
antigen binding. However, most often the constant portion of the immunoglobulin initiates 
a signal cascade that results in the release of substances other than the initial antibody that 
cause the aggregation, neutralization, or lysis of the toxic cell.  
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Immunoglobulins: 
 
Immunoglobulins G, D, and E are similar in appearance. IgG, the major immunoglobulin 
in the blood, is also able to enter tissue spaces; it works efficiently to coat microorganisms, 
speeding their destruction by other cells in the immune system. IgD is inserted into the 
membrane of B cells, where it somehow regulates the cell's activation. IgE is normally 
present in only trace amounts, but it is responsible for the symptoms of allergy. IgA guards 
the entrance to the body. It concentrates in body fluids such as tears, saliva, and secretions 
of the respiratory and gastrointestinal tracts. IgM usually combines in star-shaped clusters. 
It tends to remain in the bloodstream, where it is very effective in killing bacteria. 
1.4.2 T cells: 
T cells belong to a group of white blood cells known as lymphocytes and play a central 
role in cell-mediated and humoral immunity. Dhodapkar MV et al. (1999a) explains          
T cells can be distinguished from other lymphocyte types, such as B cells and NK cells by 
the presence of a special receptor on their cell surface that is called the T cell receptor 
(TCR). These cells develop in the thymus and contribute to immune defenses in two major 
ways. Some help regulate the complex workings of the overall immune response, while 
others are cytotoxic and directly come in contact with infected cells and destroy these 
infected cells. There are two subpopulations of T cells (CD8+ or CD4+) that develop and 
their development in the thymus can be traced by surface markers. The cells with a CD4 
marker are called helper T cells (TH cells) and the CD8 positive cells are called suppressor 
cells. The CD8+ cells develop into cytotoxic T cells. These cells have a T cell receptor, but 
they perform very different functions in the immune system (Iwakasi A et al. 2004). 
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T cell receptors recognize antigen, but not in the same way that antibodies do. Antibodies 
will recognize antigen in its native form, but antigen recognition by the T cell receptor 
requires the antigen to be digested, degraded and presented on the surface of another cell 
(an antigen presenting cell or APC) in the context of Major Histocompatibilty Complex 
(MHC). A piece of the antigen is found on the surface groove of the MHC molecule and is 
expressed on the surface of the APC (Kadowaki et al. 2001; Netea et al. 2004). 
TH cell activation takes place through the T cell receptor complex. The primary signal is 
the antigen-MHC II and T cell receptor-CD3 interaction while the co-stimulatory signal 
occurs with cytokines,CD40L and CD28 (Kadowaki N et al. 2001; Netea MG et al. 2004). 
This interaction initiates a cascade of biochemical events in the T cell that eventually 
results in growth and proliferation of the T cell. This occurs primarily through an increase 
in Interleukin-2 (IL-2) secretion by the T cell and an increase in IL-2 receptors on the        
T  cell surface. IL-2 is a potent T cell growth cytokine which, in T cell activation, acts in 
an autocrine fashion to promote the growth, proliferation and differentiation of the T cell 
recently stimulated by antigen. The T cell receptor is an antigen recognition molecule and 
therefore the T cell that best responds to the antigen presented is the one that gets turned 
on. Activated TH cells then continue to become effector cells whose role includes B cell 
help and cytokine production. The generation of an immune response, both humoral by  
B cells and cell-mediated by cytotoxic T cells (CD8+), depends on the activation of  
TH cells. The importance of these CD4+ cells has become obvious as these are the cells 
affected in AIDS.   
Mature B cells that have already seen antigen require contact with a T cell in order to 
become plasma cells or memory cells. T cells provide signals to the B cell through contact 
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of the T cell receptor -complex and MHC-antigen. In addition, the activated T cell 
produces cytokines such as and IL- 4, 5, 6 and 10 which stimulate B cell proliferation and 
differentiation into antibody secreting B cells. The type of cytokines produced by the        
T cells helps the plasma cells to produce different classes of antibodies. In response to 
bacterial invasion, B–cells of the humoral arm proliferate and produce large amounts of 
appropriate antibodies. The cellular immune response employs specialized T–cells to 
recognize and destroy host cells showing signs of cancer or infection by viruses or 
parasites. The relative mobilization of each branch of the immune system depends on the 
specific disease or condition, and the nature of the response can be influenced by the 
pathogen itself and where it enters the body. 
The balance between the cellular and humoral arms of the immune system is modulated by 
a highly integrated network of molecular and cellular interactions driven by cytokines, 
small proteins that act as intercellular chemical messengers (Koch F et al.1996). They are 
the chief communication signals of the T cells. Lymphocytes, including both T cells and    
B cells, secrete cytokines called lymphokines, while the cytokines of monocytes and 
macrophages are called monokines. Many of these cytokines are also known as 
interleukins because they serve as a messenger between white cells, or leukocytes. When 
cytokines attract specific cell types to an area, they are called chemokines. These are 
released at the site of injury or infection and call other immune cells to the region to help 
repair the damage and defend against infection. Cytokines encourage cell growth, promote 
cell activation, direct cellular traffic, and destroy target cells--including cancer cells   
(Syme R et al. 2001).  
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T cell subsets: 
T lymphocytes differ from B lymphocytes, because T cells do not secrete antibodies. The   
T cell itself becomes capable of recognizing a specific foreign agent because it expresses 
cell surface markers known as T cell antigen receptors (TCRs).These antigen-specific 
TCRs are associated with three more general surface molecules 
• CD3 molecules are found on all mature T cells. The transmembrane area of the CD3 
peptide transmits a signal to the T cell’s cytoplasm, notifying the cell that an antigen 
has been bound. This signal causes the secretion of the lymphokines responsible for the 
further recruitment and differentiation of other responsive cells. 
• CD4 molecules are found on T-helper cells. These molecules recognize and bind class 
II MHC proteins (found on DCs, monocytes, macrophages, and B cells) and transmit 
the signal for the T-helper cell to secrete even more lymphokines, including the very 
important interleukin-2. Helper cells secrete IL-4, IL-5 and IL- 6 (B cell growth 
factors) which promote the proliferation and maturation of B cells. Helper cells 
recognize antigen presented on the surface by macrophages in the form of antigenic 
peptide complexes with class II MHC molecules. Once activated, they divide rapidly 
and secrete small proteins called cytokines that regulate the immune response. These 
cells are a target of HIV infection; the virus infects the cell by using the CD4 protein to 
gain entry. The loss of TH cells as a result of HIV infection leads to AIDS. 
• CD8 molecules are found on T-killer cells. These molecules recognize and bind class I 
MHC molecules and transmit the signal for the T-killer cell to secrete proteins such as 
perforin that punch holes in the membrane of the foreign cell and directly cause its 
lysis and death. Suppressor cells recognize antigen presented on the surface as 
antigenic peptide complexes with class I MHC molecules. Class I molecules are found 
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on all cells and present antigens that are synthesized within host cells, such as viral or 
tumour antigens. 
• Memory T cells are a subset of antigen -specific T cells that occurs in the body after 
an infection has been cleared. They quickly expand to large numbers of effector T cells 
upon re-exposure to the known antigen, thus providing the immune system with 
"memory" against past infections. Memory T cells comprise two subtypes: central 
memory T cells and effector memory T cells. Memory cells may be either CD4+ or 
CD8+. 
• Regulatory T cells (Treg cells), formerly known as suppressor T cells, are crucial for 
the maintenance of immunological tolerance. Their major role is to shut down T cell 
mediated immunity towards the end of an immune reaction and to suppress auto-
reactive T cells that escaped the process of negative selection in the thymus (Fehervari 
Z et al:2004). Two major classes of regulatory T cells have been described, including 
the naturally occurring Treg cells and the adaptive Treg cells. Naturally occurring Treg 
cells (also known as CD4+CD25+FoxP3+ Treg cells) arise in the thymus, whereas the 
adaptive Treg cells (also known as Tr1 cells or TH3 cells) may originate during a 
normal immune response. Naturally occurring Treg cells can be distinguished from 
other T cells by the presence of an intracellular molecule called FoxP3. 
• γδ T cells (Girardi M, 2006) represent a small subset of T cells that possess a distinct 
TCR on their surface. The majority of T cells have a TCR composed of two 
glycoprotein chains called α- and β- TCR chains. However, in γδ T cells, the TCR is 
made up of one γ-chain and one δ-chain. This group of T cells is much less common 
(5% of total T cells) than the αβ T cells, but are found at their highest abundance in the 
gut mucosa within a population of lymphocytes known as intraepithelial lymphocytes 
(IELs). However, γδ T cells are not MHC restricted and seem to be able to recognise 
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whole proteins rather than requiring peptides to be presented by MHC molecules on 
antigen presenting cells (Holtmeier W et al. 2005).  
T cell development in the thymus: 
All T cells originate from hematopoietic stem cells in the bone marrow. These cells 
populate the thymus and expand by cell division to generate a large population of 
immature thymocytes. The earliest thymocytes express neither CD4 nor CD8, and are 
therefore classed as double-negative (CD4-CD8-) cells. As they progress through their 
development they become double-positive thymocytes (CD4+CD8+), and finally mature to 
single-positive (CD4+CD8- or CD4-CD8+) thymocytes that are then released from the 
thymus to peripheral tissues. About 98% of thymocytes die during the development 
processes in the thymus by failing either positive selection or negative selection, while the 
other 2% survive and leave the thymus to become mature immunocompetent T cells. 
Positive selection: 
Double-positive thymocytes move deep into the thymic cortex where they are presented 
with self-antigens  complexed with MHC molecules on the surface of cortical epithelial 
cells. Only those thymocytes which bind the MHC/antigen complex with adequate affinity 
will receive a vital "survival signal." The other thymocytes die by apoptosis and their 
remains are engulfed by macrophages. This process is called positive selection. Whether a 
thymocyte becomes a CD4+ TH cell or a CD8+ T cell is also determined during positive 
selection. Double-positive cells that are positively selected on MHC class II molecules will 
become CD4+ cells, and cells positively selected on MHC class I molecules will become  
CD8+ cells. 
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Negative selection 
Thymocytes that survive positive selection migrate towards the boundary of the thymic 
cortex and thymic medulla. While in the medulla, they are again presented with self-
antigen in complex with MHC molecules on antigen-presenting cells (APCs) such as DCs 
and macrophages. Thymocytes that interact too strongly with the antigen receive an 
apoptosis signal that causes their death; the vast majority of all thymocytes initially 
produced end up dying during thymic selection. A small minority of the surviving cells are 
selected to become regulatory T cells. The remaining cells will then exit the thymus as 
mature naive T cells. This process is called negative selection, an important mechanism of 
immunological tolerance that prevents the formation of self-reactive T cells capable of 
generating autoimmune disease in the host. 
T cell activation: 
T cells differentiate in the thymus and when mature, leave the thymus and circulate in the 
blood and lymph. Following mitogenic or antigenic stimulation, resting T cells are 
transformed into blast cells capable of division. T cells are activated by specific binding of 
the T cell receptor to the immunogenic complex of antigenic peptide class I or II MHC 
molecules. Stimulated by IL- 2, activated T cells proliferate and differentiate into 
functional classes (Akira S et al. 2001). During the activation of CD4+ T cells  both the     
T cell receptor and CD28 are engaged on the T cell by the Major histocompatibility 
complex peptide and B7 family members on the APC respectively. Both are required for 
production of an effective immune response. (Lambrecht BN, 2001) 
The first signal is provided by binding of the T cell receptor to a short peptide presented by 
the major histocompatibility complex (MHC) on another cell. (See Figure 1.1) This 
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ensures that only a T cell with a TCR specific to that peptide is activated. The partner cell 
is usually a professional antigen presenting cell (APC), usually a DC in the case of naïve 
responses, although B cells and macrophages can also be important APCs. The peptides 
presented to CD8+ T cells by MHC class I molecules are 8-9 amino acids in length; the 
peptides presented to CD4+ cells by MHC class II molecules are longer, as the ends of the  
binding cleft of the MHC class II molecule are open. 
The second signal comes from co-stimulation, in which surface receptors on the APC are 
induced by a relatively small number of stimuli, usually products of pathogens, but 
sometimes breakdown products of cells, such as necrotic-bodies or heat-shock proteins. 
The only co-stimulatory receptor expressed constitutively by naïve T cells is CD28, so co-
stimulation for these cells comes from the CD80 and CD86 proteins on the APC    
(See Figure 1.1).Other receptors are expressed upon activation of the T cell, such as OX40 
and ICOS, but these largely depend upon CD28 for their expression. The second signal 
activates the T cell to respond to an antigen. Without it, the T cell becomes anergic 
(decrease in response to an antigen) and it becomes more difficult for it to activate in 
future. This mechanism prevents inappropriate responses to self, as self-peptides will not 
usually be presented with suitable co-stimulation (Akira S et al. 2001). 
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Figure 1.1 T cell activation by an antigen -presenting DC (Website: www.csa.com) 
 
MHC Class I Presentation: 
• Ackermann AL et al. (2003) states MHC I glycoproteins are present on all cells 
in the body, acting to present endogenous antigens that originate from the 
cytoplasm.  
• Proteosome further degrade the antigens in the cytosol and enter the 
Endoplasmic Reticulum, where they can bind to MHC I proteins, before being 
transported via the Golgi apparatus to the cell surface.  
• Once at the cell surface, the membrane-bound MHC I protein displays the 
antigen for recognition by special immune cells known as cytotoxic T cell 
lymphocytes 
MHC Class II presentation to stimulate CD4+ T Helper cells: 
• Antigen is taken up by phagocytosis or receptor mediated endocytosis into APCs 
      only to endosomes where proteolysis occurs. 
• The peptides enter a vesicle containing MHC Class II where they bind and are 
      transported to the cell surface. 
 
Stellenbosch University  http://scholar.sun.ac.za
  
18 
 
 
 
 
 
TH17 Cells: 
Experiments done by Afzali B et al. (2007) have demonstrated that naive CD4+helper       
T cells can develop into at least four types of helper T cells, namely TH1, TH2, TH17 and 
regulatory T cells (Tregs) These experiments described that a discrete population of CD4+ 
helper T cells are a source of IL-17. These cells have been named Th17 cells. IL-17 has a 
proinflammatory role and has been implicated in many inflammatory conditions in humans 
and mice, while Tregs have an anti-inflammatory role and maintain tolerance to 
selfcomponents. 
1.4.3 Natural killer cells and cytotoxic T cells:  
At least two types of lymphocytes are killer cells - cytotoxic T cells and natural killer cells. 
Both types contain granules filled with potent chemicals and both types kill on contact. 
They bind their targets, aim their weapons, and deliver bursts of lethal chemicals. Natural 
killer cells are lymphoid cells found in the blood and peripheral lymphoid organs. Natural 
killer cells are capable of killing virus-infected cells or tumour cells in the absence of prior 
immunization and without MHC restriction. Natural killer cells and cytotoxic T cells 
produce pore forming molecules called cytolysin or perforin which has structural and 
functional similarity to components of the complement system. The cytolysin or perforin 
binds to the cell surface membranes and forms transmembrane channels, leading to the 
osmotic death of the target cells (Wentworth PA et al. 1997). 
Natural killer cells have many more granules in their cytoplasm when compared to other 
killer lymphocytes. These granules are thought to be involved in the direct lysis of foreign 
substances induced by these cells. Like the other lymphocytes, NK cells are very 
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responsive to the lymphokine IL-2 and will not proliferate without it.  To attack, cytotoxic 
T cells need to recognize a specific antigen bound to self-MHC markers, whereas natural 
killer (NK) cells will recognize and attack cells lacking these. This gives NK cells the 
potential to attack many types of foreign cells.  
1.4.4 Phagocytes: 
Some immune cells have more than one name. For example, the name "phagocytes" is 
given to the large immune cells that can engulf and digest foreign invaders, and the name 
"granulocytes" refers to immune cells that carry granules loaded with killer chemicals. 
Phagocytes include monocytes, which circulate in the blood; macrophages, which are 
found in tissues throughout the body; DCs, which are more stationary, monitoring their 
environment from one spot such as the skin; and neutrophils, cells that circulate in the 
blood but move into tissues when they are needed (Figdor CG et al. 2004; Filgueria L. 
1996). 
Macrophages are versatile cells; besides acting as phagocytic cells, they secrete a wide 
variety of signaling cytokines (called monokines). Neutrophils are both phagocytes and 
granulocytes: they contain granules filled with potent chemicals. These chemicals, in 
addition to destroying microorganisms, play a key role in acute inflammatory reactions. 
Other types of granulocytes are eosinophils and basophils, which degranulate by spraying 
their chemicals onto harmful cells or microbes. The mast cell is a twin of the basophil, 
except it is not a blood cell. Rather, it is responsible for allergy symptoms in the lungs, 
skin, and linings of the nose and intestinal tract. A related structure, the blood platelet, is a 
cell fragment. Platelets, too, contain granules. They promote blood clotting and wound 
repair, and activate some immune defenses. 
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Monocytes have important properties: 
• Monocytes express a myeloid receptor (CD14) which serves as recognition molecule 
for a wide variety of bacterial envelope molecules, such as LPS from Gram positive 
organisms and components of Mycobacterial and Gram positive cell walls. Ligation of 
this receptor leads to macrophage activation. 
• Monocytes can act as antigen presenting cells for T cells. 
• Monocytes are activated by T cell derived cytokines leading to increased phagocytosis 
and microbicidal activity (increased activity of degradative enzymes, nitrogen and 
oxygen free radical production and prostaglandins.) 
• Monocytes express receptors for antibody and complement which means that they bind 
immune complexes 
1.4.5 Granulocytes: (Wardlaw et al.  1995) 
There are three types of granulocytes   
• Neutrophils, also known as polymorphonuclear leukocytes, express receptors for 
immunoglobulin and complement and are involved in the acute inflammatory response. 
• Eosinophils carry receptors for IgE and are involved in the destruction of IgE coated 
parasites. They contribute to the reponse to allergens. 
• Basophils express high affinity receptors for IgE and are stimulated to secrete the 
chemicals responsible for immediate hypersensitivity following antigen induced 
aggregation of these receptors. 
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1.4.6 Dendritic cells  
These cells will be discussed in detail in Chapter 2 since they are the main focus of this 
dissertation. 
1.5 Cytokines 
Cytokines are small soluble factors released by cells that influence the functions and 
communicate with other cells. Cytokines, which are regulated by hormones generated by 
the endocrine system, can be classified as either TH1 or TH2 depending on their role   
(Arai K et al. 1990; Liles WC et al. 1995). TH1 and TH2 cells are thought to derive from a 
non-polarised, naive TH0 precursor that makes a wide range of cytokines: this TH0 cell 
can differentiate after activation in the presence of IL-12 and IL-18 (from DCs) into TH1 
cells that secrete IL-2, IFN-γ and TNF however in the presence of IL-4 (derived from        
B cells or lymphoid DCs) the TH0 cells differentiate into TH2 cells that secrete IL-4, IL-5, 
IL- 6 and IL-10 (Karnitz  LM et al.1995; Joyce DA et al.1996; O’Garra A et al. 1998). 
Generally, in healthy individuals the immune system has a balanced expression of TH1 and 
TH2 cytokines. If a foreign invader triggers an adaptive cellular or TH1–-type response, 
the feedback mechanism within the immune system greatly reduces the humoral or     
TH2–type response. Once the invader is controlled or eliminated, a combination of 
hormones and cytokines act quickly to return the system back towards homeostasis through 
the same feedback mechanism.  
 
TH1 cells drive the cellular immunity to fight viruses and other intracellular pathogens, 
eliminate cancerous cells, and stimulate delayed-type hypersensitivity skin reactions.    
TH2 cells drive humoral immunity and up-regulate antibody production to fight 
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extracellular organisms. The cytokines produced by the two subsets also have a cross-
regulatory role (Bueno C et al. 2001). (See Figure 1.2) In other words, an activated TH2 
cell will down regulate the TH1 cells. Likewise, TH1 cytokines down regulate the TH2 
responses   (Lucey DR et al. 1996; Moser M et al. 2000). 
 
           
 
 
 
 
 
 
Figure 1.2:  TH1/TH2 balance (Website: http://inet.uni2.dk/~iirrh/IIR/03Th/Th.htm ) 
Only the most important cytokines in relation to this thesis will be discussed. 
1.5.1 TH1 cytokines: 
Interferons (IFN) as stated by Baron S et al. (1991) modulate the activity of virtually 
every component of the immune system.Type I interferons include more than 20 types of 
interferon-alpha, interferon-beta, interferon omega, and interferon tau (Liu et al. 2005b). 
There is only one type II interferon, interferon-gamma (Colonna M et al. 2002a).Type I 
interferons, which can be produced by virtually any virus-infected cell is better able to 
induce viral resistance in cells, whereas type II interferon is produced by activated            
 
Counter regulation of TH cell subsets 
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T-lymphocytes as part of an immune response and functions mainly to promote the activity 
of the components of the cell-mediated immune system such as CTLs, macrophages, and 
NK cells.  
Interferons are among the best studied cytokines. IFN is produced by immune-activated 
cells or virus-infected cells in response to the double-stranded RNA (dsRNA) that many 
viruses produce as a part of their life cycle. Interferons exert their antiviral activity by 
binding to uninfected neighboring cells and induce them to produce enzymes that degrade 
mRNA. This not only prevents translation of viral mRNA into viral protein, but it also 
eventually kills the host cell that produces the viruses. Interferons also promote the body’s 
defenses by enhancing the activities of CTLs, macrophages, NK cells, and antibody-
producing cells (Colonna M et al. 2002a). 
Interferon-gamma (IFN-γ) is secreted by T cells (cytotoxic and TH1) and Natural Killer 
cells, activate macrophages and increase the expression of class II MHC on APC. IFN-γ 
stimulated macrophages are more phagocytic, they are more capable of killing intracellular 
pathogens and they have increased ability to present antigen. IFN-γ secreted by TH1 cells 
has a cross regulatory role in controlling TH2 function, and will induce a antibody class 
switch to IgG. It actually can inhibit the activities of the TH2 pathway by inducing IL-12 
production by macrophages. This cytokine has a role in many different types of immune 
reponses such as inflammation, antibody production and viral infection. In summary IFN-γ  
induces MHC-I and MHC-II production. It activates and increases the antimicrobial and 
tumourcidal activity of monocytes, neutrophils, and NK cells and stimulates the synthesis 
of adhesion factors on endothelial cells and leukocytes for diapedesis. (Farrar MA et al. 
1993) 
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Interferon-alpha (IFN-α) is expressed by T-lymphocytes, B-lymphocytes, NK cells and 
monocytes/macrophages.  
Interferon-beta (IFN-β) is expressed by virus-infected cells, fibroblasts, macrophages, 
epithelial cells, and endothelial cells (Eloranta ML et al. 1997). This cytokine influences 
antiviral and antiparasitic activity and induces MHC-I antigen expression. (Siegal FP et al. 
1999) 
Interleukin-1 (IL-1) has many functions on many different cells and is secreted by a 
number of cells including macrophages, monocytes and DCs. An important stimulus for  
IL-1 production by the macrophage is the presence of microbial products. IL-1 (originally 
described as T cell activation factor) helps to activate T helper cells by acting as a co-
stimulator with the antigen presenting cell receptors. It also helps promote the maturation 
and clonal expansion of B cells. IL-1 is an important part of the inflammatory response; it 
promotes both the inflammation and catabolic processes. One way it mediates this is by 
increasing the expression of cell adhesion molecules on endothelial cells of the vasculature 
which allows translocation of immune cells from the blood vessels into the tissue. One 
very interesting action of IL-1 is its action on the hypothalamus. Here IL-1, and some other 
cytokines (including IL-6, the IFN and TNF), bind to receptors on the endothelial cells 
within the hypothalamus and appear to 'reset' the thermoregulatory centre to increase the 
core body temperature thereby causing fever. IL- 1 activates B-lymphocytes, NK cells, 
polymorphonuclear leukocytes, endothelial cells, smooth muscle cells, and fibroblasts.   
IL-1 induces fever, sleep and neutrophilia and stimulates synthesis of proinflammatory 
cytokines and acute-phase proteins. It also induces coagulation and stimulates the synthesis 
of collagen and collagenase for scar tissue formation. 
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Tumour necrosis factors: Bazzoni F (1995) explains TNF plays a key role in bridging the 
innate and the adaptive immune systems. The release of TNF causes a range of activities 
that are important in immune responses to viruses and bacteria.  
These activities include: 
• Activation of neutrophils and macrophages to destroy microbes 
• The enhancement of cytokine release by mononuclear phagocyte system cells 
• The stimulation of the recruitment of neutrophils and monocytes to sites of 
infection 
• The amplification of the expression of MHC Class I molecules to enhance the 
presentation of viral peptides in intracellular infections.  
• With the presence of IFN-γ, it induces the expression of MHC Class II molecules 
Tumour necrosis factor-alpha (TNF-α) is secreted by activated mononuclear 
phagocytes, natural killer cells, mast cells and antigen- stimulated T cells. TNF-α  is a 
potent mediator of inflammatory and immune functions caused by bacteria and other 
infectious microorganisms. It is cytotoxic for some tumour cells, induces fever and sleep. It 
stimulates the synthesis of collagen and collagenase for scar tissue formation and adhesion 
factors on endothelial cells and leukocytes for diapedesis. TNF-α activates macrophages 
and promotes inflammation and catabolic processes. TNF-α is a chemoattractant for 
phagocytes and promotes neutrophil degranulation and is responsible for endotoxin-
induced septic shock. It triggers apoptosis (Kikuchi K et al. 2003). The most potent 
inducer of TNF-α by macrophages is the lipopolysaccharide (LPS) of bacterial cell walls. 
Therefore infections by Gram negative bacteria produce large amounts of this monokine.  
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Tumour necrosis factor-beta (TNF-β; lymphotoxin) carries out many of the same 
activities as TNF-α. It is primarily produced by TH1 cells and B-lymphocytes (Kikuchi K 
et al. 2003). 
Interleukin-12 (IL-12) described by Dalod M et al. (2002) activates cytotoxic T cells. 
 IL -12 also stimulates natural killer cells and TH1 cells to proliferate. It activates TH1 
induction and maturation and induces interferon-gamma production. (Biron et al.1995).  
IL-12, also known as natural killer cell stimulatory factor (NKSF) or cytotoxic lymphocyte 
maturation factor (CLMF) is produced by macrophages and B lymphocytes and has been 
shown to have multiple effects on T cells and natural killer (NK) cells (Hendzrak JA et 
al.1995; Kato T et al. 1997). These include inducing production of IFN-γ and TNF by 
resting and activated T and NK cells. Evidence indicates that IL-12, produced by 
macrophages in response to infectious agents, is a central mediator of the cell-mediated 
immune response by its actions on the development, proliferation, and activities of TH1 
cells (Scott P: 1993). These activities of IL-12 are antagonized by IL-4 and IL-10, factors 
associated with the development of T helper cells into TH2 cells and mediation of the 
humoral immune response (Stern AS et al.1996; Trinchieri G et al. 1995). 
Interleukin-8 (IL-8) is a pro-inflammatory cytokine (chemokine) derived from 
endothelial cells, fibroblasts, macrophages, and monocytes. It causes chemotaxis of 
neutrophils and T-cell lymphocytes.  
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1.5.2 TH2 Cytokines 
Interleukin-4 (IL-4) is a cytokine secreted by cells. It has many biological roles, including 
the stimulation of activated B-cell and T-cell proliferation, and the differentiation of CD4+ 
T-cells into TH2 cells. It is a key regulator of humoral pathway/arm of adaptive immunity. 
IL-4 induces immunoglobulin class switching to IgE, and up-regulates MHC class II 
production. It is a growth and differentiation factor for activated B-lymphocytes and 
activated T-lymphocytes. (Hochrein H et al. 2000; Lee JD et al.1995). 
Interleukin-5 (IL-5) is primarily produced by TH2 cells and stimulates the proliferation of 
activated B-lymphocytes and their differentiation into plasma cells. It stimulates antibody 
secretion and immunoglobulin class shift. It also induces growth and differentiation of 
eosinophils. 
Interleukin-6 (IL-6) functions in both the innate and adaptive immunity. It is secreted by 
vascular endothelial cells, fibroblasts, T and B cells and mononuclear phagocyte system 
cells. IL-6 is released in response to infection, burns, trauma, and neoplasia, and its 
functions range from key roles in acute-phase protein induction to B- and T- cell growth 
and differentiation (Chomarat P et al. 2000). IL-6 can have direct effects on cells, can 
mediate the effects of other cytokines, can be agonistic or antagonistic in conjunction with 
other cytokines, and interact with glucocorticoids.  IL-6 is induced by bacteria, viruses, 
bacterial products and chemicals that induce inflammatory reactions. The IL-6 receptor is 
found on many cell surfaces, including resting normal T-cells, activated normal B-cells, 
myeloid cell lines, hepatoma cell lines and myeloma cell lines. IL-6 stimulates the acute-
phase reaction, which enhances the innate immune system and protects against tissue 
damage (Barton B, 1996; Syme R et al.2001). The inflammatory response aims to dilute, 
Stellenbosch University  http://scholar.sun.ac.za
  
28 
 
 
 
 
 
neutralize or remove the threatening agent and initiate the process of repair or recovery. 
Inflammatory agents stimulate monocytes to secrete IL-6 which in turn induce hepatocytes 
to synthesize acute phase proteins, like CPR, clotting and complement factors and 
therefore IL-6 plays a key role in innate immunity. It also plays an important role in 
adaptive immunity. Interleukin-6 is especially important in the early stages of T-cell 
differentiation. In this phase, it reinforces the effect of IL-2 and promotes the 
differentiation of CD4 cells into TH2 cells. It controls the growth and proliferation of early 
progenitor cells in the thymus and bone marrow and is later important in both T-cell and 
Natural Killer (NK) cell activation. IL-6 also functions as the required second signal in 
both antigen- or mitogen-activated T-cells. This protein holds a very important role in the 
life of NK cells. It is first an activator and later stimulates them to perform a more effective 
lysis of a pathogen. IL-6 provides support for continued development throughout the life of 
a natural killer cell. Interleukin-6 is very important in the stimulation of differentiation and 
proliferation of B-cells. It plays a big role in the induction of permanent differentiation of 
B-cells into plasma cells. IL-6 enhances the release of antibodies by acting as a growth 
factor for already differentiated plasma cells. It stimulates mostly the release of IgG and 
IgA antibodies from these cells (Chomarat P et al. 2000; Syme R et al.2001). 
Interleukin-10 (IL-10) is a small protein that plays a big role in the regulation of the 
immune system. The two major activities of IL-10 are the inhibition of cytokine production 
by macrophages and inhibition of the accessory functions of macrophages during T cell 
activation. The effects of these actions cause IL-10 to play mainly an anti-inflammatory 
role in the immune system. It is a multifunctional cytokine that modulates the function of 
many cells, including T-lymphocytes, B-lymphocytes, NK cells, monocytes/macrophages, 
and neutrophils. IL-10 is mainly produced by the TH2 subset of CD4+ helper cells. Some 
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activated B cells, TH1 cells, activated macrophages, and some nonhematopoietic sources 
(e.g. keratinocytes, colon carcinoma, melanoma cells) also produce IL-10               
(Duramad O et al. 2003). 
1.6 General 
Immunology interfaces with medicine at many points, the most prominent currently 
being infectious diseases, cancer, transplantation, allergy, and autoimmunity. In each of 
these instances, there is a need for treatments that increase (immunize) or decrease 
(tolerize) the immune response to the disease causing antigens. The DCs comprise several 
subsets that induce and regulate the immune responses against foreign and self-antigens, 
and can therefore function as initiators of protective immunity and inducers of central or 
peripheral tolerance. The different subpopulations of DCs interact with and also influence 
other cell populations of the immune system, such as T and B lymphocytes and natural 
killer cells. The factors that determine the given DCfunctions depend on the state of 
maturation and the local microenvironment. The interactions between DCs and 
microorganisms are rather complex, but progress in the past few years has shed light on 
several aspects of these interactions. The ultimate goal of this research is to control DC 
biology to gain improved antigen specific control of the immune system. 
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Chapter 2 
The Immunobiology of Dendritic cells 
 
Abstract 
 
The most efficient antigen-presenting cells (APCs) are mature, immunologically 
competent DCs. DCs are capable of evolving from immature, antigen-capturing cells 
to mature, antigen-presenting, T cell-priming cells; converting antigens into 
immunogens and expressing molecules such as cytokines, chemokines, costimulatory 
molecules and proteases to initiate an immune response. The ability of DCs to 
regulate immunity is dependent on DC maturation. A variety of factors can induce 
maturation following antigen uptake and processing within DCs, including: whole 
bacteria or bacterial-derived antigens. The following chapter will provide an 
overview of the different types of the DCs and the process of DC maturation (e.g. cell 
surface receptors, costimulatory molecules, intracellular proteins, cytokines, 
chemokines and their corresponding receptors, and proteases). 
 
2.1 Introduction  
Immunology has long been focused on antigens and lymphocytes, but the presence of these 
two parties does not always lead to immunity. The DC system of antigen presenting cells 
(APCs) is the initiator and modulator of the immune response (Bonosia R et al.2006;    
Hart DNJ et al. 1997). First visualized as Langerhans cells (LCs) in the skin in 1868, the 
characterization of DCs began only 30 years ago. Ralph Steinman first described DCs and 
shortly thereafter it became clear that DCs existed in all lymphoid and non- lymphoid 
tissues. It was not until the 1980’s that it became widely accepted that DCs were 
“professional” antigen presenting cells. In the 1990’s researchers showed how to generate 
large numbers of DCs from CD34+ bone marrow precursors or from CD14+ monocytes in 
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vitro (Grabbe S et al. 2000; Libscomb MF et al. 2002).There is a great interest in 
exploiting DCs to develop immunotherapies for cancer, chronic infections and 
autoimmune disease (Ludewig B et al. 1998a; O’Neil D et al. 2004). 
 
 
2.2 Features indicating the important roles for DCs in the control of immunity: 
(Nelson CA et al. 1994; Morgan DJ et al. 1999; Banchereau J et al. 2000a) 
 
Potency: Studies done on DCs showed small numbers of DCs and relatively small 
amounts of antigen were able to stimulate strong T cell responses in culture.  
 
Position: DCs situated in vivo in the tissues and airways are positioned to capture antigens. 
DCs can migrate to lymphoid tissues, via lymphatics, to enter the T cell areas. There, 
antigen bearing DCs are located to select antigen – reactive T cells from the circulating 
pool of lymphocytes. 
 
Priming: Mature DCs lack many antigen – eliminating functions, such as the capacity to 
kill microorganisms or make antibodies. DCs can be pulsed ex vivo with antigens and be 
reinfused to autologous recipients. T cells recognize antigen in the context of the MHC 
haplotype of the priming DCs. The activated T cells leave the lymph node via efferent 
lymphatics; enter the blood and finally, the inflammatory site where antigen was initially 
deposited.  
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2.3 What is a dendritic cell?  
To stimulate a cellular immune response against for example a tumour, one needs more 
than just antigen and lymphocytes. Another cell is required that can bind and present 
tumour antigen(s) to T lymphocytes in a way that is immunogenic. If successful, this 
means that the immune system reacts against, rather than ignores, all other cells bearing the 
same antigen. In the early 1970’s Steinman first purified a novel leukocyte from mouse 
lymphoid tissue. These cells were called a "DC," on the basis of its unusual morphology of 
veiled dendrites (Faratian D et al: 2000). DCs were also distinguished from other antigen-
presenting cells, such as macrophages and B cells, on the basis of their capacity to 
stimulate T-cell responses, even when the other antigen-presenting cells  had been removed 
(Austyn JM:2000b).  
DCs have been referred to as “professional” antigen presenting cells, since the principle 
function of the DCs is to present antigens to resting naïve T lymphocytes. DCs are capable 
of capturing antigens, processing them and presenting them on the cell surface along with 
appropriate costimulation molecules. Unlike B lymphocytes that can respond to soluble or 
native antigen by transforming into antibody-secreting plasma cells, T lymphocytes can 
only respond to peptide fragments of protein antigens bound to surface MHC molecules. 
MHC molecules are of two types, class I and class II (Banchereau J et al. 2001b). Class I 
MHC molecules bind intracellular or endogenous antigens that have been cut into smaller 
peptides in the cytosol. Class II MHC molecules bind extracellular or exogenous antigens 
endocytosed by the antigen-presenting cell. MacDonald KP et al. (2002) states there are    
3 generally accepted stages of differentiation for all DC subtypes: DC precursors, 
immature DCs and mature DCs. These cells are traditionally divided into 2 populations by 
staining with anitibodies to CD11c and CD123 (O’Doherty U et al. 1994; Romani N et 
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al.1994a; Thomas R et al. 1994c; Howard CJ et al. 1997; Pulendran B et al. 1999;     
Huang FP et al. 2000; Shortman K et al. 2002b). These studies showed that DCs play an 
important role in the induction and maintenance of the adaptive immune response, but now 
it is evident that DCs also have important roles in innate immunity. These features make 
DCs very good candidates for therapy against various pathological conditions including 
malignancies. 
 
2.4 Types of dendritic cells: 
Myeloid DCs: (mDCs) 
mDCs have a monocytoid appearance and are CD11c+ CD123- (Olweus J et al. 1997). 
These cells are major stimulators of T cells and are found in many tissues, where they may 
be classified in two principal subtypes: Langerhans cells and interstitial, dermal or 
submucosal DCs (Thomas R et al. 1993a; Thomas R et al. 1994b). Myeloid precursor DCs 
leave the blood and home to various tissues in the response to chemoattractant gradients. 
Immature mDCs are located at sites where most pathogens enter the body. Upon exposure 
to a virus or bacterial antigen, immature mDCs bind and internalize the virus or pathogen 
and release inflammatory cytokines and chemokines. This initiates the recruitment of more 
immature mDCs and other leucocytes to the site of infection. mDCs at first release IL-12 
and stimulate a TH1 response (Cella M et al. 2000b). Within 24 hours, the production of 
the IL-12 decreases and IL-4 secreting T cells are generated to decrease the TH1 response. 
mDCs in lymph nodes produce chemokines that recruit T cells, B cells, more mDCs and 
pDCs.  
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Plasmacytoid DCs: (pDCs) 
pDCs as described by McKenna K: (2005) have certain characteristics similar to mDCs, 
but have morphological features like plasma cells and are found in blood and lymphoid 
organs (Colonna M et al.2004b). These cells accumulate in inflammatory sites. The pDCs 
lack most myeloid markers. These cells are CD 11c- CD123+and depend on IL- 3, not  
GM-CSF, for maturation (Facetti F et al.1998; Galibert L et al. 2001; Diebold SS et al. 
2003). 
  
pDCs leave the blood through high epithelium venules (HEV) (Langenkamp A et al.2000). 
The expression of CD62L on plasmacytoid DCs allows them to migrate via the HEV’s. In 
the lymph nodes the pDCs are stimulated to mature through the expression of CD40L on 
recently activated T cells (Brei’re F et al. 2002). The pDCs secrete IL-12 and express high 
levels of INF-α  and are important in innate antiviral immunity as explained by Cao W     
et al. (2007) and Asselin –Paturel C et al. (2005). These DCs can activate antitumour and  
antiviral antigen responses, but their potential as immunotherapeutic adjuvants is largerly  
unexplored, because they are difficult to obtain in large quantities. Fiebiger E et al. (2001) 
demonstrated that pDCs only minimally express cathepsins S and D, which are lysosomal 
proteases involved in antigen processing and thus leading to T cell priming.  
pDCs precursors are the major producers of type I interferon and have the unique ability to 
link innate and adaptive immunity. After producing large amounts of type I IFN in 
response to microbial stimulation, they can differentiate into DC capable of stimulating 
naive T cells and modulate the adaptive immune response (Kawamura K et al. 2006; 
Comeau MR et al. 2002). 
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Originally, scientist thought that the different subsets of DCs had unique functions: mDCs 
induced immunity and pDCs mediated tolerance. However, there is increasing evidence 
that it is not the DC subset but, more likely, the DC maturation state, activation state and 
the microenvironment that determine the outcome of the immune response 
 
2.5 DCs differentiation and trafficking pathways: 
Robinson SP et al. (1999) explains that DCs perform specific functions and travel from 
one site to the next: bone marrow derived DCs circulate as precursors in blood before they 
enter the tissues where they become immature DCs and monitor their environment  
(See Table 1.1). Interstitial DCs and Langerhans cells are found at sites that come in 
contact with the external environment, for example the mucosal surfaces and the skin. 
Immature DCs in the peripheral tissues are able to migrate towards inflammatory sites 
where they take up and break down available antigens. They then emigrate through the 
lymphatics to draining lymph nodes and there they home to T cell rich areas and interact 
with T cells and initiate an immune response (Sallusto F et al. 2000d). 
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Table 2.1 Different locations of DCs 
Location Type of DC 
Epidermis Langerhans: Express the C-Type lectin 
Langerin, have unique intracellular 
organelles called Birbeck granules and are 
found in the epidermis and oral, respiratory 
and genital mucosa 
Dermis, Interstitium Interstitial 
Circulatory system Blood 
Afferent Lymph Veiled 
Lymph nodes Lymphoid or Interdigitating 
Compiled by A. Clark: May 2007 
 
2.6 Function of DCs: 
McLellan AD (2000) explains that the most important role of DCs is the priming of 
adaptive immunity and organizing immune responses against all classes of pathogens and 
also against tumours.  The function of DCs falls broadly into three categories, each of 
which involves antigen presentation (Belz GT et al. 2002). 
2.6.1 T cell activation: 
The most prominent role of DCs is to process and present antigens to activate both CD4+ 
and CD8+ cells, since DCs are the only cells capable of activating naïve T cells 
(Maldonado-Lopez R et al. 2001; Sallusto F:2002e; Sallusto F et al. 2002f). Immature DCs 
originate in the bone marrow and migrate throughout the body. These cells lay dormant, 
waiting to interact with invading pathogens or other foreign bodies. So, the function of an 
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immature DC is to find and capture foreign bodies and antigens (Jarrossay CA et al. 2001). 
Once captured, the antigen is processed either by an exogenous or endosomal pathways or 
by endogenous or proteosomal pathways (Mempel TR et al. 2004). 
 
2.6.2 Immune tolerance: 
Tolerance is the inability of the immune system to respond to specific antigens. Central 
tolerance occurs in the thymus for T cells and in the bone marrow for B cells. The primary 
central tolerance in T cells is the induction of T cell death. DCs are found in the thymus, 
where newly produced T cells are educated to become CD4+ T cells and CD8+ cells and 
undergo selection to eliminate immunity against self components. Low affinity reactive    
T cells are positively selected and allowed to survive and reach the periphery. T cells that 
respond to DCs carrying self-peptides are destroyed in the thymus by negative selection. 
This process involves T cells which recognize MHC or peptides with high avidity. DCs 
contribute to this negative selection process along with thymic epithelial cells. The 
mechanisms of peripheral tolerance include T cell death, anergy and active suppression by 
T regulatory cells: DCs induce apoptosis in T cells or by producing IL-10, which induces   
T regulatory cells. DCs might also contribute to tolerance by inducing anergy in responder 
T cells (Steinman RM et al. 2002b). 
 
2.6.3 B cell stimulation or function: 
DCs produce a number of cytokines and factors which are critical to the activation and 
differentiation of B cells. The follicular DCs (FDCs) which are found in the germinal 
centers of lymph nodes are important in the maintenance of B cell memory. FDCs present 
native antigens to potential memory cells, of which only B cells with high affinity B cell 
receptors can bind. These cells are present in follicles of any secondary lymphoid organ. 
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The B cells can in turn take up the antigen from FDCs and present it to T cells. The 
reservoir of antigen and antibody complexes on FDCs is believed to be able to last a very 
long time (McHeyzer- Williams M et al. 2003). 
DCs appear in the periphery as immature DCs where they capture and process antigens. 
Upon capturing an antigen they undergo maturation and present antigen peptides along 
with MHC on their cell surfaces. Mature DCs then migrate to the lymphoid organs, namely 
the spleen and lymph nodes, where they express lymphocyte co-stimulatory molecules and 
secrete various cytokines. This results in selection of rare T lymphocytes with the correct 
antigen specific T-cell receptors (TCR) which proliferate and mature into effector cells. 
These newly formed effector cells then circulate through the body, carrying out immune 
responses. 
DCs must therefore: 
• be able to internalise antigen, for example by phagocytosis, to allow processing to 
occur  
• be capable of processing antigen by proteolysis, the primary mode of antigen 
degradation 
• be capable of transcribing the products of MHC class II (and/or Class I) genes and 
expressing these at the cell surface in sufficient quantity 
• be capable of associating the processed peptide fragments, several amino acids 
long, with the MHC molecules and expressing these on the cell surface 
• be capable of providing the necessary regulatory signals in the form of cytokines to 
      the responding cells.  
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2.7 Migration of DCs in vivo 
DCs travel to the lymphoid tissues such as the spleen and lymph nodes after activation 
(Macagno A et al. 2007). The movement of DCs from the blood to peripheral tissue and 
the movement from peripheral tissue into lymphoid tissue requires chemoattractants called 
chemokines. Macagno A et al. (2007) states chemokines are differentially produced at 
peripheral tissue sites by endothelial cells, epithelial cells and leukocytes in response to a 
inflammatory stimuli. Chemokines are also produced by endothelial cells and leucocytes 
within secondary lymphoid organs to regulate encounters between DCs, T cells and B cells 
(Banchereau J et al. 2001b). DCs are always present in afferent lymph nodes that access 
the T cell areas. The two subsets namely myeloid and plasmacytoid can enter lymphoid 
organs with possible different final destinations such as the B cell and T cell areas.  
Sallusto F et al. (2000d) showed in his study that immature DCs migrate toward increasing 
concentrations of inflammatory chemokines. The DCs are also exposed to increasing 
concentrations of proinflammatory cytokines like TNF-α, IL -1 and the pathogen products 
that caused the inflammatory response. In response to these DCs mature and switch the 
usage and expression of chemokine receptors from inflammatory to lymphoid homing 
receptors (MacPherson GG, 1993). 
 
In most tissues, DCs are present in a so-called ‘immature’ state and are unable to stimulate 
T cells (Lutz MB et al. 2002). Although these DCs lack the requisite accessory signals for 
T cell activation, such as CD40, CD54, CD80 and CD86, they are extremely well equipped 
to capture antigens in peripheral sites. Once they have acquired and processed the foreign 
antigens, they migrate to the T cell areas of lymph nodes and the spleen, undergo 
maturation and stimulate an immune response (De Vries IJ et al. 2003). 
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2.8 Life cycle of DCs: 
Kohrgruber N et al.(1999) explains that like other cell types within the immune system, 
immature DCs are continuously produced from hematopoietic stem cells within the bone 
marrow as two subsets or families of CD34+ progenitor DCs: mDCs and pDCs                     
(Banchereau J et al. 2001b). The pDCs migrates to the thymus to continue differentiation. 
Mostly newly generated immature DCs migrate along the following route: bone marrow, 
blood, nonlymphoid tissues, lymphatics, and then draining lymph nodes (See Figure 2.1). 
These DCs appear to have a short life span of 3–4 days. DCs mediate the transport of 
antigens from sites of peripheral inflammation to lymphoid organs and then present the 
antigens to naïve T cells. Immature DCs are endocytic and thus can capture antigens. They 
become mature DCs after stimulation with lipopolysaccharide (LPS), other pathogen-
derived substances, and inflammatory cytokines, resulting in the upregulation of CD40 and 
cell surface receptors that act as co-receptors in T cell activation, such as CD80 and CD86 
(Bender A et al. 1996). 
 
Figure 2.1: The life cycle of DCs in vivo (Website: www.zoo.zool.kyoto-u.ac.jp/imm/lab/lab-e.html) 
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2.9 Maturation of DCs: 
The initiation of a productive immune response by T cells requires co-stimulation. Mature 
DCs arise from immature precursors which are the cells that exhibit endocytic activity 
(Trombetta ES et al. 2003). Maturation is a terminal differentiation process that transforms 
DCs from cells specialized for antigen capture into cells specialized for T-cell stimulation, 
(Chapuis F et al. 1997; Rescigno M et al. 1998) accompanied by changes in the expression 
of numerous cell-surface antigens that reflect the changing functional role of the cells         
(Reis e Sousa C et al. 2004b; Sozanni S et al. 1998). 
 
Maturation is characterized by reduced phagocytic uptake, the development of cytoplasmic 
extensions or “veils”, migration to lymphoid tissues, and enhanced T-cell activation 
potential (Romani N et al. 1996b; Rovere P et al. 1998; Kalinski P et al. 1999a). 
Maturation regulates antigen processing by lowering the pH of endocytic vacuoles, 
activating proteolysis and transporting the peptide – MHC complexes to the cell surface.  
Immature DCs, such as Langerhans cells in the skin, have high cell-surface expression of 
receptors that efficiently capture antigen for uptake and processing. Hermann TL et al. 
(2005) showed in their study that the maturation of DCs is regulated by the enzyme, 
Calmodulin kinase II. 
Mature DCs in secondary lymphoid tissues, such as lymph nodes and spleen, have a lower 
capacity to capture antigens, but are extremely efficient in antigen presentation and 
stimulating naïve T cells (Aiba S, 1998). During maturation, DCs switch their pattern of 
chemokine receptor and adhesion molecule expression, allowing them to migrate to the 
secondary lymphoid tissues. In addition, the maturing DCs increase cell surface expression 
of peptide-loaded MHC class II as well as adhesion and co-stimulatory molecules, such as 
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CD80 and CD86, to allow for a productive response of the T cell. In turn, T cells activate 
the DCs through the CD40-CD40L interaction to produce cytokines (Caux C et al. 1994b). 
Once primed, the DCs migrate to secondary lymphoid compartments to present Ag-peptide 
complexes to naïve CD4+ T cells and CD8+ cytotoxic T cells (Allan RS et al. 2006). 
Following education by Ag-loaded DCs in lymph nodes, naïve CD4+ T cells differentiate 
into memory helper T cells, which support the differentiation and expansion of CD8+ CTLs 
and B cells (Veeraswamy RK et al. 2003). Helper T cells exert anti-tumour activity 
indirectly through the activation of important effector cells such as macrophages and 
CTL’s, which are capable of eradicating tumour cells or virus-infected cells directly. 
Steinman RM et al. (2007) explains during the transition from an immature DC to 
plasmacytoid-derived DC, a radical morphological transformation occurs. The round 
plasmacytoid cells acquire a typical dendritic morphology that is tightly associated with the 
specialized effector functions of DC in T cell stimulation. The dendrites enable a DC to 
efficiently interact with several T cells. In addition, as the number of dendrites increases, 
so does the surface area of the DC–T cell contact, thereby strengthening the immunological  
response. During DC differentiation, the cells acquire an antigen-presentation capacity; 
express a broad range of co stimulatory molecules that are important in the DC–T cell 
cross-talk, and lose their type I IFN production potential. 
 
Maturation of DCs can be mediated by inflammatory cytokines (IL- 1 and TNF and     
IFN-γ), T cell products (CD40 Ligand), microbial constituents (liposaccharide and CpG 
oligonucleatides) and  trauma (necrosis, transplantation) (Pan J et al. 2004). Maturation 
leads to the development of many features critical for priming, for example maturing DCs 
produce IL-12 and express different chemokine receptors to regulate the movements and 
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interactions with lymphocytes in vivo. It is clear that the maturation of DCs is crucial for 
the initiation of immunity (Ricciardi-Castagnoli P, 1997). Helper T lymphocytes trigger 
complete DC maturation through CD40-CD40L dependent and independent interactions 
(Caux C et al. 1994b). This maturation process is characterized by reduced Ag-capture 
capacity and increased surface expression of MHC and co-stimulatory molecules. 
However, the maturation of DCs is completed only upon interaction with T cells. It is 
characterized by loss of phagocytic capacity and expression of many other accessory 
molecules that interact with receptors on T cells to enhance adhesion and signalling       
(co-stimulation); for example CD58, CD54, CD80, CD86 and CD83. Expression of one or 
both of the costimulatory molecules CD80 and CD86 on the DCs are essential for the 
effective activation of T lymphocytes, and, for IL-2 production (Hellman P et al. 2007). 
These co-stimulatory molecules bind the CD28 molecules on T lymphocytes. If this fails to 
occur at the time of Ag recognition by the TCR, an alternative T lymphocyte function may 
result, namely induction of anergy. 
CD40L is one of the most potent inducers of DC maturation and is mainly expressed on 
activated CD 4+ T lymphocytes. CD40 is a costimulatory protein found on antigen 
presenting cells. CD40 binds to CD154 (CD40L) on T cells to activate the antigen 
presenting cell and produce a variety of downstream effects (O’ Sullivan B: 2003). During 
effective DC- T cell interactions, T cells become activated and they upregulate CD40L.  
CD40L can then interact with CD40 on mature DCs to trigger IL-12 release, required for 
TH1 polarization. In the macrophage, the primary signal for activation is IFN-γ from TH1 
type CD4 T cells. The secondary signal is CD40L on the T cell which binds CD40 on the 
macrophage cell surface. As a result, the macrophage expresses more CD40 and TNF 
receptors on its surface which helps increase the level of activation. The activated 
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macrophage can then destroy phagocytosed bacteria and produce more cytokines       
(Durie FH et al. 1994; Schoenberger SP et al. 1998). 
The B cell can present antigens to helper T cells. If the T cell recognizes the peptide 
presented by the B cell, the T cell synthesizes CD40L. The CD40L binds to the B cell's 
CD40 receptor which causes resting B cell activation. The T cell also produces IL-4 which 
directly binds to B cell receptors. As a result of this interaction, the B cell can undergo 
division, antibody isotype switching, and differentiation to plasma cells. The end result is a 
B cell which is able to mass produce specific antibodies against an antigenic target 
(Alderson MR et al. 1993). 
Viney JL (1999) states human monocyte -derived DCs were found to induce TH1 
differentiation, whereas DCs derived from plasmacytoid cells induced TH2 differentiation. 
DCs are a major source of many cytokines, (Penna G et al. 2002) namely, IFN-α, IL-1,   
IL-6, IL-7, IL-12 and IL-15 and also produce macrophage inflammatory protein all of 
which are important in the elicitation of a primary immune response. Also, there is 
evidence that the cytokine secretion pattern of the plastic-adherent monocyte-derived DCs 
can be induced along the TH1 (IL-12) or TH 2 (IL-10) cytokine secretory pathway. DC 
research has become increasingly popular as investigators explore their potential use in the 
development of better vaccines (to viruses, tumours, etc.), as well as treatment of 
autoimmune and allergic disorders. 
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2.10 Antigen uptake, processing and presentation  
Albert ML et al. (1998b) states immature DCs can be activated by pathogens, stress and 
inflammation which induce mobilization of cells to draining lymph nodes where they act 
as highly potent professional APCs (Schuurhuis DH et al. 2006). DCs have many uptake 
receptors that deliver antigen to processing compartments. Many of the receptors on the 
DCs are lectins with carbohydrate recognition capacity for example DEC205, mannose 
receptors (MMR) and CD 209/DC –SIGN. CD 209 is known to bind a number of microbes 
including HIV and mycobacteria. CD 207/ Langerin degrade HIV in DCs and therefore 
play a role in reducing the transmission of HIV to T cells. 
 
These cells present their intracellular content to CD4+ helper and CD8+cytotoxic T cells 
(Guermonprez P et al.2002; Gunzer M et al. 2000). DCs capture bacteria, viruses, dead or 
dying cells, proteins, and immune complexes through phagocytosis, endocytosis, and 
pinocytosis in clathrin- coated pits. Austyn et al. (1996a); Mellman I et al. (2001);   
Palucka K. et al. (2002) explain that most immature DCs show three types of endocytosis: 
macropinocytosis, phagocytosis and chlartin-mediated endocytosis.  
Immature DCs have several features that allow them to capture antigen. (See Table2.2) 
Firstly, they can take up particles and microbes by phagocytosis.  Phagocytosis is triggered 
by the attachment of extracellular particles to surface receptors, which in turn signal 
particle uptake.  Secondly, they can form large pinocytic vesicles in which extracellular 
fluid and solutes are sampled; a process called macropinocytosis (Sallusto F et al. 1995a). 
In contrast to what has been found with other cell types, macropinocytosis in DCs is 
constitutive and allows continuous internalization of large volumes of fluid               
(Levine TP et al. 1992). 
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Steinman RM et al. (2007) explains that pDCs express activating FcR, TLR7 and TLR 9 
for maturation. mDCs in the epidermis express DEC205 and Langerin and induce strong 
killer T-cell responses. Some mDCs in the dermis express DC- SIGN and mannose 
receptor which can activate antibody forming B cells. Endocytosis occurs through several 
pathways which include Fc receptors and lectins like the macrophage mannose receptor 
(MMR) and DEC 205 (Levine TP et al. 1992). Steinman RM (2001a) states in particular 
that the receptors are found in different intracellular sites. As expected, the MMR is 
abundant within peripheral early endosomes, through which most adsorptive endocytosis 
receptors recycle. In contrast, DEC-205 is abundant in late endosomes or lysosomes, which 
in DCs are rich in antigen presenting MHC class II products. [Figure2.2 (a) + (b)] 
 
The second pathway where DCs process exogenous antigens, is called crosspresentation  
(Heath WR et al.2001). This pathway permits DCs to elicit CD8 as well as CD4 T-cell 
responses to exogenous antigens such as apoptotic or necrotic tumour cells, virus-infected 
cells, and immune complexes (Albert ML et al. 1998a). Cross-presentation is linked to 
specific DC antigen uptake receptors, which may be targeted in strategies to load 
exogenous antigens onto both MHC I and II. 
 
Lipid and glycolipid antigens expressed on pathogens or self tissues are presented by DCs 
to T cells on CD1 molecules, which are structurally similar to MHC I but specialized to 
bind lipids instead of peptides. Once DCs have captured Ags, which also provide the signal 
to mature, their ability to capture more Ag rapidly declines. The captured Ags enter the 
endocytic pathway of the cell. In macrophages, most of the protein substrates are directed 
to the lysosomes, organelles with only a few MHC class II molecules, where the Ags are 
completely digested into 8-18 amino acids in length. DCs are able to produce large 
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amounts of MHC class II-peptide complexes. This is due to the specialized, MHC class II 
rich compartments (MIICs) that are present in immature DCs. During maturation of DCs, 
MIIC’s convert to non-lysosomal vesicles and discharge their MHC-peptide complexes on 
to the cell surface (Turley SJ, 2000a). 
 
Steinman RM (2001a) explained that antigen processing by DCs occurs primarily through 
an exogenous or endosomal pathway and an endogenous or proteosomal pathway. 
Harshyne LA et al: (2001) showed in his study that DCs degrade antigens within a MHC 
class II rich endosomal compartment. For MHC Class I peptide complexes to form, the 
peptides are derived by cathepsin S from newly synthesized proteins in the cytoplasm 
(Shen L et al. 2004). These peptides are processed via the proteoasome and transported 
into the endoplasmic reticulum via TAP (Transporters for antigen processing). Antigens 
acquired endogenously (ie, synthesized within the DC cytosol) are typically processed and 
loaded onto MHC I, whereas antigens acquired exogenously (from the extracellular 
environment) are processed onto MHC II (Brossart P et al. 1997; Mitchell DA et al. 1998; 
Bajenoff M et al. 2003). 
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Figure 2.2 (a) The endogenous pathway. 
Pathogen-derived or selfproteins within the 
cytosol of antigen-presenting cells (APCs) are 
enzymatically digested into peptides, mainly by 
cytosolic proteases called proteasomes, and are 
then transported by TAP molecules into the 
endoplasmic reticulum (ER). In the ER lumen, 
peptides bind to MHC class I molecules, which 
are subsequently transported via the Golgi to 
the plasma membrane. (Larsson M et al:2001a) 
 
 
Figure 2.2 (b) The exogenous pathway. 
Exogenous antigens are derived from proteins 
that are endocytosed and processed by 
proteases. Peptides bind to newly synthesized 
MHC class II molecules in specialized antigen-
processing vesicles (MHC class II enriched 
compartment; MIIC), and the complexes are 
externalized to the plasma membrane(Larsson 
M et al:.2001a) 
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DCs are also capable of antigen presentation on CD1 molecules. CD1 molecules are 
present on mDCs and are a family of nonpolymorphic histocompatibility antigens 
associated with β2M. CD1 molecules present lipid and glycolipid antigens of both, 
endogenous and exogenous origin. Antigen processing and presentaion by CD1 is different 
from that described above for MHC Class 1 and II. These molecules are synthesized in the 
ER and are expressed on the plasma membrane following traffic to the surface via 
vesicular transport. (See Figure 2.3) 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Different pathways of antigen uptake, processing and presentation (Rescigno et al: 2000)  
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2.11 Characteristics of immature and mature DCs:  
Immature DCs 
• High intracellular MHC II in the form of MIICs  
• Expression of CD1a 
• Active endocytosis for certain particulates and proteins; presence of FcgR and active 
      phagocytosis  
• Deficient T cell sensitization in vitro 
• Low/absent adhesive and costimulatory molecules (CD40/54/58/80/86)  
• Low/absent CD25, CD83, p55 
• Responsive to GM-CSF  
• Maturation inhibited by IL-10 
 
Mature DCs 
• Cell shape: Numerous processes (veils, dendrites) 
• Motility: Active process formation and movement 
• Antigen capture: Macrophage mannose receptor 
• Antigen presentation: High MHC class I and II expression 
• Abundance of molecules for T cell binding and costimulation, (e.g. CD40, CD54, CD58, 
      CD80 and CD86) 
• Cytokines: Abundant IL-12 production; resistance to IL-10 DC-restricted molecules: p55, 
     CD83 
• Absence of macrophage-restricted molecules and function: CD14, bulk endocytic activity 
     (pinocytosis, phagocytosis) 
• Stability: No reversion/conversion to macrophages/lymphocytes 
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2.12 DC interactions with lymphocytes 
Brocker T et al. (2004) explains that during the development of an adaptive immune 
response, the phenotype and function of DCs play an important role in initiating tolerance, 
memory and polarized TH1 and TH2 differentiation. Other factors that drive primary 
immunity are the concentration of antigen, the concentration of cytokines and the genetics 
of the host that may limit how the interacting cells may respond. She also states that DCs 
are the only APCs that prime naïve T cells. The study of Patterson S (2000b) showed that 
the relevant signals by DCs at the DC- T cell interface is likely the most efficient and 
physiologically relevant mechanism for initiating an immune response. 
 
Only mature DCs prime naïve T cells. (Figure 2.4 and Figure 2.5)  Under normal 
conditions the peripheral DCs reach the lymph nodes and help to maintain peripheral 
tolerance. DCs initiate or “prime” T-cell responses in secondary lymphoid organs such as 
lymph nodes, spleen, or mucosal lymphoid tissues. In the lymph nodes the number of DCs 
that display an antigen peptide is very low. T lymphocytes “scan” the surface of the DCs to 
find one that expresses their specific MHC peptide ligand. Naïve T cell activation is 
triggered upon TCR engagement with APCs expressing the right costimulatory molecules. 
The strength of the T-cell response is dependent on many factors including the state of DC 
maturation, and the type of maturation stimulus (Shortman K et al. 1997a). 
 
Al- Alwan MM et al. (2001) mentioned in his study that the contact zone between APCs 
and the T lymphocytes is referred to as the “immunological synapse.” Adhesion and 
signaling molecules distribute in concentric rings defined as the central and peripheral 
supramolecular activation clusters (c-SMAC, p-SMAC) at the interface between T cells 
and APCs (Grakoui A et al. 1999). Recent observations indicate that CD4+ T-cell help at 
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the time of priming is required to generate CD8+ T-cell memory. This effect is thought to 
be mediated by CD40- CD40L interactions between CD4+ T cells and DCs (Morse M et al. 
2002). DCs also interact directly with B cells and lymphocytes of the innate immune 
system. Activated mDCs can directly induce B-cell proliferation, immunoglobulin isotype 
switching, and plasma cell differentiation through the production of the B-cell activation. 
Activated pDCs can induce the differentiation of CD40- activated B cells into plasma cells 
through the secretion of IFN-α  and IL-6. Activated NK cells can kill immature, but not 
mature, DCs and can stimulate DCs to induce protective CD8+ T-cell responses. 
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         Figure 2.4: Interaction between infected cell and Cytotoxic T cell                  
   (Website: home.comcast.net/.../C/ClassIIpath.gif)  
           
Figure 2.5 Interaction between dendritic and CD 4+ cell 
(Website: home.comcast.net/.../C/ClassIIpath.gif)  
 
 
   Dendritic cell 
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During the development of an adaptive immune response, the phenotype and function of 
DCs play an important role in initiating tolerance, memory, and polarized TH1 and TH2 
differentiation. As discussed, DC subsets have been proposed as playing differing roles in  
defining the outcome of an immune response. Important factors other than signals 
delivered by DCs that drive primary immune responses are concentration of antigen in the 
microenvironment, concentration of cytokines and other soluble factors present in the fluid 
phase in the vicinity of the APC-T cell interface. Delivery of the relevant signals by DCs at 
the DC-T cell interface is likely the most efficient and physiologically relevant mechanism 
for initiating an immune response. CD4 and CD8 T cells respond to peptide antigen 
displayed on MHC class II and MHC class I molecules, respectively. In the absence of 
sufficient costimulation, T cells exhibit no response to an antigen or antibody (anergy) or 
undergo apoptosis.  
Cell surface receptors not only facilitate antigen uptake, but also mediate physical contact 
between DCs and T cells (Miggin SM et al. 2006). The soluble cytokine profile secreted 
by DCs varies with the different stages of DC development and maturation thus 
influencing the different effector functions characteristic of immature versus mature DCs. 
A wide variety of cytokines may be expressed (not necessarily simultaneously) by mature 
DCs including IL-12, IL-15, IL-18, IFN-α , IFN-γ, IL-4, IL-10, IL-6, IL-17, IL-16, and 
TNF-α. The exact cytokine range expressed will depend on the nature of the stimulus, 
maturation stage of the DC and the existing cytokine microenvironment. The distinct 
cytokine patterns released by mature DCs ultimately determine their TH1/TH2 polarizing 
capacities. Antigens that prime DCs to secrete IL-12 will typically induce TH1 
differentiation, whereas antigens that inhibit IL-12 production (e.g. IL-10) will promote 
TH2 differentiation. Experiments have shown that within 48 hours of antigen stimulation, 
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all T cells specific for that antigen are retained in the draining lymph node. By day five 
following antigen stimulation, effector T cells leave the lymph nodes in large numbers and 
travel to the infection site. 
2.13 DCs and B lymphocytes 
DCs are known to have major effects on B-cell growth and immunoglobulin secretion.      
B cells and DCs are both APCs and both are essential for antibody responses but for 
entirely different reasons; DCs activate and expand T-helper cells, which in turn induce   
B-cell growth and antibody production. DCs stimulate the production of antibodies directly 
and the proliferation of B cells that have been stimulated by CD40L on activated T cells.  
Differences between DCs and B cells as APCs 
- DCs have higher levels of MHC II and accessory molecules 
- DCs can make large amounts of IL-12 
- DCs can internalize antigens by means of Fc and multilectin receptors; B cells have 
antigen-specific immunoglobulin receptors and inhibitory FcgR 
 
2.14 DCs in Cancer  
The cytotoxic T-lymphocytes are one of the critical effector cells that are able to lyse and 
destroy tumour cells. Receptors on the surface of T-cells recognise proteins called tumour 
associated antigens on the surface of tumours. However, the process is complex and in 
order for the T-cell to become activated, it must recognise the tumour associated antigen 
and it must have a co-stimulatory signal in order to kill off a cancer cell, as in the absence 
of this the T-cells become tolerant to the antigen and the tumour continues to grow.  
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Animal studies done by Esche C et al. (1999) showed evidence that DCs can induce 
immunity to tumours. In tumour cells, the tumour-derived soluble factors (TDSFs) such as 
vascular endothelial growth factor (VEGF) act as a strong stimulator of immature DCs. At 
the primary tumour site the induced mDCs and pDCs are recruited through chemokines 
and their receptors where they are functionally changed into tumour-associated immature 
DCs (TiDCs) that contribute to tumour immunity (Schuler et al:1997). The TiDCs are able 
to capture apoptotic tumour cells by phagocytosis through a complex composed of the 
receptor CD36. The TiDCs-captured apoptotic cells (TiDCs-Cp) become more stable and 
resistant to apoptosis than immature DCs, in which they contribute to the stimulation of 
immune tolerance. Importantly, despite the fact that the TiDCs-Cp can be matured by 
inflammatory signals, the MHC-tumour antigen cannot be presented efficiently to naive  
T cells, resulting in the continued induction of immune tolerance. 
  
The potential to use the patient’s own immune system to kill tumour cells shows a growing 
interest in immunotherapy. One such approach uses bone marrow-derived DCs (DCs), 
phenotypically distinct and very potent antigen-presenting cells, to present tumour-
associated antigens and, thereby, generate tumour-specific immunity (Reis e Sousa et 
al.2003a). Recent studies aim to take cells, such as DCs, out of a patient (or out of a 
healthy donor) and effectively activate them in vitro with bacterial antigens and then 
(re)infuse them into the patient. This enables the DCs to mature and eventually present the 
same bacterial antigens as appear in the patient body to the naïve T cells. When these 
special mature DCs are injected back to the patient’s system, they present the bacterial 
antigens to the patient's immune system, and those T cells that can respond mount an attack 
on the patient’s infected or cancer cells.  The idea being that the (re)infused DCs can then 
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activate the immune system (T cells) to destroy the infected or cancer cells in the patient - 
now that they know what they are looking for (Berard F et al. 2000). 
 
The CTLs arrest in close contact to tumour cells expressing their associated antigen. In 
regions where most tumour cells are dead, CTLs resume migration, sometimes following 
collagen fibers or blood vessels. CTLs also infiltrate tumours in depth, but only when the 
tumour cells express the cognate CTL antigen. In tumours that do not express the 
associated antigen, CTL infiltration is restricted to peripheral regions, and lymphocytes 
neither stop moving nor kill tumour cells (Fong L et al. 2000; Gabrilovich DI et al. 1996). 
Antigen expression by tumour cells therefore determines both CTL motility within the 
tumour and deep tumour infiltration. 
A number of studies done demonstrated the safety and feasibility of DC immunotherapies. 
By modifying DCs, researchers are able to trigger a special kind of autoimmune response 
that includes a T cell attack of the cancer cells (Colaco CA, 1999; Nouri – Shirazi M et al. 
2000) (Figure 2.6). Other studies showed that a cancer antigen alone is not enough to 
activate the DCs, and therefore scientists first fuse a cytokine to a tumour antigen with the 
hope that this will send a strong antigenic and activation signal (Geiger J et al. 2000). 
Next, they culture a patient's DCs in the incubator and let them take up this fused cytokine-
tumour antigen. This enables the DCs to mature and eventually display the same tumour 
antigens as appear on the patient's cancer cells (Hermans IF et al. 1998a). When these in 
vitro matured DCs are given back to the patient, the cells present the acquired tumour 
antigens to the pasient’s T cells that can mount an attack on the patients cancer cells   
(Jenne L et al. 2000; Dhodapkar MV et al. 2000b).(Please refer to Figures 2.6 and 2.7). 
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Steinman RM et al. (2007c) states that DCs can be used for the prevention and treatment of 
cancer for the following reasons: 
• The attack on cancer by the immune system is broad enough to include multiple 
targets, including mutant proteins expressed by the cancer  
• DCs have the potential to activate and increase the different arms of the  
               cell-mediated resistance such as NK cells and γδ T cells, each of which       
               recognizes different changes in cancer cells 
• DCs generated ex vivo and DCs in systemic lymphoid organs retain their  
      immunizing capacities in cancer patients. These features of DCs can be used to    
      generate therapeutic immunity or to prevent cancer during the early stages of  
      disease.  
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Figure 2.6: Teaching the patient’s own DCs (Website:www.nwbio.com) 
 
  
Figure 2.7: The DC processes the antigen and presents it to cytotoxic T cells. The activated T cells 
proliferate and secrete cytokines. This results in the production of a cascade of immune effector cells which 
will now recognize the cancer cell and destroy it. (Website: www.nwbio.com)  
 
 
 
       DC treatment for cancer 
Stellenbosch University  http://scholar.sun.ac.za
  
60 
 
 
 
 
 
2.15 DCs and their role in HIV pathogenesis: 
DCs are professional antigen presenting cells that sample the environment at sites of 
pathogen entry. Sentinel immature DC develop into mature effector DC upon activation by 
microorganisms, and migrate to the draining lymph nodes where they stimulate naïve     
TH cells. HIV-1 has been proposed to make use of this migratory process, being captured 
by the DC and delivered to the lymph node where the virus is transmitted to CD4+ T cells 
(Donaghy H et al. 2006c). The lymph node then becomes the principal site of virus 
production (Lore K et al. 2005). DC can capture HIV through several receptors, of which 
DC-SIGN is the best studied example. After capture, the virus dissociates from DC-SIGN 
and resides in an unidentified non-lysosomal compartment (Sol- Foulon N et al. 2002). 
After T cell encounter, HIV is recruited to the site of T cell interaction. This so-called 
“infectious synapse” depends on strong cell-cell adhesion (Garcia E et al. 2005;            
Lore K et al. 2005; Piqueras B et al. 2006). 
 
Groot F et al. (2006b) explained that the mDCs including dermal DCs, Langerhans cells 
and interstitial DCs are associated with HIV-1 capturing during sexual transmission, 
whereas pDCs play an important role in the innate immune response to viruses, including 
HIV-1. They also discovered that differently matured mDCs have different HIV-1 
transmission efficiencies (Smed- Sorensen A et al. 2005). The study also revealed that 
regardless of their state of maturation, pDCs inhibit HIV-1 replication in T cells through 
the secretion of IFN-γ. This study showed that the two main DC subsets have opposing 
roles in HIV-1 infection of T cells. Several other studies (Barron MA et al. 2003; Donaghy 
H et al. 2001a; Pacanowski J et al. 2001) showed that the numbers of mDCs and pDCs are 
reduced in HIV infected patients.  
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2.16 DCs and autoimmunity: 
Bayry J et al. (2003) explain that autoimmune disorders develop when the immune 
response targets the body’s own cells and tissues. In autoimmunity the breakdown of 
tolerance occurs. DCs acquire autoantigens, mature and defectively stimulate normally 
inactive autoreactive T cells that express a TCR either specific for or able to crossreact 
with the presented self-peptide. In an autoimmune response, these "self-proteins" are being 
presented to T cells which cause the T cells to become "self-reactive". Researchers believe 
that targeting DCs may stop the faulty immune response at a higher "upstream" level since 
T-cells frequently receive their information from DCs. Studies done by Bayry J et al. 
(2003) explained DCs can be pulsed with the endogenous antigen to produce the relevant 
"self-peptide". The relevant self-peptide is different for each individual because MHC 
products are highly polymorphic and each individual MHC molecules might bind different 
peptide fragments. The "self-peptide" may then be used to design competing peptides or to 
induce tolerance to the self protein in the individual in need of treatment. 
 
Autoimmune disease occurs when autoreactive T cells cause tissue damage which can lead 
to infection. Antigen presenting cells migrate to the sites of infection and express co-
stimulatory molecules and cytokines that allow naïve T cells to react to self peptides 
expressed by the tissue cells. In the case of autoimmunity, the most well known cell types 
that are being dysregulated are the T cells and B cells. B cells produce large quantities of 
antibodies, and various mechanisms can lead to tissue injury, for example, by the formation 
of large deposits of immune complexes. Studies done lately showed that DC play a much 
larger role in autoimmune responses than originally thought (Turley SJ: 2000). DCs cannot 
differentiate between the antigens they capture at the site of inflammation and thus will 
accidently present self-antigens along with pathogen-specific antigens. DCs also play a 
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central role in peripheral T cell tolerance, by inducing T cell anergy or unresponsiveness to 
self-antigens. The activation of naive T cells by DCs requires 2 signals, antigen 
presentation and costimulation. Disruption of the co-stimulatory pathways has been shown 
to be effective in blocking the pathogenic process in several models of autoimmune 
diseases. Due to its immune inhibitory function, DCs have great potential for treatment of 
autoimmune diseases, for organ transplantations, and for immunotherapy. The  
CD40/ CD40L plays an important role in the activation of T cells and therefore it will 
provide an ideal target for therapeutic intervention studies.  
 
Recent studies by Belz GT et al. (2002) showed that DCs can induce tolerance in the 
steady state. This evidence is critical to the prevention of the autoimmune response. Since 
most autoimmune diseases are associated with an ongoing immune response, it is 
important to make use of the ability of specific DCs populations and convert the immune 
response from a pathogenic response to a protective one.  
 
2.17 Identification of DCs by flow cytometry: 
What is Flow cytometry? 
A flow cytometer, called a Fluorescence Activated Cell Sorter (FACS), has several key 
components (Givan AL, 2001; O’Gorman MRG et al. 2001) 
• A light or excitation source, typically a laser that emits light at a particular 
wavelength; 
• A liquid flow that moves the suspended cells through the instrument and past the 
laser; 
• A detector, in this case a photomultiplier tube, which is able to measure the brief 
            flashes emitted as cells flow past the laser beam. (Figure 2.8) 
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Figure 2.8 Basic picture to show the components of a typical flow cytometer (Website: www.scq.ubc.ca) 
 
In a flow cytometer, single cells move past the excitation source and the light hitting the 
cells is either scattered or absorbed and then re-emitted (fluorescence). This scattered or re-
emitted light is collected by the detector. 
Bakke AC (2001) explains that various fluorescent dyes are commercially available and 
the most common fluorescent dyes are: 
• fluorescein isothiocyanate (FITC)  
• phycoerythrin (PE) 
• peridinin chlorophyll protein (PerCP)  
• allophycocyanin (APC)  
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The amount a cell scatters or fluoresces light is measured by the detector and subsequently 
needs to be displayed for interpretation. These profiles of cells are normally displayed as 
dot plots or histograms (Bleesing JJ et al. 2001). 
2.18 Identifying DCs 
The primary subsets of DC precursors that have been described in human blood are 
distinguished by the absence of expression of several lineage markers for monocytes, 
lymphocytes and NK cells, and the differential expression of CD11c and CD123          
(Van Voorhuis WC et al. 1982). 
• Plasmacytoid DCs                             lin 1- CD11c- CD123+ 
• Myeloid DCs                                     lin 1- CD11c+ CD123- 
These include the presence of large amounts of class II MHC antigens and the absence of 
various lineage markers such as CD3, CD14, CD19, and CD56 (Shortman, K et al. 2002b).  
The inclusion of HLA-DR in addition to CD11c, CD123 and lineage cocktail allows the 
discrimination of CD123+ DCs from basophils (Macey MG et al.1998). DCs also express 
costimulatory molecules including CD80 and CD86, which are upregulated during DC 
activation. CD86 is a marker of early DC maturation, while CD80 only appears in mature 
DCs. Two other markers for mature DCs are CD83 and CMRF-44. CD83 also stains 
activated B cells and CMRF-44 will also stain macrophages and monocytes (Zhou LJ et al. 
1995). The identification of DCs by surface phenotyping may be accomplished by 
demonstrating a high level of MHC class II or a costimulatory molecule such as CD80 and 
the absence of the lineage markers. 
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We included he lineage cocktail 1 (lin 1) to distinguish between DCs and other 
lymphocytes. This cocktail contains antibody clones which stain neutrophils, monocytes, 
lymphocytes and eosinophils. It includes CD3, CD14, CD16, CD19, CD20 and CD56. 
Basophils and peripheral blood dendritic cells can be distinguished from other leucocytes 
by their lack of staining with lin 1.This cocktail can be used for studies of dendritic cell 
subsets and basophils in peripheral blood. 
2.19 Cytokine production by DCs: 
Another important measure of the functional potential of DCs is their ability to produce 
certain cytokines upon stimulation. Nakahara S et al. (2003) showed DCs stimulated with 
LPS, TNF-α and killed Streptococcus pyogenes produced a significant amount of IL-12 
and IFN-γ. Other studies (Prussin C. et al.1995; Macatonia SE et al. 1995b; Tang HL et al. 
1999) demonstrated that mature DCs express IFN-α, IL-12 and IL-6. Through their 
secretion of particular cytokines (and chemokines) at particular times, DCs contribute to 
regulating their own migration, the recruitment of other immune cells, and the polarization 
of the T-cell response.The major cytokines that play a role in DCs are IL-12, IL-4, IL-10, 
IL-6, TNF-α and IFN-γ. Langenkamp A et al. 2000; Fiebieger E et al. 2001 state in their 
studies that some stimuli trigger IL-12 production that leads to a TH1 response. Other 
stimuli fail to do so and favor the TH2 response. His study showed that soon after 
stimulation DCs primed TH1 responses and at later time points the same cells primed a 
TH2 response. 
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Flow cytometric analysis of cytokine production by DCs: 
The method used is known as multiplexing, which means the simultaneous assay of many 
analytes in a single sample (Oliver KG et al. 1998; Savary CA et al. 1998). The           
BD™ Cytometric Bead Array (CBA) is used to detect a series of particles with discrete 
fluorescence intensities to simultaneously detect multiple soluble analytes (Camilla C et al. 
1998; Chen B et al. 1999b; Cook E et al. 2001). This method is combined with flow 
cytometry to create a powerful multiplexed assay (Bueno C et al. 2001; Fulton R et al. 
1997; McHugh TM et al.1994; Chen R et al. 1999). For this study we will determine the 
levels of cytokines secreted by DCs during their maturation process. These cytokines 
include IFN-γ, IL- 12, IL -10, IL- 6, TNF-α, IL- 4, IL-2, IL-8 and IL-1β. See full 
methodology in Chapter 6. 
2.20 Mixed Killed Bacteria: Candidates for activation and maturation of DCs  
Mixed bacterial vaccines are produced from disease causing organisms. Selected species of 
the disease causing bacteria are grown in culture, washed with 0.9% saline, centrifuged, 
resuspended in salt solution and killed with phenol. The vaccine used in this study is 
Mixed killed Bacterial Vaccine (MBV) obtained from Dr. Brigitte Riedelsheimer 
(Düsselsdorf, Germany.) It contains whole bacteria, but no phenol. The concentration of 
the bacteria in the vaccine is 109/ml CFU/ml  
Staphylococcus aureus, Streptococcus pneumoniae, Moraxella (Neisseria) catarrhalis,  
Klebsiella pneumoniae, Heamophilus influenza, Corynebacterium diphtheria, 
Streptococcus pyogenes, Pseudomonas aeruginosa, Proteus vulagaris, Proteus mirabilis, 
Candida krusei and Candida albicans and include the following bacterial species 
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Nakahara S et al. (2003) and Veckman V et al. (2004) showed in their studies that DCs can 
be stimulated with killed Streptococcus pyogenes. Streptococcus pyogenes causes 
pharyngitis, scarlet fever and impetigo or cellulites. The results of this study showed that 
DCs incubated with the S. pyogenes peptide did produce TH1 type cytokines and can 
efficiently induce potent CTL responses, specific to the epitope peptide of tumour –
associated antigen presented on the DCs (Celluzzi CM et al. 1996; Fujimoto T et al. 1997). 
With this study in mind it was hypothesized that the MBV used in this study might 
modulate DC maturation. Hopefully the matured DCs will present all these epitopes to the 
T cells and activate the immune system. 
 
In the study of  Nakahara S et al. (2003), they state that a  potent immune response could   
be efficiently induced only with mature DCs. Maturation of DCs can be influenced by 
many cytokines like TNF-α and GM-CSF. Other studies done by Sallusto F et al. (1999c) 
showed that these cytokines alone cannot induce full maturation of DCs. In addition to 
these cytokines, studies by Cella M et al. (1997) and Rissoan MC et al. (1999) described 
that bacteria can stimulate DC maturation. A study done by Romagnoli G et al. (2003) 
showed that Candida albicans triggered DC maturation and activation. The study also 
showed that DC maturation induced by Candida triggered a TH1 response. The cells 
secreted IFN-γ and IL-2, but no IL-4 and IL-10. It has been hypothesized that the MBV 
and Coley’s Toxin might modulate DC maturation and hopefully induces potent Cytotoxic 
T cells, specific to the peptide presented by the DCs. 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
68 
 
 
 
 
 
2.21 Coley’s Toxins 
From 1891 until his death in 1936, Coley studied the effects of inoculation with live 
bacterial cultures on human malignancy. Coley developed a vaccine consisting of extracts 
of killed Gram-positive Streptococcus pyogenes and Gram-negative Serratia marcescens, 
which became known as `Coley's toxins’. These toxins produce many of the symptoms of 
bacterial infections, such as fever and chills, without the need to worry about producing an 
actual infection (Bickels J et al.2002). A key aspect that Coley found to be necessary for 
tumour regression was the induction of a mild to moderate fever. Basu S (2003b) states 
that even brief exposure to elevated temperatures has a powerful effect on the immuno-
stimulatory capacity of DC. Elevation of body temperature can cause maturation of DC in 
skin and other tissues. The mature DCs are better presenters of antigen to the naive T cells 
in the lymph nodes. The elevation of cytokine levels such as TNF- α, frequently related 
with fever, also contributes to DC maturation. 
Coley's Toxins were used successfully against different types of cancer. After an injection, 
high fever usually develops, but this is intended. The cancer tissue may become necrotic, 
which then must be removed by drains. One of the biologically active ingredients in Coley 
toxins is a lipopolysaccharide (LPS) which causes hyperthermia. This purified LPS induces 
a fever for three to four hours that enhances lymphocyte activity and boosts tumour 
necrosis factor (TNF). Coley and other researchers have emphasized that some tumour 
types appear to be more susceptible to the toxins than others, in particular, sarcomas or 
other tumours of mesenchymal origin such as renal and ovarian carcinomas and possibly 
some lymphomas.  
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Recent microscopic studies of human cancers have found that there are generally high 
concentrations of immune cells within the tumour. Unfortunately, these immune cells are 
not receiving the proper signals to fight the cancer. Thus, the cancer continues to grow and 
spread despite the presence of many immune cells. Coley found that when his vaccine 
caused a fever, the cancer would start to shrink and the number of immune cells in the 
blood would increase dramatically. Fevers are routinely suppressed with drugs such as 
acetaminophen, aspirin or ibuprofen. The immune system over time becomes tolerant to a 
particular dose and therefore Coley would slowly increase the dose until a fever was once 
again produced. Doses were increased to compensate for the reticuloendothelial system's 
increasing capacity to clear the contents of Coley's Toxins.  He also found that even though 
the tumour would start to shrink when the vaccine caused a fever, if he stopped injecting 
the vaccine too early, the cancer would start to grow again. Therefore, the immune cells 
could be stimulated to fight the cancer, but only for a limited time. Coley's Toxins were 
used against different types of cancer from the year 1893 to 1963. In 1963 Coley's Toxins 
were assigned "new drug" status by the Food and Drug Administration (FDA), making it 
illegal in the U.S. to prescribe this kind of therapy outside of clinical trials. However, as 
Coley's Toxins are known and thus not patentable, no clinical trials have been financed 
since then. The illegalization of Coley's Toxins in the United States has led to a loss of 
unwritten knowledge of how to exactly create and apply Coley's Toxins. 
Why was his treatment not successfully assimilated into the practice of medicine? The 
literature lists the following reasons:  
• There were several preparations in use, and they were of very uneven quality.   
               Many physicians relied on inferior and variable commercial preparations. The  
               toxins  were never standardized. 
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• The administration of the toxins was an imprecise art that took many weeks or 
months. Many surgeons had neither the patience to learn it nor the required 
hospital beds for the extended time that was often needed (Bickles J et al.2002)  
The Coley’s Toxin used in this study, obtained from Dr Brigitte Riedelsheimer, 
(Düsselsdorf, Germany) consists of Streptococcus pyogenes and Serratia liquefaciens 
peptides at a concentration of 109 CFU/ml (Heat killed). Streptococcus pyogenes infections 
are sometimes accompanied by the release of toxins from the bacteria.  
 
2.22 The effects of fever on immune cell functions: 
Effects of fever on components of the immune response have been reported including 
effects on innate and acquired immunity and on cytokine expression and function.         
Van Oss CJ et al. (1980) showed in their study that human polymorphonuclear cell (PMN) 
motility and phagocytosis are potentiated in the case of fever, but PMN chemotaxis is not 
enhanced, and bactericidal capacity is only weakly and inconsistently increased by 
exposure to these temperatures. They also confirmed in their study that macrophage 
functions are enhanced during episodes of fever, including expression of Fc receptors, 
phagocytosis, pinocytosis and killing of intracellular bacteria. However, like PMNs, 
macrophages have markedly reduced function at temperatures > 41 °C. By contrast, the 
cytotoxic activity of human natural killer (NK) cells has been shown to be reduced in the 
case of fever, demonstrating that the effects of fever on immune function are cell specific. 
Basu S et al. (2003) proved in his study that elevation in body temperature causes 
maturation of DCs in the skin and other tissues. With these facts in mind we hypothesized 
that the Coley’s toxin would enhance the maturation and activity of the DCs. 
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2.23 Aim of this study 
 
The DC system of APCs is the initiator and modulator of the immune response. DCs have 
been referred to as “professional” APCs, since the principle function of the DCs is to 
present antigens to resting naïve T lymphocytes. DCs (only mature DCs) are the only 
APCs that prime naïve T cells and only mature DCs can prime naïve T cells. The aim of 
the study was the following: 
1. To develop a method of detecting circulatory DCs by phenotypic analysis using 
flow cytometry 
2. To use the MBV and Coley’s Toxin to determine whether these bacterial products 
could induce the activation and maturation of the DCs 
3. To analyse the cytokine profile of DCs in order to determine whether the activation 
/maturation process gave rise to a beneficial biological outcome in vitro 
 
DC based therapies have potential application across a wide variety of diseases, ranging 
from infectious diseases such as HIV to cancer, inflammatory disease and autoimmune 
diseases. The market potential for a successful treatment is large (Cerundolo V et al. 
2004). Mohamdzadeh M et al. (2004) states that market opportunities include the 
manipulation of DC activity for the development of effective therapeutic vaccines, the 
modulation of DC’s activity to manage autoimmune diseases and targeting the underserved 
markets through the development of novel therapies that make use of the immune system 
to prevent and treat disease. These cells have the potential to be used as enhancers of 
responses to infectious diseases and due to their capacity to induce a primary immune 
response DCs can be used as vectors (vaccine carriers) for immunotherapy (Paczesny S et 
al. 2003). 
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Chapter 3 
Identification of dendritic cells in health and disease by making use of  
 Flow Cytometry 
Abstract: 
This chapter describes a flow cytometric method for the phenotypic identification of 
DCs in normal individuals and in different diseases. In this chapter we also 
investigated the maturation status of DCs in different diseases. DC subsets are 
distinguished by different markers. These cells do not express several lineage markers 
for lymphocytes, monocytes and NK cells. The DC expresses CD11c (in the case of 
mDCs) and CD123 (in the case of pDCs). The inclusion of HLA-DR in addition to the 
previous described markers allows the discrimination of CD123 + DCs from 
basophils. Whole blood samples (heparinized) are needed for the assay. The assay 
requires two tubes per sample which enables quick analysis of these rare subsets with 
a small sample volume. This assay was applied to peripheral blood samples obtained 
from healthy individuals and individuals with cancer, HIV and HIV and TB infected 
patients. There is a great interest in exploiting DCs to develop immunotherapies for 
cancer, chronic infections and autoimmune disease, 
 
3.1 Introduction: 
Identified by Ralph Steinman more than 30 years ago (Steinman et al.1973) based on its 
curious morphology with long dendritic processes, this cell was difficult to study and 
define until the advent of modern culture techniques. In this chapter we will describe all 
the flow cytometry markers that can help in identifying DCs. The assay is designed to 
detect two different subsets of peripheral blood DCs, CD123+ and CD11c+. The inclusion 
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of HLA-DR in addition to CD11c and CD123 allows the discrimination of CD123+ DCs 
from basophils. Basophils express similar levels of CD123 as the CD123+ DC subset, but 
can be discriminated by their lack of HLA-DR expression (Ida JA et al. 2006). 
• Plasmacytoid DCs                             lin 1- CD11c- CD123+  
• Myeloid DCs                                     lin 1- CD11c+CD123-  
DCs also express costimulatory molecules including CD80 and CD86, which are 
upregulated during DC activation. (These activation markers are described in chapter 4). 
DCs are crucial in the defence against pathogens. Invading pathogens are recognized by 
Toll-like receptors (TLRs) and receptors such as C-type lectins expressed on the surface of 
DCs. However, it is becoming evident that some pathogens, including viruses, such as 
HIV-1, and non-viral pathogens, such as Mycobacterium tuberculosis, subvert DC 
functions to escape immune surveillance by targeting the C-type lectin DC-SIGN         
(DC-specific intercellular adhesion molecule-grabbing nonintegrin) (Geijtenbeek TB et al. 
2000). Notably, these pathogens misuse DC-SIGN by distinct mechanisms that either 
circumvent antigen processing or alter TLR-mediated signalling, skewing T-cell responses 
(Kwon DS et al: 2002). This implies that adaptation of pathogens to target DC-SIGN 
might support pathogen survival. In infectious diseases, the particular DC activation state 
is dependent on which microbe is encountered, which TLR are engaged, and whether the 
TLR are functioning normally (Kapsenberg ML: 2003; Pulendran B et al.2004b).          
TLR signaling is essential for generating effective TH1 immunity against for example     
M. tuberculosis. 
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3.2 DCs and Mycobacterium tuberculosis: 
 
Infection with Mycobacterium tuberculosis continues to be a major cause of mortality and 
morbidity throughout the world. Mycobacteria persist in macrophages within the 
granuloma in the organs of infected hosts. A study done by Demangel C et al. (1999) 
showed that BCG loaded DCs induced appropriate maturation of the DCs, in vitro, 
including stimulating IL-12 secretion. From the phagosomes, where they reside, they are 
believed to secrete proteins, also called “secretory antigens” (Beatty W et al. 2000). In this 
study they explain that these antigens contribute to the development of protective 
immunity by serving as targets for the immune system early in the infection where they are 
likely to be taken up by antigen-presenting cells (APCs). Among the most potent of these 
APCs are the different subsets of DCs that have the ability to stimulate inactive, naive, and 
memory T lymphocytes (Banchereau J et al. 2001b). Immature DCs are programmed for 
antigen capture and they express low levels of surface major histocompatibility complex 
[MHC] and costimulatory molecules. After contact with various stimuli—such as 
lipopolysaccharide (LPS), tumour necrosis factor alpha (TNF-α), CD40 ligand and certain 
antigens they undergo a process of maturation (Nelson EL et al: 1999). Recently, the      
19-kDa lipoprotein of Mycobacterium tuberculosis has been shown to induce the 
maturation of DCs. During maturation, they up-regulate their MHC (class I and II) and 
costimulatory molecules (CD80, CD86, CD40, and CD54) and are very efficient T cell 
stimulators. Therefore, antigens that are able to induce maturation of DCs play a major role 
in defining the character of primary immune responses against the pathogen and, thereby, 
have an important role in determining the course of an infection  
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DCs are the major antigen-presenting cells in the induction of cellular responses to 
intracellular pathogens, such as mycobacteria. The interaction of DC with microbial 
antigens may be the controlling factor in the development of a TH1-orientated protective 
immunity. Demangel C (2000) explained mycobacteria-infected DC have an enhanced 
capacity to release pro-inflammatory cytokines and chemokines and are potent inducers of 
interferon-gamma-producing cells in vivo. DCs are likely to play a key role in                
anti-mycobacterial immunity and protection against tuberculosis. DCs exhibit the unique 
ability to ingest pathogens at the sites of infection, and to migrate to secondary lymphoid 
organs, such as the lymph nodes, to present pathogen-derived antigens to naive T cells. 
Several in vitro and in vivo studies, in mice and rats, have shown that DCs can be activated 
upon infection with various mycobacteria, including M. tuberculosis and the vaccine strain 
M. bovis BCG (Henderson RA et al.1997; Demangel C et al. 1999). Mycobacteria-
activated DCs express surface presentation, co-stimulation and migratory molecules (Kim 
KD et al. 1999). 
Mycobacterium tuberculosis, the cause of tuberculosis, remains a pathogenic organism 
capable of infecting a large number of individuals and of resisting the immune response of 
the infected host. The main constituents of this response are the antigen presenting cells 
such as DCs cells, macrophages and T lymphocytes. Studies of the interactions between  
M. tuberculosis and the antigen presenting cells has shown that DCs do not permit 
intracellular growth of M. tuberculosis, unlike that seen in macrophages. A hostile 
intracellular compartment creates a bacteriostatic environment. M. tuberculosis is 
internalised by binding to a C-type lectin receptor (DC-SIGN) (Tailleux L et al. 2003). 
This receptor recognises polysaccharide compounds on the surface of M. tuberculosis. This 
sugar-lectin bond may compensate for the bond between bacterial compounds and         
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Toll receptors, partially inhibiting the protective inflammatory reaction or compensating 
for an excessive inflammatory reaction. This bond encourages both the persistence of 
quiescent bacteria in the DCs and the reciprocal adaptation of the host and the bacteria 
over the course of time. Freshly isolated human lung DCs were found to express DC-
SIGN. The intracellular behavior of M. tuberculosis inside DCs differs compared to 
macrophages, with a failure of replication. The intracellular compartment of the DC, 
disconnected from the exocytic and endocytic pathways, and is characterized by the 
absence of endoplasmic reticulum and Golgi features. 
 
Animal studies done showed mycobacteria-infected DCs can stimulate mycobacterial 
antigen-specific T cells in vitro and give protection against mycobacteria. In vivo, it is 
likely that mycobacteria-infected DCs can stimulate the development of IFN-γ-secreting   
T cells, essentially through the secretion of IL-12. Giacomini E et al. (2001) showed that 
DCs in cultures exposed to M. tuberculosis up-regulated surface MHC class II and 
increased the DC maturation marker CD83, and CD40, CD54, CD58, CD80, and CD86. 
Henderson et al. (1997) found that DCs phagocytose M. tuberculosis efficiently, a process 
resulting in up-regulation of MHC class I and MHC class II. CD40, CD54, CD58, and 
CD80 were also increased in M. tuberculosis infected DCs. Jiao et al. (2002) showed in his 
study an increased number of DC following BCG administration. They next analyzed the 
expression of costimulatory molecules by these cells required for T cell activation. Fifteen 
to 20% of DC showed an increase of CD86 and CD83 from 4 to 48 h post infection. The 
increase of CD80 and CD40 occurred more slowly but was observed on a much larger set 
of DC at day 2. 
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3.3 DCs and HIV:  
DCs play a critical role in the generation of an effective immune response against 
incoming pathogens. Bancehraeau J et al. (2000a) explained that DCs act as antigen-
presenting cells , transporting processed antigens from peripheral tissue to draining lymph 
nodes. In the lymph nodes the DCs present the antigens to circulating T cells, initiating an 
antigen-specific T-cell response. Persisting HIV infection leads to the destruction of T 
cells. DCs are early targets for infection by HIV at peripheral sites. In early infection, HIV 
enters both DCs and macrophages/monocytes at mucosal sites by utilizing target cell 
surface CD4 and a chemokine receptor CCR 5 (Larsson M et al. 2004b). Infected 
monocytes stimulated with GM -CSF and IL-4 develop into DCs and the exposure to LPS 
stimulates the DCs to mature and migrate to secondary lymphoid tissue where they can 
infect CD4+ T cells. Because of their important role in inducing the antiviral response, 
many viruses and bacterial pathogens target DC and T cells (Alcami A et al. 2000; 
Tortorella D et al. 2000). 
 
Upon exposure of mucosal surface to HIV-1 during transmission, different cells are 
exposed to the virus. Among these are immature DC, Langerhans cells, and resting T cells. 
Immature DC, through viral engagement with C-type lectins, may be one of the first 
leukocytes to capture HIV-1with subsequent replication and crossing of mucosal surfaces, 
thereby transmitting virus to nearby CD4+ T cells for amplification through DC and T-cell 
interaction. Recent studies have also demonstrated that DCs infected with HIV-1 
selectively fail to mature, and are defective in interleukin 12 (IL-12) production. 
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mDCs are professional antigen-presenting cells for T cells, and include Langerhans cells, 
dermal DCs, and interstitial DCs. These cells have been associated with HIV-1 capture and 
sexual transmission, whereas pDCs play an important role in the innate immune responses 
to different types of viruses, including HIV-1. Groot F et al. (2006) found in his study that 
mDCs enhance HIV-1 infection through capture of the virus and subsequent transmission 
to T cells, and that differently matured mDC subsets have different HIV-1 transmission 
efficiencies. These differences were not due to soluble factors, viral capture differences, or 
the expression of integrins ICAM-1, -2, -3, or LFA-1 (Sanders RW et al.  2002). 
 
DCs play a major role in HIV pathogenesis (Rowland Jones SL, 2000). Studies done by 
(Pacanowski J et al.2001; Chehimi J et al.:2002; Donaghy H et al.2003b) showed that the 
numbers of both mDCs and pDCs are substantially reduced in the blood of patients 
infected with HIV-1 and that the DCs are functionally impaired with respect to T-cell 
proliferation and cytokine production (Macatonia et al. 1990a; Pacanowski J et al. 2001; 
Donaghy H et al. 2003b). Epithelial DCs appear to be one of the first cells infected after 
sexual transmission and transfer the virus to CD4 lymphocytes, simultaneously activating 
these cells. Such transfer may occur locally in inflamed mucosa or after DCs have matured 
and migrated to local lymph nodes. Therefore, the mechanism of binding, internalization, 
infection and transfer of HIV to CD4 lymphocytes is of great interest. 
Stebbing J et al. (2006) explained that mDCs enhance and pDCs inhibit HIV replication in 
T cells, a process mediated by different mechanisms for each DC subset: mDCs actively 
transmit HIV to T cells, and factors that are secreted during mDC maturation or after T-cell 
encounter probably do not influence this process. Secreted factors during pDC activation 
were completely responsible for the inhibition of HIV-1 infection of T cells. pDCs secrete 
high amounts of IFN-α, which inhibits HIV replication, but most interestingly, they also 
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secrete a small molecule less than 3 kDa in size that inhibits HIV replication. An interisting 
pathway that is well developed in DCs is the exogenous pathway for nonreplicating viral 
antigens to be presented on class I MHC products. This should allow DCs to stimulate 
CD8+ T cells after uptake of antibody-coated HIV-1 and dying infected T cells. 
Recently, the role of the C-type lectin DC-SIGN as a DC receptor for HIV has been 
intensively studied with in vitro monocyte-derived DCs. However, it is clear that other     
C-type lectin receptors such as Langerin on Langerhans cells and mannose receptor on 
dermal DCs are at least equally important for gp120 binding on epithelial DCs. Therefore, 
DC manipulation for maximal antigen presentation and TH1 cytokine production may 
form the basis of a new generation of vaccines, with improved efficacy against 
mycobacterial infections. 
Interactions between HIV-1 and the cell surface 
Exposure of DC to gp120 led to an upregulation of activation markers indicative of 
functional maturation (Manca F et al. 1994; McCarthy DA et al. 1997). Despite their 
phenotype, however, these cells retained antigen uptake capacity and showed an impaired 
ability to secrete cytokines and chemokines and to induce T-cell proliferation. HIV-1 
enters cells by direct fusion with the plasma membrane or through receptor-mediated 
endocytosis. Uptake via nonspecific endocytosis is considered to be less significant. HIV-1 
acquires surface glycoproteins including Env. Poon DTK et al. (2000) explains that Env is 
made up of the surface glycoprotein gp120SU. The gp120SU is noncovalently bound to the 
gp41TM  transmembrane protein. This complex binds to CD4 and various coreceptors, 
usually CXCR4 or CCR5 and allows for viral entry. Fusion is pH independent and 
facilitates the insertion of HIV-1 cores into the cytoplasm, which, depending upon the cell 
type, may lead to productive infection (See Figure 3.1-3.5). 
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In contrast, endocytosis can result in inactivation and concomitant degradation of virions 
within acidified endolysosomes and, in most cells, in nonproductive infection      
(Dezutter-Dambuyant C et al. 1991). In the case of mDCs, vesicular uptake of HIV-1 
primarily occurs via CD4 (which acts as an endocytic receptor) and through CLR’s such as      
DC-SIGN (McDonald D et al. 2003). Far less is known about how pDCs interact with 
HIV-1. pDCs express CD4, CXCR4, and CCR5, but not DC-specific ICAM-3–grabbing 
nonintegrin (DC-SIGN). Studies showed pDCs undergo profound activation in response to 
HIV-1 including secretion of IFN-α, which may protect pDCs and surrounding cells from 
HIV infection. 
 
Figure 3.1: HIV-1 interacts with a cell-surface receptor, primarily CD4, and become more closely associated 
with the cell by interacting with other cell- surface molecules, such as CCR5 and CXCR4. 
(Website:www.student.biology.arizona.edu) 
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Figure 3.2: The CD4 molecule on the cell surface interact with the CD4 binding site on the HIV-1 gp120.  
Website: (www.student.biology.arizona.edu) 
 
 
Figure  3.3  Changes in both the CD 4 receptor and the viral envelope allows the binding of gp120 to another 
cell surface receptor, such as CCR5.  Website: (www.student.biology.arizona.edu) 
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Figure 3.4:  After the second attachment the viral envelope and the cell surface moves closer together and 
allow interaction between gp41 on the viral envelope and a fusion domain on the cell surface. HIV fuses with 
the cell (Website: www.student.biology.arizona.edu) 
 
Figure 3.5: The viral nucleoid enters into the cell. The cycle of viral replication begins (Website: 
www.student.biology.arizona.edu) 
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C-type lectin receptors play a role in virus transfer to T cells, either with or without 
infection. Both these processes are important in vitro, and both may have a role in vivo, 
although the low-level infection of immature DCs may be more important as it leads to 
HIV strain selection and persistence of virus within DCs for at least 24 h, sufficient for 
these cells to transit to lymph nodes. The exact details of these processes are currently the 
subject of intense study. 
Groot F et al. (2006 ) have shown that during HIV infection both mDCs and pDCs are 
reduced in number, that their function is impaired, and that through C-type lectins such as 
DC-specific intercellular adhesion molecule 3–grabbing nonintegrin (DC-SIGN) they 
capture and transmit the virus at the DC–T-cell interface, the infectious synapse. 
 
Figure 3.6 mDCs enhance transmission of HIV-1 across the infectious synapse; pDCs inhibit this process via 
IFN- (Website:.http://bloodjournal.hematologylibrary.org/cgi/content/full/108/6/1785/FIG1)   
A study done by Groot F et al. (2006c) compared differently matured mDCs and pDCs 
from peripheral blood for their influence on HIV-1 infection of T cells. The study showed 
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that mDCs strongly promoted HIV-1 infection whereas pDCs severely inhibit HIV-1 
replication. The differential impact of mDCs and pDCs on HIV-1 infection may reflect the 
different location and function of these cells in the human body. The numbers of both 
mDCs and pDCs in blood of HIV-1–infected patients are reduced. (See Figure 3.6) 
3.4 DCs that attack cancer: 
DCs, located in most tissues of the body, capture and process antigens, which are then 
displayed as MHC-peptide complexes on the DC surface. This works well against foreign 
cells that enter the body, but cancer cells often evade the self/non-self detection system 
(Amigorena S et al. 1998). In most cases, tumour rejection is initiated by CD8+ cytotoxic  
T lymphocytes (CTLs), which infiltrate solid tumours, recognize tumour antigens, and kill 
tumour cells (Ashley D et al. 1997; Boczkowski et al. 2000; Dallal et al. 2000).  
Tumor antigens are presented by MHC I or MHC II molecules on the surface of tumor 
cells. These antigens can sometimes be presented by tumor cells and never by the normal 
ones. In this case, they are called tumor-specific antigens (TSAs) and typically result from 
a tumor specific mutation. More common are antigens that are presented by tumor cells 
and normal cells, and they are called tumor-associated antigens (TAAg). Cytotoxic            
T lymphocytes that recognized these antigens may be able to destroy the tumor cells before 
they proliferate or metastasize. 
Ardavan et al. (2004) explains that immunotherapy in cancer builds a cancer specific 
immune response that will help the patient to fight cancer. By modifying DCs, researchers 
are able to trigger a special kind of autoimmune response that includes a T cell attack of 
the cancer cells (Colaco CA. 1999; Nouri – Shirazi M et al. 2000). Only mature DCs can 
present the tumour antigens to the T cells. When the DC begins to mature, it also starts 
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moving, or migrating toward a lymph node. The lymph nodes contain large numbers of 
lymphocytes (T cells). The neck, armpits, and groin areas all have clusters of nodes that lie 
close to the skin. Essential co-stimulatory molecules are upregulated on DCs as they 
migrate to secondary lymphoid organs (the spleen and lymph nodes) where they liaise with 
naïve T cells, inducing the activation and proliferation of Ag specific CTLs. The CTLs are 
the body's main defense against tumour cells. When the right CTL comes in contact with 
the DC, it will become activated and begin to proliferate, ready to kill any cancerous or 
pre-cancerous cell. The CTLs arrest in close contact to tumour cells, expressing their 
cognate antigen. In regions where most tumour cells are dead, CTLs resume migration, 
sometimes following collagen fibers or blood vessels. CTLs also infiltrate tumours in 
depth, but only when the tumour cells express the cognate CTL antigen. In tumours that do 
not express the cognate antigen, CTL infiltration is restricted to peripheral regions, and 
lymphocytes neither stop moving nor kill tumour cells (Fong L et al. 2000; Gabrilovich DI 
et al. 1996). Antigen expression by tumour cells therefore determines both CTL motility 
within the tumour and deep tumour infiltration.  
Effective DC function in cancer involves several interlinked biological processes that 
occur in sequence (Vicari AP et al. 2004). 
(a) TAAg presentation and recognition in tissues which involves proteolytic intracellular 
cleavage and peptide surface representation. 
(b) DC activation and trafficking to regional tumour-draining lymph nodes (LNs), and 
interaction with CD4+ T cells via the TCR and associated co-stimulatory molecules (CD40, 
CD80 and CD86), resulting in the generation of Ag-specific CTLs, and 
(c) migration of CTLs to the tumour site and induction of cancer cell death. 
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3.5 Materials and Methods 
3.5.1 Method for identification of DCs:  
Source of blood samples: 
Heparinized blood samples were collected from 10 healthy individuals, 10 HIV+ patients, 
5 patients with HIV and TB and 5 patients with lymphoma. In the case of the different 
disease groups, routine blood samples were obtained from the NHLS laboratory at 
Tygerberg hospital. These samples had been drawn for routine cilincal management of the 
respective patients and the remaining volumes were going to be discarded. No patient 
demographics of any blood samples were recorded. All samples were coded. The samples 
were nonselected and randomly chosen. Two samples were used frompatients seen in the 
private sector: these patients gave consent for a project to measure immune markers in 
response to photo-therapy. The SAMA reference number for this study is WYE001/006 (6 
Sept.06).The 10 normal individuals were healthy volunteers. 
 
 Blood were collected in EDTA and heparinized tubes. Monoclonal antibodies (obtained 
from Becton Dickinson) were added to 100µl of the individual’s blood. Following an 
incubation of 15 minutes, red blood cells were lysed and the white blood cells were washed 
and fixed with paraformaldehyde. Prepared samples were acquired on a flow 
cytometer(BDTM FACSCalibur). CellQuest™ software was used for acquisition with a 
threshold set on FSC to exclude debris. DCs occur with low frequency in peripheral blood. 
To make sure enough DCs were acquired a minimum of 2000 events in Gate 2 were 
acquired. In the case of mDCs Gate 2 was set on CD11c APC and in the case of pDCs Gate 
2 was set on HLA-DR PerCP. pDCs are CD11c negative but HLA-DR positive. 
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Preparation of working solutions: 
Sterile Phosphate buffered saline (PBS) 
• 1L Schott bottle was filled with double distilled water and autoclaved 
• One bottle Dulbecco’s phosphate buffered saline (obained from Sigma Aldrich) was 
added to the 1L of  autoclaved water and stored at 4OC 
 
FACS lysing solution (10x concentrate) 
• Lysing solution is used for lysing red blood cells following direct immunofluorescence 
staining of human peripheral blood cells with monoclonal antibodies. It lyses 
erythrocytes under gentle hypotonic conditions while preserving the leucocytes. 
• FACS lysing solution contains <15% formaldehyde and< 50% diethylene glycol 
• Lysing solution was diluted 1:10 with distilled water (e.g. 10ml FACS lysing + 90ml 
      (distilled water) 
• The working solution can be stored at room temperature for up to 1 month 
 
5% Fixative: 
• Paraformaldehyde (obtained from MERCK) was diluted 1:20 with PBS (e.g. 5ml  
      paraformaldehyde + 95ml PBS) and stored at room temperature for up to 1 month 
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Method: 
The recommended amount of antibodies (See Table 3.1) and 100 µl heparinized whole 
blood were mixed together in Falcon Tubes. Tubes were incubated for 15 minutes at room 
temperature in the dark and 2ml of FACS Lysing Solution were added to each tube. Tubes 
were vortexed and incubated for 10 minutes at room temperature in the dark. Tubes were 
centrifuged at 1800rpm for 5 minutes and the supernatant was discarded. Tubes were 
vortexed gently to resuspend the pellet and 1 ml PBS was added to each tube. Tubes were 
centrifuged again at 1800rpm for 5 minutes, the supernatant discarded and the pellet of 
cells was resuspended in 500 µl of 5% paraformaldehyde. Tubes were analyzed on a FACS 
Calibur Flow cytometer. 
 
Data Acquisition and Analysis: 
CaliBRITE™ beads and FACSComp™ software were used to adjust the 
photomultiplier tube (PMT) voltages and fluorescence compensation, and to check the    
sensitivity of the instrument. Prepared samples were acquired on a flow cytometer. 
CellQuest™ software was used for acquisition with a threshold on FSC to exclude debris. 
DCs occur with low frequency in peripheral blood. To make sure enough DCs were 
acquired a minimum of 2000 events in Gate 2 were acquired. In the case of mDCs, Gate 2 
was set on CD11c APC and in the case of pDCs, Gate 2 was set on HLA-DR PerCP. pDCs 
are CD11c-, but HLA-DR +. The same software was used for data analysis.  
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Table 3.1 Mixture of monoclonal antibodies used for the identification and 
maturation markers on DCs 
 
TUBE 
NUMBER 
 
Mixture of Monoclonal 
Antibody 
 
Functional Subset 
 
1 20µl CD80  – FITC     
20µl HLA DR – PerCP 
20µl CD123 – PE 
5µl CD11c – APC 
 Maturation status of 
pDCs/mDCs 
 
2 20µl CD83  – FITC     
20µl HLA DR – PerCP 
20µl CD123 – PE 
5µl CD11c – APC 
Maturation status of  
pDCs/mDCs 
 
3 20µl LIN 1  – FITC     
20µl HLA DR – PerCP 
20µl CD123 – PE 
5µl CD11c – APC 
 Identification of 
pDCs/mDCs 
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3.6 Results: 
Flow cytometric results: 
Identification: 
Fig 3.7 demonstrates the dot plots used for the identification of mDCs and pDCs. 
Primary gating strategy (FSC vs SSC) was used to yield gate 1 (R1) which include 
all lymphocytes and monocytes. Secondary gating on HLA R indicated all activated 
lymphocytes. CD11c and CD123 were used for the identification of mDCs and 
pDCs. 
      
    
Data.001
10 0 10 1 10 2 10 3 10 4
LIN1 FITC
 
 
 
         
 
Data.002
10 0 10 1 10 2 10 3 10 4
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Data.005
100 101 102 103 104
HLA DR PERCP
R2
Data.006
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FSC-Height
R1
Figure 3.7: Example of DC identification. Dot plot A indicates the gating strategy (FSC vs SSC) 
used to yield gate 1 (R1) within which the expression of HLA-DR by all activated lymphocytes is 
measured. (Dot plot B). Dot plot C indicates the CD 123/CD11c expression by DCs . mDCs are 
CD11c+/ CD123-. pDCs are CD11c-/ CD123+. Dot plot D indicates different types of lymphocytes. 
DCs are lin 1- while all the other lymphocytes are lin1+. 
B 
D 
A 
C 
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Maturation markers: 
Figure 3.8 demonstrated the dot plots used to determine the maturation status of 
mDCs and pDCs. Primary gating strategy (FSC vs SSC) was used to yield gate 1 
(R1) which include all lymphocytes and monocytes. Secondary gating on HLA DR 
for pDCs and CD11c for mDCs was used to identify the DCs. In these gates the 
maturation status of the DCs were measured looking at CD80 and CD83. 
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Figure 3.8: Dot plot A indicates the gating strategy (FSC vs SSC ) used to yield gate 1 (R1) which include 
lymphocytes and monocytes. Dot plot B indicates a secondary gate on CD11c  and Dot plot C indicates a 
secondary gate on HLA DR Dot plot D and E represent the mature mDCs which are CD80+ HLA DR+ and 
CD83+ HLA DR+.. Dot plots F and G represent the mature pDCs which are CD80+ CD123+ and CD83+ 
CD123. 
C B 
F GED
A 
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This method used is a simple four colour method for the identification of the major subsets 
of DCs in whole blood using commercially available reagents. To make sure enough DCs 
were acquired a minimum of 2000 events in Gate 2 were acquired. The same software 
(CellquestTM) was used for data analysis. In the case of mDCs, Gate 2 was set on CD11c 
APC and in the case of pDCs, Gate 2 was set on HLA-DR PerCP. pDCs are CD11c-, but 
HLA-DR +. The same software was used for data analysis.  
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Statistical analysis of data: 
An unpaired t test was used for the analysis of data sets. All results were considered 
statistically significant when p< 0.05. All groups were compared to the normal 
group.Ranges were determined for mDCs and pDCs as well as the maturation markers, 
CD80 and CD83, for both pDCs and mDCs. (See Table 3.2) 
Table 3.2 Normal reference ranges  
Type of DC and maturation 
markers  
Normal range obtained 
from 10 healthy 
individuals (%) 
Myeloid DCs 1.7-19.41 
CD80 (mDCs) 1.3 – 8.19 
CD83(mDCs) 6.24 – 21.49 
Plasmacytoid DCs 0.86-7.74 
CD80 (pDCs) 0.0 -9.75 
CD83(pDCs) 0.39-5.5 
 
Since there is no published reference ranges for CD80 and CD83, we created these  
ranges above from the data obtained from the 10 normal individuals. Interestingly enough 
Della Bella S et al. 2006 analysed the number and phenotype of DCs in peripheral blood 
from 70 healthy subjects. Their results showed that the mean %mDCs was 16.50% and the 
%pDCs 7.2%.These data fits in with the ranges obtained in table 3.2 in this study. 
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Results of measurement of DCs in blood from patients with different diseases: 
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Figure 3.9: Myeloid DCs in peripheral blood from individuals with different diseases.  
Significant columns are indicated with 
Figure 3.9 indicates the measurement of the % mDCs in different diseases. The average 
% mDCs in each group were 6.4% (Normal), 1.47% (HIV), 13.5% (HIV+TB) and 6.92 
% (Cancer). The % mDCs were increased in the case of HIV with TB (n=5) and 
decreased in the case of HIV (n=10). 
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Figure 3.10 %CD80 expressed by myeloid DCs in peripheral blood from individuals 
with different diseases.  Significant columns are indicated with 
 
Figure 3.10 indicates the measurement of CD80 expression by mDCs. The average 
expression of CD80 in each group was 6.4% (Normal), 9.8% (HIV) and 26.8% (HIV+TB) 
and 4.3% (Cancer). The expression of CD80 was increased by HIV+TB (n=5) (p<0.001). 
The HIV (n=10) group also showed a slight increase in the expression of CD80 (non 
significant). Percentage values were calculated from average values and compared to the 
normal samples (n=10). 
 
p<0.001 
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Figure 3.11 % CD83 expressed by myeloid DCs in peripheral blood from individuals 
with different diseases.  Significant columns are indicated with 
 
Figure 3.11 indicates the regulation of CD83 expression by mDCs in different diseases. 
The average expression of CD83 in each group was 6.5% (Normal), 14.2 % (HIV), 
26.8% (HIV+TB) and 10.5 % (Cancer). The expression of CD83 was upregulated by 
HIV+TB (n=5) (p=0.001) and the HIV group (n=10) (non significant) and cancer (n=5) 
(non significant) showed a slight increase in the expression of CD83. 
 
 
 
 
 
 
 
 
 
 
p=0.001 
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Plasmacytoid DCs:      
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Figure 3.12 Plasmacytoid DCs in peripheral blood from individuals with different 
diseases.   
 
Figure 3.12 indicates the % pDCs cells measured in the peripheral bloods of patients 
diagnosed with different diseases: the average % in each group were 3.6% (Normal), 
2.6% (HIV), 1.98% (HIV+TB) and 1.53% (Cancer). The % pDCs cells was slightly 
decreased in the case of HIV (n=10), HIV+TB (n=5) and Cancer (n=5), but these were 
not significantly different when compared to the normal controls.  
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Figure 3.13 %CD80 expressed by plasmacytoid DCs in peripheral blood from 
individuals with different diseases.  Significant columns are indicated with 
 
Figure 3.13 indicates the measurement of CD80 expression by pDCs .The average 
expression of CD80 in each group were 3.3% (Normal), 0.82% (HIV), 2.76% (HIV+TB) 
and 1.52% (Cancer). The expression of CD80 was significantly (p=0.02) decreased not 
only by HIV (p=0.02) (n=10), but also the cancer (n=5) (non significant) group showed a 
decrease in CD 80 expression. 
 
 
 
  
p=0.02 
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Figure 3.14 %CD83 expressed by plasmacytoid DCs in peripheral blood from individuals  
with different diseases.  Significant columns are indicated with 
 
Figure 3.14 indicates the regulation of CD83 expression by plasmacytoid DCs in 
different diseases. The average expression of CD83 in each group were 2.23% (Normal), 
1.36 % (HIV), 4.69 % (HIV+TB) and 1.86 % (Cancer).The expression of CD80 was 
significantly upregulated (p=0.03) by HIV+TB (n=5) and the HIV (n=10) (non 
significant) and cancer (n=5) (non significant) group showed a slight decrease in the 
expression of CD83.  
 
 
 
 
 
 
 
 
p=0.03 
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3.7 Discussion 
 
This study showed that both mDCs and pDCs can be identified in peripheral blood by 
making use of a quick and easy method. We identified both types of DCs in the peripheral 
blood of 10 normal healthy individuals  and in the peripheral blood of patients presenting 
with different diseases. A normal reference range was determined after analyzing the data 
of the normal individuals (See Table 3.2). The data of the different disease groups were 
compared to the normal group. The first disease we look at was HIV. Several studies have 
shown that during HIV infection, both DC subsets are reduced in the blood. (Donaghy H et 
al. 2006c; Schmidt B et al. 2006b) showed in their study that pDCs and mDCs are reduced 
in AIDS patients. The results from this study also showed a decrease in the  
% mDCs (p=0.006) and % pDC (although non significant) in HIV infection.             
Meyers JH et al. (2007) showed in their study that the levels of pDCs present in blood 
from HIV-infected volunteers were significantly lower than those of HIV-negative 
individuals. They also suggest in this study that HIV-infected cells may also directly fuse 
with and kill pDCs, which could explain the decrease of pDCs in HIV. The maturation 
markers done on mDCs showed a slight increase in both the % CD80 and % CD83. Piguet 
V and Steinman RM (2007) explained in their study that HIV-infection of DCs does not 
lead to maturation, but in cases of high viral loads maturation of DCs can occur. This 
statement might explain the slight increase in maturation markers in the HIV group. In this 
study the viral loads were unknown, but it might have influenced the increase in 
maturation markers.  
 
Fonteneau JF et al. (2004) demonstrated in his study that the mDC do not mature upon 
contact with HIV-1, but they do mature indirectly as a consequence of the production of 
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cytokines by HIV activated pDCs. The maturation status of the pDCs in this study was 
lower than the normal (% CD80: p=0.02). We also looked at the correlation between the 
CD4% and the %mDC or %pDC. The correlation was non significant. Further studies need 
to be done on HIV to make final conclusions. In this study we had no background or 
treatment status of the patients (n=10). A more specific study will show more accurate 
results. Blocking DC-SIGN-mediated capture of HIV represents a potential therapeutic 
antiviral strategy for HIV disease. An intriguing pathway that is well developed in DCs is 
the exogenous pathway for non replicating viral antigens to be presented on class I MHC 
products. This should allow DCs to stimulate CD8+ T cells after uptake of antibody-coated 
HIV-1 and dying infected T cells. 
The second group of patients were only discovered when we recruited blood to test DC 
subsets in HIV: the results of these patients looked different and it was discovered that 
these patients were HIV+ and had clinical signs of active TB (diseased). Although a small 
group (n=5), the results were interesting. The % mDC (p=0.02) and % pDC (although non 
significant) showed an increase in the peripheral blood when compared to the healthy 
controls. The maturation markers % CD80 (p<0.001) and % CD83 (p=0.001) in mDCs 
were increased. In the case of pDCs maturation markers % CD83 (p=0.003) were increased 
and the % CD 80 were almost the same as that of the control group. The % CD80 in case 
of HIV and TB was higher than in the HIV only group, which showed that TB does play a 
role in the maturation of DCs. Several in vitro and in vivo studies, in mice and rats, have 
shown that DCs can be activated upon infection with various mycobacteria, including      
M. tuberculosis and the vaccine strain M. bovis BCG (Henderson RA et al.1997). 
Mycobacteria-activated DCs express surface presentation, co-stimulation and migratory 
molecules (Kim et al.1999). Animal studies done showed mycobacteria-infected DCs can 
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stimulate mycobacterial antigen-specific T cells in vitro, and confer protection against 
mycobacteria. In vivo, it is likely that mycobacteria-infected DCs can stimulate the 
development of IFN-γ-secreting T cells, essentially through the secretion of IL-12.  
In the case of cancer we only recruited 5 patients with lymphoma. Lymphomas fall into 1 
of 2 major categories: Hodgkin lymphoma/disease and other lymphomas (non-Hodgkin 
lymphomas/NHL). Hodgkin disease develops from a specific abnormal B lymphocyte 
lineage. NHL may derive from either abnormal B or T cells and are distinguished by 
unique genetic markers. Lymphoma can occur at any age, including childhood. Hodgkin 
disease is most common in 2 age groups: young adults aged 16-34 years and in older 
people aged 55 years and older. Non-Hodgkin lymphoma is more likely to occur in older 
people. The results of this study showed that the % mDCs and % pDCs in this group were 
in the same range as the normal group or slightly decreased. Esche C et al. (1999) and 
Timmerman JM et al. (1999) proved in their studies that cancers are able to escape from 
the immune system by several mechanisms, for example, by inducing apoptosis in DCs so 
that they are unavailable to generate a productive immune response. 
The maturation markers done on mDCs showed a slight increase in the % CD83. The 
results were very similar to those of the normal group. The % CD80 showed a slight 
decrease compared to the normal group, but it was not significant. The results of the  
% pDC and the maturation markers done on the pDC showed a decrease. Smyth MJ              
et al. (2001) explains an important property of tumour cells is that they typically do not 
release danger signals so that even if immature DCs take up and process tumour antigens 
or apoptotic tumour cells, they may fail to mature. The study of DCs and DCs maturation 
in different diseases needs further investigation: more sample numbers and better defined 
patient groups. 
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Chapter 4 
In vitro activation of dendritic cells using a Mixed killed  
Bacterial Vaccine (MBV) 
 
Abstract: 
This chapter describes a flow cytometric method to measure the activation and 
maturation status of DCs. In this study, we investigated the response of human DCs 
to MBV and LPS. Previous studies showed DCs could be activated using killed 
Streptococcus pyogenes. With this study in mind it was hypothesized that the MBV 
used in this study might modulate DC maturation. The results of this study showed 
that the MBV did indeed induce the maturation of both pDCs and mDCs as measured 
by increased surface expression of costimulatory molecules such as CD80 and CD83.  
Interactions between DCs and microbial pathogens are fundamental to the generation 
of innate and adaptive immune responses. Upon the activation and stimulation with 
bacteria or bacterial components such as lipopolysaccharide (LPS), immature DCs 
undergo a maturation process that involves expression of costimulatory molecules, 
HLA molecules, and cytokines and chemokines, thus providing critical signals for 
lymphocyte development and differentiation.  
 
4.1 Introduction 
DCs express costimulatory molecules including CD80 and CD86, (Chow A et al. 2002) 
which are up-regulated during DC activation. CD86 is a marker of early DC maturation, 
while CD80 only appears in mature DCs. Two other markers for mature DCs are CD83 
and CMRF-44. CD83 also stains activated B cells and CMRF-44 will also stain 
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macrophages and monocytes. In this study CD83 and CD80 were used as activation 
markers and LPS and TNF-α were used to stimulate mDCs and pDCs to obtain positive 
controls. Cella M et al. (1997) explains that CD80 antigen acts as the ligand for both the 
CD28 and CTLA-4 glycoproteins, which are expressed on T lymphocytes. The CD80 
antigen interacts with the CD28 and CTLA-4 glycoproteins to provide a stimulus for        
T-lymphocyte activation. The interaction of the CD80 and CD28 antigens mediates 
heterotypic cell adhesion and also results in augmentation of T-lymphocyte proliferation 
and cytokine production. The ligation of the CD80 and CD28 antigens also enhances 
cytotoxic effectors of cytotoxic T lymphocytes (CTL). The CD80 antigen is expressed on 
activated B lymphocytes and monocytes and is constitutively expressed on DCs. The 
CD80 antigen is also expressed on activated human peripheral blood T lymphocytes,  
CD4+ and CD8+ T-lymphocyte clones, and NK cell clones. CD3-activated T lymphocytes 
are able to induce normal or leukemic B lymphocytes to express the CD80 antigen and 
significantly higher levels of the CD54 antigen (Hellman P et al. 2007). 
 
Along with CD86, these molecules provide the necessary stimuli to prime T cells against 
antigens presented by antigen-presenting cells. Bender A et al. (1996) states that CD83 is 
expressed on cultured DCs, interdigitating, follicular, and circulating DCs as well as some 
proliferating lymphocytes and human cell lines. CD83 serves as a useful marker for mature 
human blood DC identification. In this study LPS was used as stimulant to obtain a 
positive control for mDCs. LPS is a large molecule consisting of a lipid and a 
polysaccharide (carbohydrate) joined by a covalent bond and is a major component of the 
outer membrane of Gram-negative bacteria, contributing greatly to the structural integrity 
of the bacteria, and protecting the membrane from certain kinds of chemical attack 
(Verhasselt V et al. 1997). LPS is an endotoxin, and induces a potent response from 
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normal immune cells (de Smedt T et al. 1996). TNF-α was included in this experiment as a 
stimulant to obtain a positive control for pDCs (Nelson EL et al. 1999). TNF-α is produced 
by monocytes, macrophages and T and B cells. Yu O et al. (2003) confirmed that pDCs 
express CD80, CD86 and CD83 in the presence of TNF-α.  
The vaccine used in this study is MBV. This has previously been described. Briefly, it 
contains a mixture of different bacteria, but no phenol. The concentration of the vaccine is 
109 CFU /ml of each bacterial species listed: Staphylococcus aureus, Streptococcus 
pneumoniae, Moraxella (Neisseria) catarrhalis, Klebsiella pneumoniae, Heamophilus 
influenza, Corynebacterium diphtheria, Streptococcus pyogenes, Pseudomonas 
aeruginosa, Proteus vulagaris, Proteus mirabilis, Candida krusei and Candida albicans  
4.2 Materials and methods: 
4.2.1 Study design:  
Seeing that the effect of the MBV on DCs is unknown, we had to determine which 
concentration of the vaccine works the best as well as to determine the kinetics of 
activation. Five milliliter Heparinized blood samples were collected from 2 healthy 
individuals. A dose response of the MBV was done to determine the optimal activation of 
the vaccine. Human mononuclear cells are often required in order to conduct specialized 
assays. The Peripheral Blood Mononuclear cells are therefore isolated from the remaining 
blood elements by density gradient centrifugation. The isolated cells were incubated with 
different concentrations of the MBV and incubated for 8, 12 and 24 hours. Cells were 
centrifuged and the supernatants removed. The supernatants were stored at -20°C for 
cytokine detection as described in chapter 6. Monoclonal antibodies to CD80 or CD83 
were added to the cells to determine the activation and maturation status of the DCs. 
Prepared samples were acquired on a flow cytometer (BDTM FACSCalibur). CellQuest™ 
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software was used for acquisition with a threshold on FSC to exclude debris. Since DCs 
cells occur with low frequency in peripheral blood, we acquired a minimum of 2000 events 
in Gate 2 in order to ensure that sufficient events were analysed. In the case of mDCs, Gate 
2 was set on CD11c APC and in the case of pDCs, Gate 2 was set on HLA-DR PerCP. 
pDCs are CD11c-, but HLA-DR +. The same software was used for data analysis.  
  
4.2.2 Preparation of reagents 
RPMI 1640 growth medium (GIBCO® 61870) (Obtained from Sigma Aldrich) 
Fetal Bovine Serum (Obtained from Adcock Ingram) (GIBCO®) (decomplemented at 56oC 
for 30 minutes in waterbath) 
Histopaque-1077 solution (Obtained from Sigma Aldrich) 
Distilled or deionized water 
 
 Sterile Phosphate buffered saline (PBS): 
 1L Schott bottle was filled with double distilled water and autoclaved 
 One bottle Dulbecco’s phosphate buffered saline (obtained from Sigma Aldrich) 
      was added to the 1L of  autoclaved water and stored at 4OC 
 
 5% Fixative: 
• Formaldehyde (obtained from MERCK) was diluted 1:20 with PBS (e.g. 5ml  
      formaldehyde + 95ml PBS) and stored at room temperature for up to 1 month 
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LPS: 
One milliliter sterile PBS was added to the stock of 1mg LPS (Obtained from Sigma 
Aldrich). We made a 1/10 dilution of the stock solution (50µl LPS+450µl RPMI). 20µl of 
this dilution was added to each tube for LPS. 
 
TNF-α: 
A recombinant stock solution 10 ng/ml TNF-α (Obtained from R&D Systems) was diluted 
1/10 (50µl TNF-α+450µl RPMI).Twenty mikroliter of this dilution was added to each tube 
for TNF-α activation. 
 
Preparation of MBV: 
The MBV used in this study was kindly provided by Dr. Brigitte Riedelsheimer, 
Dusseldorf, Germany.  This preparation is used clinically by oncologists in Germany to 
induce a non-specific immune response as part of their therapeutic approach to cancer 
patients.  Different concentrations of the MBV were tested to determine the optimal dose 
for the in vitro activation and maturation of DCs: please refer to Table 4.1 for the 
preparation of the different concentrations of the MBV  
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PBMC preparation 
Principle of density gradient centrifugation: 
The density of human mononuclear cells is 1.077 g/L. When diluted blood is layered onto 
a complex carbohydrate solution having the exact density as that of the cells, followed by 
centrifugation, the cells with the identical density will be “trapped” at the interface 
between the blood and the carbohydrate solution and not move further into the solution.  
All other blood elements with higher densities will travel through the interface and settle at 
their respective densities (including red blood cells, granulocytes, etc). The cells of interest 
can be easily recovered at the interface, washed and used in subsequent assays or stored for 
later usage (See Figure 4.1) 
 
Method for PBMC preparation: 
 
The procedure should be performed in a biosafety cabinet under sterile conditions. Three 
15ml sterile conical tubes per sample were labeled as “Ficoll”, “PBS”, “Lymphocytes” 
respectively. The Histopaque-1077 (Ficoll) was allowed to reach room temperature and 
4ml were added to the 15ml sterile conical tube labelled as “Ficoll”. Five milliliter 
Heparinized whole blood was mixed by inverting the tube several times. The blood was 
transferred to another sterile conical tube labelled as “PBS” and double diluted in the 
conical tube with sterile PBS by mixing it gently. The diluted blood was carefully layered 
onto the Ficoll solution and centrifuged at 1800rpm at 4OC for 25 minutes. After the 
centrifugation, the mononuclear cells formed a visible, clear interface between the Ficoll 
and the plasma.The plasma layer was removed and the mononuclear cell layer was 
transferred to a sterile 15 ml conical tube labelled as “Lymphocytes” using a sterile Pasteur 
pipette. The tube was filled with sterile PBS, capped and centrifuged for 15 minutes at 
1500rpm.The supernatant was removed and discarded. Tubes were vortexed and the tube 
filled with sterile PBS and centrifuged again at 1800rpm for 10 minutes. After the 
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centrifugation, the supernatant was removed and discarded. Tubes were vortexed and 1 ml 
of RPMI growth medium containing 10% Fetal Calf Serum was added to each tube. 
Twenty microliter of the cell suspension was added to 180 µl of Trypan blue and 10µl of 
the trypan blue/cell mixture was placed beneath the cover slip on a Haemocytometer. The 
lymphocyte count was done under a microscope to determine the concentration of the cells. 
The cells were made up to a final concentration of 1 x 106cells/ml. 
  
 
Figure 4.1 These photos show the different layers that forms after loading the diluted blood on Histopaque-
1077 and centrifuging. (Taken 22 March 2007 10:00) 
 
 
 
 
 
 
 
 
Plasma/PBS 
mixture 
Interface layer of 
mononuclear cells 
Histopaque-1077 
RBC’s/Granulocytes 
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4.3 Dose response of MBV 
Three sets of 7 Falcon tubes (Obtained from BD Biosciences) were labelled and the 
following added to each tube (See Table 4.1) 
Table 4.1: 
Tube number 
and contents 
Cells at 
concentration of 
1x106cells/ml 
Volume of 
MBV/LPS/TNF-α 
Volume of 
RPMI 
1 : Unstim 500µl 0 500µl RPMI 
2 : LPS 500µl 20µl LPS  (2µg/ml) 480µl RPMI 
3. TNF-α 500µl 20µl TNF-α  (0.2µg/ml 480µl RPMI 
4: 1/10 500µl 50µl MBV 450µl RPMI 
5: 1/50 500µl 10µl MBV 490µl RPMI 
6: 1/100 500µl 5µl MBV 495µl RPMI 
7: 1/200 500µl 2.5µl MBV 497.5µl RPMI 
 
One set was incubated for 8 hours, one for 12 hours and one for 24 hours. After the desired 
incubation periods, the cells were centrifuged at 1800rpm for 5 min. The supernatant was 
aspirated and put in cryovials and kept frozen at -20°C: these were used to determine 
cytokine production as described in chapter 6. One ml PBS was added to the cells in each 
tube. The cells were vortexed and used for the measuring of activation/maturation markers 
following the staining of the surface activation markers as described below. 
 
The recommended amount of antibodies (same as used in chapter 3 to identify the DCs) 
and 100 µl of the cultured PBMC’s were mixed together in two Falcon Tubes. The LIN 1 
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cocktail was not included in this study, because of lack of funds. Tubes were incubated for 
15 minutes at room temperature in the dark and 2ml of FACS Lysing Solution were added 
to each tube. Tubes were Vortexed and incubated for10 minutes at room temperature in the 
dark. Tubes were centrifuged at 1800 rpm for 5 minutes and the supernatant was discarded. 
Tubes were Vortexed gently to resuspend the pellet and 1 ml PBS was added to each tube. 
Tubes were centrifuged again at 1800rpm for 5 minutes, the supernatant discarded the 
pellet of cells was resuspended in 500 µl of 5% paraformaldehyde. Tubes were analyzed 
on a FACS Calibur Flow cytometer. 
 
4.4 Data Acquisition and Analysis: 
CaliBRITE™ beads and FACSComp™ software were used to adjust the 
photomultiplier tube (PMT) voltages and fluorescence compensation, and to check the    
sensitivity of the instrument. Prepared samples were acquired using the CellQuest™ 
software with a threshold set on FSC to exclude debris.  
 
4.5 Results:  
4.5.1 Flow cytometric analysis of mDCs post MBV activation: 
Data analysis showed that the MBV did induce the expression of CD80 and CD83 on both 
mDCs and pDCs and does play an important role in DC maturation. An unexpectedly high 
background was found of the unstimulated sample: we detected relatively high CD80+ and 
CD83+ events in the unstimulated samples although the stimulated samples showed even 
higher positive events. The only explanation that we can propose is that due to the fact that 
we used PBMC’s to measure the maturation of DCs, these cells could have possibly been 
activated indirectly during the sample preparation. It is difficult to study DC in fresh 
peripheral blood since these cells are far outnumbered by lymphocytes and monocytes and it 
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is known that monocytes can become activated by the plastic tube during cell separation 
(plastic adherence) and secrete cytokines that can induce the maturation of DCs. What we 
were seeing in the unstimulated samples could in fact be a representation of indirect DCs 
activation. Measurement of cytokine release (as reported in chapter 6) seems to confirm in 
vitro activation of these cultures. The results in chapter 6 showed an increased secretion of 
cytokines in the Unstimulated cultures. This is however speculative.Test done at local 
laboratories showed that less than one in three batches Heparin Vacuum Tubes are not 
contaminated with LPS which causes DC maturation (Dr. E. Pool, personnal 
communication). This could be an explanation why the unstimulated values for the dose 
response could be higher than the unstimulated values tested for the 10 normal individuals.  
We used two different batches during the period of blood draw.  
 
An example of the dose-response of the DCs to the MBV is shown in Figure 4.2.  It is 
clearly visible that although the unstimulated cultures exhibited raised CD80+ cells, those 
cultures which had received the stimulus showed even higher values, and this data was 
statistically significant as indicated. Tkachenko N et al. (2005) tested different culture 
media for the generation of DCs and discovered that the growth and maturation of DCs in 
culture can be influenced by a variety of factors. In this study they claim that media 
supplemented with FCS can influence the DC maturation. FCS contains endotoxin, for 
example LPS, which can activate the DCs, even though the concentrations are very low.     
 
Another possible explanation for the high percentages of activated DCs detected in the 
unstimulated preparations is that these cells could have become “enriched” during the 
culture period.  It is plausible that during the culture, cells such as lymphocytes and 
monocytes died leaving increased (relative to the other cell populations) numbers of DCs 
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in the gated area). Since the purity of the gated cells at the end of the culture period was 
not verified using specific monoclonal antibodies to lymphocytes and monocytes, this 
cannot be stated with certainty. This rationale is based on the fact that during lymphocyte 
cultures, there is a natural enrichment which takes place due to the selection of the 
activation stimulus such as the mitogen or antigen used. 
 
It must also be brought to the attention of the reader that the culture of the DCs with the 
MBV induced various amounts of debris: in the 12 and 24 hours cultures, the primary 
gating proved difficult at times and although it may appear that the 12 or 24 hours induced 
the highest expression of the activation markers, it was decided to analyse only the 8 hour 
data: this showed that the 1/50 dilution of this stimulus induced the highest CD80 and 
CD83 expression on the DCs. In parallel, LPS which was used as a positive control proved 
to be able to induce very high levels of the activation markers (Figure 4.4). The results for 
the maturation markers obtained during the dose reponse were higher than the results 
obtained from the 10 healthy volunteers. The only explanation for this is the group size. 
The dose response was done on only two individuals. 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
114 
 
 
 
 
 
%CD80:Myeloid dendritic cells
US LP
S
1/
10
1/
50
1/
10
0
1/
20
0
US LP
S
1/
10
1/
50
1/
10
0
1/
20
0
US LP
S
1/
10
1/
50
1/
10
0
1/
20
0
0
20
40
60
80
8
12
24
[MBV]
%
CD
80
 
 
Figure 4.2 Representative data of the dose response of MBV to induce the expression of CD80 
by myeloid DCs after 8, 12 and 24 hours incubation.  
 
Statistical analysis of dose reponse data: 
For the analysis of the dose response data we used a Paired T test. All results 
were considered statistically significant when p< 0.05. All groups were 
compared to the unstimulated group to see the effect of the mixed killed 
bacterial vaccine. 
Table 4.2 
Statistical analysis of 8 hour dose response: CD80 mDCs 
Unstim vs LPS p =0.013 
Unstim vs 1/10 p =0.012 
Unstim vs 1/50 p<0.05 
Unstim vs 1/100 p<0.05 
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To confirm the data of the dose response blood was drawn from 10 normal healthy 
individuals. Samples were treated the same as in the dose response method 
explained above. We decided to use the 1/50 dilution of the MBV. Cells were 
incubated for 8 hours with medium, TNF-α, LPS and MBV. TNF-α was included 
in this experiment as a positive control for pDCs and LPS as a positive control for 
mDCs. The data from the individual groups were analysed by the Wilcoxon 
matched paired test and the results were considered statistically significant when   
p< 0.05. All groups were compared to the unstimulated group to see the effect of 
the MBV: the presence of MBV significantly influenced the maturation status of 
DCs in vitro. The MBV showed a very significant increase in both the % CD83 
(p=0.002) and % CD80 (p=0.002) expressed by mDCs. It also appears that the 
 % mDCs increased significantly (p=0.04) but as explained earlier, this was 
possibly due to the “enrichment” of these cells during the culture period (Figure 
4.3) 
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Figure 4.3 Data from healthy individuals (n=10) stimulated with MBV to measure the percentage myeloid 
DCs after 8 hour incubation.  Significant values are indicated with 
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From Figure 4.3 above, the % mDCs in each group were 5.7% in the unstimulated 
cultures, 8.2% (LPS stimulated) and 7.4% (MBV stimulated). This increase in the % 
mDCs may be due to enrichment of Gate 2 (as explained earlier).  This data just confirms 
the results of the dose response done above: 1/50 dilution of the MBV was used and the 
cells were incubated for 8 hours after which they were stained for the cell surface 
expression of the activation markers.As shown in Figure 4.4, mDCs incubated with the 
MBV were induced to express high levels of the CD80 antigen.   
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Figure 4.4 Data from healthy individuals (n=10) stimulated with MBV to measure the expression of CD80 
by myeloid cells after 8 hour incubation.  Significant values are indicated with 
 
The expression of CD80 in each group was 4.3% (unstimulated cells), 20.6% (in cultures 
incubated with LPS) and 23.4% (MBV-induced expression).  The expression of CD80 was 
up-regulated not only by LPS (p=0.002) but also by the MBV (p=0.002) when this was 
compared to the unstimulated cultures. It was interesting to note that the MBV group of 
cultures showed a higher %CD80 expression than the LPS group: this could be due to the 
mixture of bacteria used rather than a single preparation of endotoxin. 
 
p=0.002 
 p =0.002 
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Similarly, when the expression of CD83 activation marker was analysed, the MBV 
induced high levels of this marker (Figure 4.5).  After incubation at 37°C for 8 h, cells 
were harvested and the expression of cell surface antigens was analyzed by FACS 
analysis. The average expression of CD83 in each group was 13.5% (US), 27.4% (LPS) 
and 28.9% (MBV). The expression of CD83 was up-regulated not only by LPS 
(p=0.002), but also by the MBV (p=0.002).  
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Figure 4.5 Data from healthy individuals (n=10) stimulated with MBV to measure the expression of CD83 
by myeloid cells after 8 hour incubation. Percentage values were referenced against the unstimulated 
samples. Significant values are indicated with  
 
4.5.2 Flow cytometric analysis of pDCs post MBV activation  
 
By using the different set of monoclonal antibodies which identified the pDCs, it was 
possible to show that the presence of MBV significantly influenced the maturation status 
of pDCs in vitro. The MBV induced a very significant increase in both the % CD83 
(p=0.004) and % CD80 (p=0.004) expression by pDCs. Once again, we observed a relative 
increase in the pDCs after the culture periods (Figure 4.6) and the same explanation as 
provided above refers: this could be due to an in vitro “enrichment” during the culture 
p=0.002 p=0.002 
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period and it seems as if more pDCs are obtained after the incubation.  This is not feasible 
due to the fact that these cells do not proliferate.  From this figure, it appears that the 3.2% 
pDCs in the unstimulated almost doubled in the presence of TNF-α (5.4%) or MBV 
(6.9%) and these were statistically significant (p=0.01). 
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Figure 4.6 Data from healthy individuals (n=10) stimulated with MBV to measure the %plasmacytoid DCs 
after 8 hour incubation. Significant values are indicated with 
 
 
Despite the above, the analysis of the cells following the incubation using the different 
stimuli revealed an increased/upregulated expression of the markers indicating 
maturation.  After incubation at 37°C for 8h, cells were harvested, and the expression of 
cell surface antigens was analyzed by FACS analysis. From Figure 4.7, CD80 expression 
on TNF-α cultured cells was 5.6% (p =0.03) and those incubated in the presence of the 
MBV tested 7.1% positive (p=0.004) compared to the unstimulated cultures (2.6%).   
p=0.01 
 p=0.01 
%
p
D
C
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
119 
 
 
 
 
 
PDC:%CD80
US TN
F
MB
V
0
5
10
15
20
[MBV]
%
CD
80
 
Figure 4.7 Data from healthy individuals (n=10) stimulated with MBV to measure the expression of CD80 
by plasmacytoid DCs after 8 hour incubation.  
 
There was a similar trend for the analysis of CD83 expression (Figure 4.8):  
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Figure 4.8 Data from healthy individuals (n=10) stimulated with MBV to measure the expression of CD83 
by plasmacytoid DCs after 8 hour incubation. Significant values are indicated with 
 
After incubation at 37°C for 8 h, cells were harvested and the expression of cell surface 
CD83 expression was analyzed by FACS analysis. The average expression of CD83 in 
each group was 2.6% (US), 6.2% (TNF-α incubated cells) and 12.7% (MBV cultures). 
The expression of CD83 was up-regulated not only by TNF-α (p=0.03), but also by the 
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MBV (p=0.004). The MBV group showed a higher %CD80 expression than the TNF-α 
group.  
 
4.6 Discussion 
 
Mature DCs arise from immature precursors which are the cells that exhibit endocytic 
activity (Trombetta ES et al.2003). Maturation is a terminal differentiation process that 
transforms DCs from cells specialized for antigen capture into cells specialized for T-cell 
stimulation, (Chapuis F et al.1997; Rescigno M et al.1998) accompanied by changes in the 
expression of numerous cell-surface antigens that reflect the changing functional role of 
the cells (Reis e Sousa C et al. 2004b). Maturation is characterized by reduced phagocytic 
uptake, the development of cytoplasmic extensions or “veils”, migration to lymphoid 
tissues, and enhanced T-cell activation potential (Romani N et al. 1996b Rovere P             
et al.1998).  
It is clear that the maturation of DCs is crucial for the initiation of immunity. The 
maturation of DCs is completed only upon interaction with T cells. It is characterized by 
loss of phagocytic capacity and expression of many other accessory molecules that interact 
with receptors on T cells to enhance adhesion and signaling (co-stimulation); for example 
CD80, CD86 and CD83. Expression of one or both of the costimulatory molecules CD80 
and CD86 on the DCs are essential for the effective activation of T lymphocytes, and, for 
IL-2 production. These co-stimulatory molecules bind the CD28 molecules on                   
T lymphocytes  
The activation and maturation of DCs by bacterial products has been proven by (Nakahara 
S et al. 2003; Reis de Sousa C et al. 2003a). With this study in mind it was hypothesized 
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that the MBV used in this study might modulate DC maturation. This study determined the 
effects of the mixed killed bacteria at a number of concentrations on the maturation status 
of both mDCs and pDCs. The first part of the results of this study demonstrated the dose 
response done to determine the concentration that plays a significant role in the maturation 
of DCs and the incubation time needed for this. The second part demonstrated the data 
generated to confirm the data of the dose response. 
 
After incubating the DCs with different concentrations of mixed killed bacteria, the data 
after 8 hours showed the best results to measure the maturation status of the DCs. In a 
study done by Camporeale A et al. (2003) they also pulse DCs with a CTL epitope and 
showed that DCS exposed to LPS for 8 hours had a more powerful TH1 response than 
untreated DCs, or DCs exposed to LPS for 48 hours. This study showed 8 hour DCs were 
the most potent protective and therapeutic vaccine against B16 melanoma. The dose 
response also showed the scatter for primary and secondary gating after 8 hours was 
integrable and therefore we only used the 8 hour data. We found increases in the 
expression of the maturation markers CD80 and CD83 on DCs in response to stimulation 
with the MBV, LPS and TNF-α. 
 
Benvenuti F et al. (2004) showed in their study that maturation of DCs change the physical 
interaction with naïve CD 4 + T cells. Immature DCs create very short contact of low 
stability. In contrast, mature DCs created longer contacts. The mixed killed bacteria had 
significantly increased the %CD83 (p =0.004) in the case of mDCs as well as pDCs 
(p=0.002). The vaccine also increased the %CD80 expression in myeloid (p=0.002) as well 
as pDCs (p=0.004).  We also observed that, in both DC populations, CD83 expression 
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seemed higher than the CD80 expression: whether this has any significance remains 
unknown to us at present.  
With the results of the study in mind we hypothesized that the MBV could be used 
therapeutically - however this needs to be tested under clinical conditions. We know that 
the same MBV is used clinically by oncologists in Germany and that interesting clinical 
responses are observed (Dr. B. Riedelsheimer, personnal communication). It would 
however be important to test the MBV under clinical conditions in South Africa. 
Nevertheless, our hypothesis is based on the fact that the response of pDCs to the MBV 
provides a key mechanism to control the HIV infection, because a decline in pDCs in 
chronic HIV-1 infection is associated with high viral loads and opportunistic infections. 
Patterson S et al. (2001c) explains that pDCs play a big role in the antiviral immune 
responses. They recognize viral components, leading to type I interferon production, and 
affect adaptive defense strategies designed to eliminate viral pathogens. Perhaps our data 
will shed some light on the potential use of this vaccine as a form of immunotherapy. 
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Chapter 5 
In vitro activation of dendritic cells using Coley’s Toxin 
Abstract: 
This chapter describes a flow cytometric method to determine the activation and 
maturation status of DCs post activation using Coley’s Toxin.  A key aspect that 
Coley found to be necessary for tumour regression was the induction of a mild to 
moderate fever. Researchers proved that elevation in body temperature causes 
maturation of DCs in the skin and other tissues. Coley's Toxin used in this study is a 
mixture consisting of peptides of heat killed bacteria of species Streptococcus pyogenes 
as well as Serratia  liquefaciens. One of the biologically active ingredients in Coley 
toxins is  LPS. In vivo LPS induces a fever for three to four hours that enhances 
lymphocyte activity and boosts the expression of TNF-α, IL-6 and IL-1β. The 
elevation of cytokine levels such as TNF-α contributes to DC maturation.With these 
results in mind we hypothesized that the Coley’s toxin would enhance the maturation 
and activation status of the DCs in peripheral blood cells when incubated in vitro The 
results of this study showed that Coley’s Toxin did indeed induce the maturation of 
both pDCs and mDCs as measured by increased surface expression of costimulatory 
molecules such as CD80 and CD83.  
 
5.1 Introduction: 
Mature DCs arise from immature precursors which are the cells that exhibit endocytic 
activity (Trombetta ES et al. 2003). Maturation is a terminal differentiation process that 
transforms DCs from cells specialized for antigen capture into cells specialized for T-cell 
stimulation (Chapuis F et al.1997; Rescigno M et al. 1998) accompanied by changes in the 
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expression of numerous cell-surface antigens that reflect the changing functional role of 
the cells (Reis e Sousa C et al. 2004b). Maturation is characterized by reduced phagocytic 
uptake, the development of cytoplasmic extensions or “veils”, migration to lymphoid 
tissues, and enhanced T-cell activation potential (Rovere P et al. 1998; Romani N et 
al.1996b). The vaccine used in this chapter is known as Coley’s Toxin (obtained from     
Dr Brigitte Riedelsheimer) and it consist of peptides from Streptococcus pyogenes as well 
as Serratia  liquefaciens.  
 
From 1891 until his death in 1936 Coley studied malignancies and the effects of 
inoculation with live bacterial cultures. Coley developed a vaccine that consist of extracts 
of killed Gram-positive Streptococcus pyogenes and Gram-negative Serratia marcescens, 
which became known as Coley's toxin. Wieman B et al. (1994) explained that the major 
effect of Coley’s Toxin comes primarily from LPS (an endotoxin) of Gram-negative 
bacteria. Different studies showed different effects of fever on the immune response and on 
cytokine expression and function.  For instance, Van Oss CJ et al. (1980) showed in their 
study that human polymorphonuclear cells (PMN) phagocytose better in the presence of 
fever but that PMN chemotaxis is not enhanced. They also confirmed in their study that 
macrophage functions are enhanced in the case of fever, including the expression of         
Fc receptors, phagocytosis, pinocytosis and killing of intracellular bacteria. However, like 
PMNs, macrophages have markedly reduced function at temperatures > 41°C. The 
cytotoxic activity of human natural killer (NK) cells has been shown to be reduced in the 
case of fever. Basu S et al. (2003b) proved in their study that elevation in body temperature 
causes maturation of DCs in the skin and other tissues. Veckman V and Julkunen I (2007) 
showed in their study that Streptococcus pyogenes activates the maturation of both pDCs 
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and mDCs. With these facts in mind we hypothesized that the Coley’s toxin would 
enhance the maturation and activity of the DCs. 
Cancer studies have shown that there are high concentrations of immune cells within the 
tumour. Unfortunately, these immune cells are not receiving the proper signals to fight the 
cancer. Thus, the cancer continues to grow and spread despite the presence of many 
immune cells. In studies done by Coley the results showed that when his vaccine caused a 
fever, the cancer would start to shrink and the number of peripheral immune cells would 
increase. He also found that even though the tumour would start to shrink when the vaccine 
caused a fever, if he stopped injecting the vaccine too early, the cancer would start to grow 
again. Therefore, the immune cells could be stimulated to fight the cancer, but only for a 
limited period of time. 
5.2 Materials and Methods: 
5.2.1 Study design:  
Heparinized Blood samples were collected from 2 healthy individuals. A dose response of 
Coley’s Toxin was done to determine the optimal activation of the vaccine. Human 
mononuclear cells are often required in order to conduct specialized assays. The peripheral 
blood mononuclear cells are therefore isolated from the remaining blood elements by 
density gradient centrifugation. The isolated cells were incubated with different 
concentrations of the MBV and incubated for 8, 12 and 24 hours. Cells were centrifuged 
and the supernatants removed. The supernatants were stored at -20°C for cytokine 
detection described in chapter 6. Monoclonal antibodies to CD80 and CD83 were added to 
the cells to determine the activation and maturation status of the DCs. Prepared samples 
were aquired on a flow cytometer (BDTM FACSCalibur). CellQuest™ software was used 
for acquisition with a threshold set on FSC to exclude debris. DCs occur with low 
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frequency in peripheral blood. To make sure enough DCs were acquired a minimum of 
2000 events in Gate 2 were acquired. In the case of mDCs, Gate 2 was set on CD11c APC 
and in the case of pDCs, Gate 2 was set on HLA-DR PerCP. pDCs are CD11c-, but        
HLA-DR +. The same software was used for data analysis.  
 
5.2.2 Reagents preparation: 
RPMI 1640 growth medium (GIBCO® 61870) (Obtained from Sigma Aldrich) 
Fetal Bovine Serum (Obtained from Adcock Ingram) (GIBCO®) (decomplemented at 56oC 
for 30 minutes in waterbath) 
Histopaque-1077 solution (Obtained from Sigma Aldrich) 
Distilled or deionized water 
 
Sterile Phosphate buffered saline (PBS) 
 1L Schott bottle was filled with double distilled water and autoclaved 
 One bottle Dulbecco’s phosphate buffered saline(obtained from Sigma Aldrich)  
      was added to the 1L of  autoclaved water and stored at 4OC 
 
5% Fixative: 
• Paraformaldehyde (obtained from MERCK) was diluted 1:20 with PBS (e.g. 5ml  
      paraformaldehyde + 95ml PBS) and stored at room temperature for up to 1 month 
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LPS: 
1 ml Sterile PBS was added to the stock of 1mg LPS (Obtained from Sigma Aldrich). We 
made a 1/10 dilution of the stock solution (50µl LPS+450µl RPMI). 20µl of this dilution 
was added to each tube which was to be activated using the LPS. 
 
TNF-α: 
A recombinant stock solution 10 ng/ml TNF-α (Obtained from R&D Systems) were 
diluted 1/10 (50µl TNF-α + 450µl RPMI). Twenty microliter of this dilution was added to 
each tube for TNF-α activation. 
 
5.3 Preparation of Coley’s Toxin and determination of optimal dose: 
The Coley’s toxin used in this study was a gift from Dr Brigitte Riedelsheimer, Dusseldorf, 
Germany.  It is used for fever therapy in cancer patients.  Different concentrations of the 
Coley’s Toxin were tested to determine the optimal dose for activation and maturation of 
DCs: refer to Table 5.1. The optimal dose was determined as that which induced the 
highest expression of the activation markers CD80 or CD83. 
 
The maturation of DCs in vitro was achieved by adding different concentrations of the 
toxin to blood obtained from two healthy donors. These cells were incubated for 8, 12 and 
24 hours and analyzed. LPS was added as a positive control for mDCs and TNF-α as 
positive control for pDCs. Three sets of Falcon tubes (BDTM Biosciences) were labelled 
and the following added to each tube (See Table 5.1): 
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Table 5.1: 
Tube number 
and contents 
Cells at 
concentration of 
1x106cells/ml 
Volume of 
Coley’s/LPS/ TNF-α 
Volume of RPMI 
1 : Unstim 500µl 0 500µl RPMI 
2 : LPS 500µl 20µl LPS (2µg/ml) 480µl RPMI 
3. TNF-α 500µl 20µl TNF-α (0.2µg/ml) 480µl RPMI 
4: 1/10 500µl 50µl Coley’s 450µl RPMI 
5: 1/50 500µl 10µl Coley’s 490µl RPMI 
6: 1/100 500µl 5µl Coley’s 495µl RPMI 
7: 1/200 500µl 2.5µl Coley’s 497.5µl RPMI 
 
One set was incubated for 8 hours, one for 12 hours and the last set for 24 hours. After 
each incubation period the cells were centrifuged at 1800rpm for 5 min. The supernatant 
was aspirated and put in cryovials to determine cytokine production described in chapter 6. 
One ml PBS was added to the cells in each tube. The cells were vortexed and used for the 
analysis of activation/maturation markers.   
 
The recommended amount of antibodies (as indicated in chapter 3) and 100 µl PBMCs  
(0.1 x 106 PBMCs) were mixed together in two Falcon Tubes. Tubes were incubated for 15 
minutes at room temperature in the dark and 2ml of FACS Lysing Solution were added to 
each tube. Tubes were vortexed and incubated for 10 minutes at room temperature in the 
dark. The tubes were centrifuged at 1800rpm for 5 minutes and the supernatant was 
discarded. Tubes were vortexed gently to resuspend the pellet and 1 ml PBS was added to 
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each tube. Tubes were centrifuged again at 1800rpm for 5 minutes, the supernatant was 
discarded and the pellet of cells was resuspended in 500 µl of 5% paraformaldehyde. 
Tubes were analyzed on a FACS Calibur Flow cytometer. 
 
5.4 Data Acquisition and Analysis: 
CaliBRITE™ beads and FACSComp™ software were used to adjust the 
photomultiplier tube (PMT) voltages and fluorescence compensation, and to check the    
sensitivity of the instrument. CellQuest™ software was used for acquisition with a 
threshold on FSC to exclude debris. Since DCs occur with low frequency in peripheral 
blood, we acquired a minimum of 2000 events in Gate 2 to ensure sufficient events were 
analysed. In the case of mDCs, Gate 2 was set on CD11c APC and in the case of pDCs, 
Gate 2 was set on HLA-DR PerCP.pDCs are CD11c-, but HLA-DR +. The same software 
was used for data analysis.  
  
5.5 Results: 
Once again, we observed a high background measurement of CD80 and CD83 expression 
in the unstimulated cultures.  The same explanations as provided in Chapter 4 apply (see 
Figure 5.1 as an example of the dose response of the cells to Coley’s toxin used). Once 
again, the 1/50 dilution used for 8 hours induced reproducible results without too much 
debris in the cell cultures. Very similar and reproducible results were obtained for the 
expression of CD83 marker using the same dose of the toxin (data not shown). For this 
reason, further experiments were conducted using the 1/50 dilution of the toxin provided 
and an incubation period of 8 hours used for optimal stimulation. This applied to both 
mDCs as well as pDCs. The results for the maturation markers obtained during the dose 
reponse were higher than the results obtained from the 10 healthy volunteers. The only 
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explanation for this is the group size and the fact that we changed batches of heparin 
tubes.The dose response was done on only two individuals and a different batch of heparin 
tubes were used for the blood draw. 
. 
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Figure 5.1 Dose response of Coley’s Toxin to measure the expression of CD80 by 
mDCs after 8, 12 and 24 hours incubation 
 
Statistical analysis of dose reponse data: 
For the analysis of the dose response data we used a Paired T test. All results 
were considered statistically significant when p< 0.05. All groups were 
compared to the unstimulated group to see the effect of the mixed killed 
bacterial vaccine. 
 
 
5.5.1 Flow cytometric analysis of mDCs post Coley’s Toxin activation: 
The assay was applied to blood samples obtained from 10 healthy controls. Samples were 
treated the same as in the dose response method explained above: The  1/50 dilution of 
Coley’s toxin was used and the cells were incubated for 8 hours in the presence of medium 
(unstimulated) or LPS or TNF-α or Coley’s Toxin. TNF-α was included in this experiment 
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as a positive control for pDCs and LPS as a positive control for mDCs.  The individual 
groups were analyzed by the Wilcoxon matched paired test and all results were considered 
statistically significant when p< 0.05. All groups were compared to the unstimulated group 
to see the effect of Coley’s Toxin.  
 
The presence of Coley’s Toxin significantly influenced the maturation status of DCs in 
vitro. Coley’s Toxin induced a very significant increase in both the %CD83 (p=0.002) and 
%CD80 (p=0.002) expression by mDCs.  Once again, we observed a relative increase in 
the percentage mDCs in the cultures post activation (Figure 5.2).  Once again, the only 
explanation that we can offer to explain this phenomenon may be due to the “enrichment” 
of these cells during the culture period or the culture medium used: the unstimulated 
cultures displayed 5.8 % cells staining with the antibodies specific for mDCs, 8.2 % for the 
LPS cultures and 8.0 % for the Coley’s toxin incubated cultures (Figure 5.2). 
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Figure 5.2: Data from healthy individuals (n=10) stimulated with Coley’s Toxin to 
measure the % mDCs after 8 hours incubation. Significant columns are indicated 
with 
 
p=0.03 p=0.03 
%
m
D
C
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
132 
 
 
 
 
 
The analysis of the activation markers CD80 and CD83 in the mDCs showed a 
significant increase of these markers following the incubation with the stimuli (Figure 
5.3 and Figure 5.4).   After incubation at 37°C for 8 h, cells were harvested, and the 
expression of cell surface antigens was analyzed by FACS analysis. The expression of 
CD80 in each group were 4.3% (US), 20.6% (LPS) and 22.3% (Coley’s).The expression 
of CD80 was increased, not only by LPS (p=0.002), but also by Coley’s (p=0.002). 
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Figure 5.3  Data from healthy individuals (n=10) stimulated with Coley’s Toxin to 
 measure the expression of CD80 by mDCs after 8 hours incubation. Significant columns are  
indicated with 
 
Very similar results were observed when the CD83 data was analysed: Figure 5.4 indicates 
the increase of CD83 expression by mDCs incubated with medium alone (US) cells plus 
LPS or cells plus Coley’s Toxin. The average expression of CD83 in each group was 
13.5% (US), 27.2% (LPS) and 26.8% (Coley’s). The expression of CD83 was significantly 
increased not only by LPS (p=0.002), but also by Coley’s (p=0.002).  
p=0.002 
 p=0.002 
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Figure 5.4 Data from healthy individuals (n=10) stimulated with Coley’s Toxin to 
 measure the expression of CD83 by mDCs after 8 hours incubation. Significant columns are 
indicatedl with 
 
5.5.2 Flow cytometric analysis of pDCs post Coley’s Toxin activation: 
 
The presence of Coley’s Toxin significantly influenced the maturation status of DCs in 
vitro. Coley’s Toxin showed a very significant increase in the %CD83 and a less 
impressive increase in % CD80 expression by pDCs. The % pDCs also increased 
significantly (p=0.01) when analysed after the incubation period (Figure 5.5): after 
incubation at 37°C for 8h, the percentage pDCs in each group were 3.6% (US), 6.6% 
(TNF-α) and 6.6% (Coley’s). This significant increase of % pDCs in the TNF (p=0.01) 
and Coley’s (p=0.01) is possibly due to enrichment of the cells analysed in Gate 2 as 
previously explained.  
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Figure 5.5 Data from healthy individuals (n=10) stimulated with Coley’s Toxin to  
measure the % pDCs after 8 hour incubation. Significant columns are indicated with 
 
The expression of the activation markers as measured by CD80 or CD83 staining using 
the monoclonal antibodies was once again very similar to that measured in mDCs.  
However, the pDCs post activation with TNF-α or the Coley’s toxin did not show 
statistically significant up-regulation of the CD80 antigen.  In Figure 5.6, the up-
regulation of CD83 expression by pDCs incubated with medium alone (US) or cells plus 
TNF-α or cells plus Coley’s Toxin is shown. The average expression of CD83 in each 
group was 2.3% (US), 6.2% (TNF-α) and 10.1% (Coley’s). This increased expression of 
CD83 was significant for both the TNF-α (p=0.01) as well as for the Coley’s toxin 
(p=0.002) (Figure 5.6).  
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Figure 5.6 Data from healthy individuals (n=10) stimulated with Coley’s Toxin to measure the  
expression of CD83 by pDCs after 8 hours incubation. Significant columns are indicated with 
 
 
On the other hand, the same culture conditions did not induce any significant enhanced 
expression of the CD80 marker (Figure 5.7). We did expect an increase in expression of  
%CD80. This figure clearly shows that CD80 expression was not statistically 
significantly (p=0.06) different between the medium alone 3.0% or TNF-α incubated 
cells (4.0%) or the cultures that had received the Coley’s toxin (5.1%). In Figure 4.7 the 
TNF-α did show a significantly increase of the % CD80. The unstim value in the 
experiment with MBV was lower.The differential expression of the CD80 on pDCs post 
activation remains unclear at present. Duramad O et al. (2003) explained in their study 
that IL-10 is a potent anti-inflammatory cytokine that can be produced by different cell 
types. IL-10 can inhibit both TH1 and TH2 responses by affecting APC function and DC 
maturation. They also claim that IL-10 inhibits the activation of pDCs and induces 
apoptosis of pDCs. The IL-10 can be secreted by the other cells in the PBMC 
preparation, but recently Tomoki I et al. (2007) discovered that pDCs prime IL-10 
producing T-regulatory cells. Only pDCs express inducible costimulator ligand     
p=0.01 
p=0.002 
%CD83: Plasmacytoid dendritic cell 
 
Stellenbosch University  http://scholar.sun.ac.za
  
136 
 
 
 
 
 
(ICOS-L). The ICOS-L expression allows pDCs to induce the differentiation of naïve 
CD4 T cells to produce IL-10. These cells do not produce the TH2 cytokines IL-4, IL-5 
and    IL-13.These IL-10 producing cells are called T regulatory cells. 
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   Figure 5.7 Data from healthy individuals (n=10) stimulated with Coley’s Toxin  
   to measure the expression of CD80 by pDCs after 8 hours incubation.  
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5.6 Discussion 
 
Mature DCs arise from immature precursors which are the cells that exhibit endocytic 
activity (Trombetta ES et al. 2003). Maturation is a terminal differentiation process that 
transforms DCs from cells specialized for antigen capture into cells specialized for T-cell 
stimulation (Chapuis F et al. 1997; Rescigno M et al. 1998), accompanied by changes in 
the expression of numerous cell-surface antigens that reflect the changing functional role 
of the cells (Reis e Sousa C et al. 2004b). Maturation is characterized by reduced 
phagocytic uptake, the development of cytoplasmic extensions or “veils”, migration to 
lymphoid tissues, and enhanced T-cell activation potential (Rovere P et al.1998; Romani N 
et al. 1996b). 
 
The activation and maturation of DCs by bacterial products has been proven by Nakahara 
S et al. 2003; Reis de Sousa C et al. 2003a. With this study in mind it was hypothesized 
that Coley’s Toxin used in this study might modulate DC maturation. This study 
determined the effects Coley’s Toxin at a number of concentrations on the maturation 
status of both myeloid and pDCs. The first part of the results of this study demonstrated the 
dose response done to determine the concentration that plays a significant role in the 
maturation of DCs and the incubation time needed for this. The second part demonstrated 
the data generated to confirm the data of the dose response. 
The activation of DCs by bacterial products (S. pyogenes) has been proven by Nakahara S 
et al. (2003). S. pyogenes infections are sometimes accompanied by the release of toxins 
from the bacteria. These toxins produced many of the symptoms of bacterial infections, 
such as fever. A key aspect that Coley found to be necessary for tumour regression was the 
induction of a mild to moderate fever. Basu S  (2003) states that even brief exposure to 
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increased body temperature can cause maturation of DC in skin and other tissues. The 
increase in the levels of cytokines such as TNF-α related with fever, also plays a role in 
DC maturation. 
We found increases in the expression of the maturation markers CD80 and CD83 on DCs 
in response to stimulation with Coley’s Toxin, LPS and TNF-α. Coley’s toxin had 
significantly up-regulated the expression of CD83 (p =0.002) in the case of mDCs as well 
as pDCs (p=0.002).  The vaccine also up-regulated the %CD80 in myeloid (p=0.002) but 
not on pDCs. We also observed that, in both DC populations, CD83 expression was more 
pronounced than the CD80 increase. With the results of the study in mind we hypothesized 
that Coley’s Toxin can play an important role in the treatment of infectious diseases like 
HIV. The response of pDCs to Coley’s Toxin provides a key mechanism to control the 
HIV infection, because a decline in pDCs in chronic HIV-1 infection is associated with 
high viral loads and opportunistic infections.  Patterson S et al (2001c) explains that pDCs 
cells play a big role in the antiviral immune responses. They recognize viral components, 
leading to type I interferon (IFN) production, and affect adaptive defense strategies 
designed to eliminate the virus. 
Together, these findings are consistent with the known role of mDC in T-cell priming and 
an immune regulatory role for pDCs. Thus, pDCs migrate rapidly from peripheral blood to 
lymph nodes following activation, where they can influence mDCs and T cells. We suggest 
that the potent and simultaneous activation of both DC subsets by Coley’s Toxin makes 
this a useful reagent for screening DC function in clinical specimens by the assay described 
above, as well as a potentially useful immune adjuvant for clinical use. 
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Chapter 6 
Cytokine profile of in vitro activated and matured dendritic cells 
Abstract: 
This chapter describes a flow cytometric method for the quantitation of cytokines 
secreted by DCs activated by Coley’s Toxin and Mixed Killed bacteria. The method 
used is known as multiplexing, where the simultaneous assay are used to detect many 
analytes in a single sample. The BD™ Cytometric Bead Array (CBA) flex set was 
used to quantitatively measure different cytokines: these included Interleukin-6     
(IL-6), Interleukin-4 (IL-4),  Interleukin-10 (IL-10), Tumor Necrosis Factor- α   
(TNF-α), Interferon-gamma (IFN-γ) and Interleukin-12p70 (IL-12p70) protein levels 
in a single sample. The results of this study showed that both Coley’s Toxin and the 
MBV induced cytokine profiles capable of leading to both TH1 and TH2 responses. 
 
6.1 Introduction 
Cytokines are small soluble factors released by cells to communicate and influence the 
functions of other cells through the interaction with different surface receptors. According 
to Baggiolini M (1998), the main characteristics of cytokines are 
• Cytokines have many different effects to different cells 
• Cytokines posses autocrine functions (feedback mechanism) thereby acting 
directly on the cell that released it. 
• Cytokines have a paracrine effect on the cells immediately around them 
• Cytokines can act like hormones and have endocrine effects on cells and organs 
• They may induce the release of other cytokines 
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• Cytokines may act synergistically to achieve a greater effect than the sum of 
their individual actions. 
Maturation of DCs can be influenced by a variety of cytokines including IL-1, GM-CSF, 
and TNF-α . To optimally induce DC maturation, especially in humans, these cytokines 
have been used at various timings, concentrations, and durations and in various 
combinations. TNF-α might be one of the most commonly used cytokines for this purpose. 
However, it has recently been reported that TNF-α alone cannot induce full maturation of 
DCs. Nakahara S et al. (2003) showed in their study that multiple cytokines are needed to 
induce full maturation of DCs.  They also state that in addition to these cytokines, bacteria 
and molecules like LPS have been shown to stimulate DC maturation. Although cytokines 
activate the maturation of DCs, literature shows that IL-10 effectively inhibits the 
maturation of DCs (Spight D et al: 2004; Wallet MA et al.2005). Thus, it is now evident 
that multiple cytokines should be used for this purpose. In addition to these cytokines, 
bacteria  and related molecules including LPS (cell wall component of Gram-negative 
bacteria) have been shown to induce DC maturation (Rescigno M  et al. 1999)  
DCs form intimate contact with T cells and these interactions induce the release of 
soluble cytokines by both cell types. T cell cytokine responses dominated by the 
production of high levels of IFN-γ and little IL-4 by CD4 T cells are called TH1 cell 
responses and are known to be induced by antigen presenting cells producing IL-12. In 
contrast, T cell responses dominated by IL-4 production with little IFN-γ are called TH 2 
T cell responses. A variety of external stimuli can be applied to DC to regulate their 
production of IL-12 and the production of IFN-γ or IL-4 in the T cells with which they 
interact. Recent studies suggested that distinct types of DC may regulate distinct types of 
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T cell responses: for instance, pDCs appear to give rise to TH2 T cell cytokine responses, 
whereas monocyte-derived DC, which represent a typical mDC, give rise to TH1 T cell 
responses. Veckman V et al: (2004) proved in their study that S. pyogenes does induce 
the maturation of monocyte derived DCs. The stimulation with S. pyogenes  resulted in 
the expression of CD80, CD83 and CD86. Their study also showed a TH1 cytokine and 
chemokine response, after the DCs were stimulated with S.pyogenes.  Duramad O et al. 
(2003) explained in their study that IL-10 is a potent anti-inflammatory cytokine that can 
be produced by different cell types. IL-10 can inhibit both TH1 and TH2 responses by 
affecting APC function and DC maturation. They also claim that IL- 10 inhibits the 
activation of pDCs and induces apoptosis of pDCs. The IL-10 can be secreted by the 
other cells in the PBMC preparation, but recently Ito T et al. (2007) discovered that 
pDCs prime IL-10 producing T-regulatory cells. Only pDCs express inducible 
costimulator ligand (ICOS-L). The ICOS-L expression allows pDCs to induce the 
differentiation of naïve CD4 T cells to produce IL-10. These cells do not produce the 
TH2 cytokines IL-4, IL-5 and IL-13. These IL-10 producing cells are called T regulatory 
cells 
 
We examined the secretion of TH1-type cytokines (IL-12p70, TNF-α and IFN-γ) and TH2-
type cytokines (IL-4, IL-6 and IL-10) from DCs after stimulation with TNF-α, LPS, 
Coley’s Toxin and Mixed Killed Bacteria. The method used for this assay is known as 
multiplexing, which means that  simultaneous assay are used to detect many analytes in a 
single sample. The BD™ Cytometric Bead Array (CBA) Flex set is used to detect a series 
of multiple soluble analytes. In this study we used the BD CBA Human Soluble Protein 
Flex set: it is a particle-based immunoassay and each bead provides a capture surface for a 
specific protein (resembles an individually coated well in an ELISA plate). Only a small 
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volume sample is needed for this assay and the value of an unknown can be obtained in 
substantially less time compared to an ELISA. The BD™ CBA Flex set can be used to 
quantitatively measure IL-6, IL-4, IL-10, TNF-α, IFN-γ  and IL-12p70 protein levels in a 
single sample. 
 
6.2 Preliminary assays: 
 
The method for Flexsets is a new method developed by BD Biosciences. In a preliminary 
set of experiments, we were provided 7 flexsets in order to test the method before we 
assayed samples from the dose responses as well as the samples from the 10 healthy 
individuals. For this we used Flexsets supplied by BD Biosciences free of charge: these 
consisted of IL-2, IL-6, IFN-γ , IL -8, IL-1β and IL-4.  
 
Once the method had been set up and validated, we modified the flexsets used for this 
study and this consisted of IL-12 p70, TNF, IL-10, IFN-γ, IL-6, IL-4 and IL-2. We 
replaced the IL-8 and IL-1β flexset of the preliminary test with IL-12p70, IFN -γ and 
added IL-10 as well to determine if the in vitro activated DCs elicited a TH1 or a TH2 
response. The results of the preliminary tests actually showed very high levels of IL-1β 
and IL-8 which indicates an inflammatory response: both the Coley’s Toxin and the MBV 
stimulated cultures secreted IL-1β and IL-8 at high levels (>5000 pg/ml).  These samples 
were not diluted and re-assayed to fit on the standard curve and to determine the real value. 
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6.3 Samples analysed: 
Since the flow cytometric analysis of surface expression of the activation markers CD80 
and CD83 indicated that the 8 hour incubation with 1/50 dilutions of both the MBV and 
the Coley’s toxin induced maximal upregulation, we concentrated on the supernatants 
generated from these cultures to assay the cytokines. These had been generated and 
stored at -20oC until assayed. 
 
Blood was drawn from 10 normal healthy individuals and these samples were treated in the 
same manner as described in the previous chapters: cells were incubated for 8 hours with 
medium, TNF-α, LPS, the optimal concentration of MBV and Coley’s Toxin. The data 
was analysed by the Wilcoxon matched paired test. All results were considered statistically 
significant when p< 0.05 compared to the unstimulated cultures. 
 
6.4 Results 
The high background value of the unstimulated sample as observed in the surface 
expression of the activation markers were confirmed once again:  the supernatants of these 
cultures revealed high levels of the cytokines although the stimulated cultures exhibited 
even higher levels, especially those having received the bacterial products (either the MBV 
or the Coley’s toxin). Tkachenko N et al. (2005) tested different culture media for the 
generation of DCs and discovered that the growth and maturation of DCs in culture can be 
influenced by a variety of factors. In this study they claim that media supplemented with 
FCS can influence the DC maturation. FCS contains endotoxin, for example LPS, which 
can activate the DCs, even though the concentrations are very low.     
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As can be seen in the following tables, each cytokine measured for each donor 
has been tabulated with the corresponding stimulus used: The means and standard 
deviation of these results were not calculated due to the variation in results.  
 
Table 6.1(a) IL-6 (pg/ml) released upon stimulation with various activators: 
Individual Unstim LPS TNF Coley’s MBV 
1 87.44 >5000 >5000 >5000 >5000 
2 116.04 2220.41 2371.74 2495.59 1899.17 
3 81.78 3128.30 2324.04 4282.47 1618.38 
4 63.57 >5000 2560.11 1997.07 845.12 
5 231.58 3260.72 >5000 2910.21 836.91 
6 1487.25 >5000 >5000 1539.84 >5000 
7 114.85 1562.99 2970.81 2277.35 3294.75 
8 90.40 >5000 >5000 >5000 >5000 
9 3773.60 >5000 1997.07 2470.28 1327.17 
10 292.65 >5000 >5000 4420.94 >5000 
 
Table 6.1(b) 
Statistical analysis : IL- 6 
Unstim vs LPS p= 0.002 
Unstim vs TNF-α p= 0.004 
Unstim vs Coley’s p= 0.006 
Unstin vs MBV p= 0.02 
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From Table 6.1 above, it can be seen that the individual responses to the stimuli varied 
from one individual to the next and that the LPS and/or TNF-α induced much higher 
levels of IL-6 when compared to the experimental products, namely, the MBV or the 
Coley’s toxin. 
   
Table 6.2(a): TNF-α (pg/ml) secretion profile of the cultures:  
Individual Unstim LPS TNF Coley’s MBV 
1 8.1 460.31 690.39 449.54 1784.67 
2 87.44 243.46 363.29 426.72 915.33 
3 111.24 426.72 430.78 370.24 1156.33 
4 87.44 817.87 491.90 266.70 735.06 
5 117.30  403.16 246.38 253.00 333.58 
6 218.91 1234.84 829.93 1572.62 1228.63 
7 88.43 273.15 370.24 595.03 1015.40 
8 28.43 501.33 842.16 802.10 3454.19 
9 556.60 985.64 478.10 813.91 1228.58 
10 200.53 809.94 842.16 884.39 1842.65 
 
Table 6.2(b) 
Statistical analysis : TNF-α 
Unstim vs LPS p= 0.002 
Unstim vs TNF-α p= 0.004 
Unstim vs Coley’s p= 0.006 
Unstin vs MBV p= 0.02 
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The data presented in Table 6.2 above indicates the concentrations of TNF-α secreted by 
PBMC’s incubated with either medium alone (US) or cells plus LPS, TNF-α, MBV or 
Coley’s Toxin.  The data from each individual were compared to the individual’s unstim 
value using the Wilcoxon test and all the data were statistically significant.  The MBV 
induced higher levels of TNF-α than the LPS.  
Table 6.3(a) IL-10 (pg/ml) secretion post-activation using various stimuli: 
Individual Unstim LPS TNF Coley’s MBV 
1 0 47 139.16 84.66 81.87 
2 0 14.96 0 16.39 20.17 
3 0 14.96 0 27.29 17.87 
4 0 142.01 14.61 20.56 13.41 
5 0 33.56 10.35 38.83 9.00 
6 0 59.05 26.89 6.66 32.06 
7 0 19.97 21.36 42.21 47.00 
8 0 53.13 12.73 48.25 88.49 
9 3.67 70.60 6.82 39.38 23.42 
10 0 35.09 16.76 34.58 40.22 
 
Table 6.3(b) 
Statistical analysis : IL- 10 
Unstim vs LPS p= 0.002 
Unstim vs TNF-α p= 0.008 
Unstim vs Coley’s p= 0.002 
Unstin vs MBV p= 0.002 
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Table 6.3 above shows the measured levels of IL-10 secreted by PBMC’s incubated with 
either medium alone (US) or cells plus LPS or TNF-α or the MBV or the Coley’s Toxin. 
Each individual served as his/her own control with the stimulated values compared to the 
unstimulated value. Significant induction of IL-10 release was noted for all cultures with 
the levels secreted in the presence of Coley’s toxin and the MBV being less than that 
induced by LPS group (but higher than the TNF-α cultures). 
   
Table 6.4(a) IL-2 (pg/ml) induced secretion by various stimuli: 
Individual Unstim LPS TNF Coley’s MBV 
1 16.15 13.47 23.23 8.51 6.68 
2 6.7 34.49 16.15 10.46 0 
3 8.51 0 0 8.5 13.47 
4 0 8.81 8.51 8.51 0 
5 0 6.68 13.11 23.23 8.51 
6 16.51 8.51 0 29.54 25.39 
7 3.92 0 8.51 8.51 18.64 
8 16.15 0 8.71 33.52 16.15 
9 12.01 8.51 23.23 18.64 6.51 
10 8.51 8.51 0 0 8.51 
  
Table 6.4 (b) 
Statistical analysis : IL- 2 
Unstim vs Coley’s p= 0.04 
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Since IL-2 is a predominant T cell derived cytokine, it was decided to measure this 
cytokine in the supernatants of the cell cultures in order to determine whether the MBV 
and/or the Coley’s toxin were general polyclonal activators or many cell types or whether 
they were more specifically targeted to the monocytes and DCs. It can be seen in the 
above table (Table 6.4) that only the Coley’s Toxin induced statistically significant 
amounts of IL-2 to be released from the cell cultures.  The LPS, TNF-α and the MBV 
cultures (although the stimulated cultures may have shown some enhanced secretion) did 
not show significantly increased levels of the cytokine when compared to the 
corresponding unstimulated value.  This is not unexpected since the stimuli used are 
predominantly inducers of inflammatory cytokine release rather than T cell derived, 
immune regulatory cytokine inducers.   
 
Table 6.5(a) IFN-γ (pg/ml) secretion by PBMC’s activated using various stimuli: 
 
Individual Unstim LPS TNF COLEY MBV 
1 
0 0 0 110 359 
2 
0 0 0 16 0 
3 
2 0 0 17 13 
4 
0 0 0 0 0 
5 
0 0 0 44 47 
6 
0 0 0 176 84 
7 
4 0 0 18 14 
8 
0 0 0 25 11 
9 
0 0 0 9 29 
10 
0 0 0 8 0 
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Table 6.5 (b) 
Statistical analysis: IFN-γ 
Unstim vs Coley’s p=0.002 
Unstim vs MBV p= 0.008 
 
In Table 6.5 above, the results of secreted IFN-γ by PBMC’s incubated with either 
medium alone (US) or cells plus LPS, or TNF-α oR the MBV or the Coley’s toxin are 
presented.  Once again, since IFN-γ is secreted predominantly by activated T cells and 
NK cells, it was not surprising that the LPS and TNF-α did not induce the release of this 
cytokine from the PBMCs in vitro.  It was however interesting that both the MBV and 
the Coley’s toxin were able to induce the cytokine under the same culture conditions.  
This implies that these bacterial products target T cells specific for these antigens and 
induce the activation of the T cells (and possibly the NK cells in the cell preparation).  
DCs are not known to release this cytokine: it has been described that IFN-α is one of the 
cytokines released from mature DCs amongst others so the origin of this factor could not 
be from T cells and/or NK cells. 
 
The assay for the IL-12p70 measurements in the supernatants obtained after 8 hours of 
stimulation revealed no measurable levels of this cytokines in any of the cell cultures, 
irrespective of the stimulus used (data not shown). This surprising observation could be 
explained in one of two ways: either the time period for optimal IL-12p70 release was too 
short compared to other cytokines or the dose of the stimuli used was not optimal.  Since 
the analyses of only the 8 hour cultures were conducted for all the cytokines (as reported 
above), it was decided to assay the supernatants obtained from the dose-response 
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experiments whereby 2 individuals were used and the supernatants collected over various 
time periods.  The data of the 12 hour cultures are shown hereunder (Table 6.8). 
 
Table 6.6(a) IL-12 p70 (pg/ml) secretion in response to Coley’s toxin (12 hours 
culture): 
Individual Unstim 1/10 1/50 1/100 1/200 
1 27.53 59.63 57.63 52.36 58.63 
2 37.92 69.61 60.07 70.50 69.79 
 
Table 6.6(b) 
Statistical analysis: IL- 12 p70 
Unstim vs 1/10 p= 0.004 
Unstim vs 1/50 p= 0.048 
Unstim vs 1/100 p= 0.043 
Unstim vs 1/200 p=0.008 
 
It is very evident from the results presented in Table 6.6 above that the absence of IL-
12p70 in the 8 hour culture supernatants was indeed due to the culture period being too 
short.  Irrespective of the dose of the toxin used, the cytokine was measurable in these 
cultures and the levels were statistically significantly raised when compared to the 
unstimulated values. At this stage, due to financial constraints, we were not able to repeat 
the assay for IL-12p70 in the supernatants obtained from the same 10 individuals reported 
above: we did however assume that the 12 hour supernatants would have tested positive for 
this cytokine. Although limited in data size, we would like to postulate that Coley’s toxin 
is possibly capable of inducing the in vitro maturation of immature DCs (iDCs) and to 
produce significant amounts of IL-12p70, a T-helper 1-type promoting cytokine. The same 
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may also apply to the other stimuli although we do not have the full data set to substantiate 
this claim. 
 
6.5 Discussion 
The soluble cytokine profile secreted by DCs varies with the different stages of DC 
development and maturation. A wide variety of cytokines may be expressed by mature 
DCs including IL-12, IL-1α, IL-1ß, IL-8, IL-15, IL-18, IFN-α, IFN-ß, IFN-γ, IL-4, IL-10, 
IL-6, IL-17, IL-16 and TNF-α (Aiba S,1998 and Hellman P et al. 2007). The cytokine 
patterns released by mature DCs determine their TH1/TH2 polarizing capacities and 
explain whether the outcome of an immune response is predominantly humoral or cell 
mediated in nature. 
 
In this study, we instigated the secretion of TH1-type cytokines (IL-12, IFN-γ and TNF-α) 
and TH2-type cytokines (IL-4, IL-6, and IL-10) from DCs after stimulation with TNF-α, 
LPS, MBV and Coley’s Toxin. After incubation at 37°C for 8h in a CO2 incubator, 
supernatants were collected and tested for cytokine concentration using the BD CBA Flex 
set. LPS-treated DCs produced low amounts of both IL-12 and IL-10 
 
In this study induction of high levels of IFN-γ production suggests that soon after bacterial 
encounter, DC produce TNF-α and IL-1β which can activate neighboring non-infected 
DCs as well as macrophages. Subsequently, those DCs produce IL-6 and IL-12 for the 
activation of B and T cells respectively (Rescigno M et al. 2000b). The PBMC’s incubated 
with Coley’s Toxin and MBV demonstrated a mixed THl/TH2 profile with secretion of  
IL-2,  IL-4, IL-6, IL-10,TNF-α, IFN-γ  and IL-12 
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The data reported here indicated that the PBMC’s from the initial two individuals, used for 
the dose-resonse experiments, incubated with the stimuli did secrete IL-12 after incubation 
with Coley’s Toxin and promote a rapid IFN-γ response, confirming several studies 
(Heufler C et al. 1996; Gorak PM et al.1998). DCs can produce IL-12 in its bioactive 
form: the assay used here was specific for the 70-kDa heterodimer, which favors the 
differentiation of precursor TH0 cells into TH1 effectors (Trinchieri G, 1998). Furthermore 
Coley’s Toxin was a more powerful inducer of IL-12 than the MBV (no IL-12 was 
detected after incubation with the MBV, even after 12 hours of culture). IL-12 production 
is critical for the promotion of an effective cellular immune response by activating and 
differentiating T lymphocyte to the TH1 pathway.  
 
The data presented here suggest that both Coley’s Toxin and the MBV might be 
stimulators for maturing DCs for TH1 responses designed for use in cancer therapy or for 
intracellular infections. The results of other studies showed that myeloid DCs seem to 
control the type of inflammatory response by secreting two functionally conflicting factors, 
and the ratio of IL-12 to IL-10 is thought to determine the balance of a TH1 versus TH2 
response. The absolute amount of IL-10 was larger than that of IL-12 for both Coley’s and 
the MBV, but IL-4 was not secreted in the case of MBV. The interaction of DCs with 
Coley’s Toxin, leading to IL-12 production followed by the rapid production of IFN-γ, is 
an important response at the innate level. These cytokines are capable of promoting TH1 
development and thus influencing the development of the adaptive immune response 
(Kikuchi T et al.2004). 
 
PBMC’s incubated with Coley’s and MBV both produced high levels of the TH2-
polarizing cytokine IL-10. It is well established that monocytes and macrophages 
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synthesize IL-10. It is also well known that IL-10 has an important regulatory role on 
monocyte function and on DC maturation. The MBV and Coley’s Toxin stimulation 
induced secretion of TNF-α and IFN-γ at a high level that was markedly and significantly 
higher than the unstimulated value. Furthermore the MBV and Coley’s Toxin stimulation 
also induced IL-6 and IL-10 secretion at a high level that was markedly and significantly 
higher than the unstimulated value. These results suggest that cells stimulated with MBV 
and Coley’s Toxin secrete TH1 and TH2-type cytokines at a high level. 
IFN-γ, TNF-α, IL-1β, IL-6 and IL -8 are typical inflammatory cytokines that are secreted 
by the PBMCs in the presence of Coley’s Toxin and the MBV. Sallusto et al. (2000) 
showed in his study that immature DCs migrate toward increasing concentrations of 
inflammatory chemokines. The DCs are also exposed to increasing concentrations of 
proinflammatory cytokines like TNF-α, IL- 1 and the pathogen products that caused the 
inflammatory response. In response to these DCs mature and switch the usage and 
expression of chemokine receptors from inflammatory to lymphoid homing receptors 
(MacPherson GG, 1993). 
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Chapter 7 
 
General Discussion and Conclusions 
 
The aim of this study was to determine whether a suspension of MBV and a preparation of 
Coley’s Toxin would have any significant effects on the activation and maturation status of 
DCs.  This was of importance because only mature DCs can present the antigens of 
pathogens to T cells in order to activate the immune cells which carry out the effector 
functions. Measuring the influence of these two vaccines on DCs could help us to 
understand the requirements for the functions of DCs and thereby, develop DC based 
therapies. DC based therapies have potential application across a wide variety of diseases, 
ranging from infectious diseases such as HIV to cancer, inflammatory disease and 
autoimmune diseases.  In recent years, we have seen several published clinical studies 
whereby the authors have generated activated DCs in vitro and used these for the treatment 
of the patient from whom it was generated (autologous immune therapies) (Lu W, Arreaes 
LC, Ferreira WT et al. 2004; Andrieu JM and Lu W :2007; Egan MA: 2007). 
 
We presented this study with a detailed literature review on the immune system outlying 
the roles of the different cells involved in the immune system and the effect of different 
cytokines produced by these different cells. In Chapter 2, we discussed DCs in general. 
During this literature review it became clear the DC system of APCs is the initiator and 
modulator of the immune response and they determine the outcome of a successful antigen 
clearance.  Mature DCs arise from immature precursors which are the cells that exhibit 
endocytic activity (Trombetta et al: 2003). Maturation is characterized by reduced 
phagocytic uptake, the development of cytoplasmic extensions or “veils”, migration to 
lymphoid tissues, and enhanced T-cell activation potential (Romani et al.1996b; Rovere et 
al.1998). 
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In chapter 3 we described a flow cytometric method using a combination of monoclonal 
antibodes describing various surface markers in order to identify different types of DCs: 
we could distinguish between the major DC subsets by the absence of expression of several 
lineage markers for lymphocytes, monocytes and NK cells and the expression of CD11c in 
the case of mDCs and CD123 in the case of pDCs. The inclusion of the HLA-DR marker 
in addition to the previous described markers allows the discrimination of CD123 + DCs 
from basophils. 
 
Once we had shown our ability to identify the two subsets of DCs, we investigated the 
relative frequency of these cells in blood samples obtained from patients diagnosed with 
various infectious diseases. These included patients with cancer, HIV-infected individuals 
and other patients co-infected with HIV and TB. Our reasoning for the selection of these 
diseases is as follows: 
• The cancer microenvironment consists of a variable combination of tumor cells, 
stromal fibroblasts, endothelial cells and infiltrating leukocytes, such as 
macrophages, T lymphocytes, and DCs. DCs are highly potent antigen presenting 
cells (APCs) which play a critical role in the regulation of the adaptive immune 
response. Because of their instrumental role in the immune system and their natural 
adjuvant properties, there is a great interest in exploiting DCs to develop 
immunotherapies for cancer, chronic infections and autoimmune disease. 
• Several studies have shown that during HIV infection, both DC subsets are reduced 
in the blood (Pacanowski J et al. 2001; Schmidt B et al. 2005). Our results 
(although small in sample size, n = 10) showed a decrease in the %mDCs and 
%pDC in bloods from HIV infected patients when compared to healthy controls, 
thereby confirming the findings of (Pacanowski J et al. 2001 and Schmidt B et al. 
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2005a). Further studies are needed in order to reach final conclusions since we had 
no details of the medical status of these patients, especially as to their treatments 
(or lack thereof).  It is however interesting that new studies are being published 
whereby the manipulation of peripheral blood DCs of HIV-infected patients have 
shown tremendous promise as to the control of viraemia and the ability to induce a 
CD4 cell recovery (Lu W, Arreaes LC, Ferreira WT et al. 2004; Andrieu JM and 
Lu W: 2007; Egan MA: 2007).   
 
• A third group of patients were only discovered when we recruited blood samples to 
include in our study.  These patients turned out to be a subset of HIV-infected 
patients (n = 5): the results of these patients looked different and it is only when we 
requested details from the clinician that it was discovered that these patient had TB 
as well as HIV, in other words, they were co-infected. The subsets of DCs 
measured appeared different: the %mDC and %pDC showed an increase in the 
peripheral blood and were in fact, significantly higher than the levels observed in 
blood samples from healthy controls. Furthermore, the maturation markers CD80 
and CD83 in mDCs were up regulated. In the case of pDCs, the maturation marker 
CD83 was upregulated but this did not apply to the expression of CD80 (this was 
almost the same as for the control group). In this small group of patients, the 
%CD80 expression was higher than in the HIV infection only group, which implies 
that TB plays a role in the maturation of DCs and that the mycobacterial infection 
may over-ride an underlying immune suppressed state.  This deserves further 
investigation since it may also represent a new biomarker of tuberculosis infection 
and the levels of the maturation markers on DCs may give an indication of the 
clinical stage of tuberculosis disease. 
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• In the case of cancer we only recruited 5 patients with newly-diagnosed lymphoma:  
the results of this study showed that the %mDCs were slightly increased as well as 
the maturation markers for mDCs (not significant). The % pDCs and the maturation 
markers for pDCs were slightly decreased (not significant). Studies done by Sevko 
AL et al. (2007) showed a decrease in the maturation markers CD80 and CD83. 
 
Interactions between DCs and microbial pathogens are fundamental to the generation of 
innate and adaptive immune responses. Upon stimulation with bacteria or bacterial 
components such as lipopolysaccharide (LPS), immature DCs undergo a maturation 
process that involves expression of costimulatory molecules, HLA molecules, and 
cytokines and chemokines, thus providing critical signals for lymphocyte development and 
differentiation. In this study, we investigated the response of human DCs to MBV and 
LPS. Previous studies showed that DCs could be activated with killed Streptococcus 
pyogenes. With this study in mind it was hypothesized that the MBV used in this study 
might modulate DC maturation. The results of this study showed that the MBV and LPS all 
significantly induced DC maturation as measured by increased surface expression of 
costimulatory molecules such as CD80 and CD83.  
 
Similarly, we investigated the effects of Coley’s Toxin on the maturation status of DCs. 
We hypothesized that the Coley’s Toxins used in this study might modulate DC 
maturation. Coley's is a mixture consisting of peptides of killed bacteria of species 
Streptococcus pyogenes as well as Serratia liquefaciens. The results of this study showed 
that Coley’s Toxin could be used as effective agent to induce maturation of DCs, which 
appears to be a powerful tool for various types of immunotherapy.  At present, it is one of 
the agents used by complimentary oncologists in Germany for the treatment of patients 
Stellenbosch University  http://scholar.sun.ac.za
  
158 
 
 
 
 
 
post-surgical removal of the tumour burden (Dr. Brigitte Riedelsheimer, personal 
communication).  Our findings therefore represent some in vitro data which supports the 
use of this biological agent. 
 
The data shown in chapter 6, namely the measurement of different cytokines in the cell 
supernatants of the activated cells, showed that both the MBV and Coley’s Toxin induced 
the secretion of TNF-α and IFN-γ at very high levels that were markedly and significantly 
higher than the unstimulated value. Furthermore the MBV and Coley’s Toxin stimulation 
also induced IL-6 and IL-10 secretion under the same culture conditions, suggesting that 
these two experimental agents are able to induce the secretion of both TH1 and TH2-type 
cytokines from the T cells in the cultures.  Previous studies have shown clearly that 
bacterial products do indeed induce the secretion of a TH1 response (Nakahara S et al. 
2003).  
 
Suggestions for future studies: 
DC based therapies have potential application across a wide variety of diseases, ranging 
from infectious diseases such as HIV to cancer, inflammatory disease and autoimmune 
diseases. The market potential for a successful treatment is large (Cerundolo V et al. 
2004). Mohamdzadeh M et al. (2004) states that market opportunities include the 
manipulation of DC acivity for the development of effective therapeutic vaccines, the 
modulation of DC activity to manage autoimmune diseases and targeting the underserved 
markets through the development of novel therapies that make use of the immune system 
to prevent and treat disease. These cells have the potential to be used as enhancers of 
responses to infectious diseases and due to their capacity to induce a primary immune 
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response, DCs can be used as vectors (vaccine carriers) for immunotherapy (Paczesny S   
et al. 2003). 
 
One of the shortcomings of the present study is that we did not determine the longevity of 
the activated DCs cells once they had been induced to mature in vitro and to secrete the 
immune regulatory cytokines.  This needs to be addressed in future studies since it would 
determine the need for the frequency for re-stimulation or the need for “booster” 
administrations of the cells when being used for immunotherapy.  The need for the 
addition of the “survival” growth factors such as GM-CSF post activation has not been 
investigated and certainly deserves attention. 
 
The observation of the increased mDCs and pDCs in the circulation of HIV and TB        
co-infected patients is certainly an interesting observation and this requires thorough 
investigation in larger groups of patients with better defined clinical staging and treatment 
status. 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
160 
 
 
 
 
 
References: 
• Abbas AK and Lichtman AH (2003): Cellular and molecular Immunology.5th Edition 
Saunders.  
• Ackerman AL and Cresswell P (2003): Regulation of MHC class I transport 
         in human DCs and the dendritic-like cell line KG-1.  J. Immunol. 
         170: 4178–4188. 
• Aderem A and Ulevitch RJ (2000): Toll- like receptors in the induction of the innate 
immune response. Nature. 406: 782-787. 
• Afzali B, Lombardi G, Lechler RI et al. The role of T helper 17 (Th17) and regulatory 
T cells (Treg) in human organ transplantation and autoimmune disease. Cli. And 
Immunol. Exp. 148:32-46 
• Ahuja SS, Reddick RL, Sato N et al. (1999): Dendritic cell based anti-infective 
strategies: DCs engineered to secrete IL -12 are a potent vaccine in a murine model of 
an intracellular infection. J. Immunol. 163: 3890-3897. 
• Aiba S (1998): Maturation of dendritic cells induced by cytokines and haptens. 
         Tohoku J. Exp. Med. 184: 159–172. 
• Akira S, Takeda K and Kaisho T (2001): Toll-like receptors: critical proteins linking 
         innate and acquired immunity. Nat. Immunol.2: 675. 
• Al-Alwan MM, Rowden G, Lee TD and West KA (2001):The dendritic cell 
         cytoskeleton is critical for the formation of the immunological synapse. 
         J. Immunol. 166: 1452-1456.  
• Albert ML, Sauter B and Bhardwaj N (1998a): Dendritic cells acquire antigen from 
        apoptotic cells and induce class I-restricted CTLs. Nature Mar 5:392 (6671): 86-9. 
Stellenbosch University  http://scholar.sun.ac.za
  
161 
 
 
 
 
 
• Albert ML, Pearce SFA, Francisco LM et al. (1998b): Immature dendritic cells 
phagocytose apoptotic cells via avb5 and CD36, and cross-present antigens to cytotoxic 
T lymphocytes. J. Exp. Med. 188: 1359 – 1368. 
• Alcami A and Koszinowski UH (2000): Viral mechanisms of immune evasion. Trends 
Microbiol. 8: 410-418. 
• Alderson MR, Armitage RJ, Tough TW et al. (1993): CD40 expression by human 
monocytes: regulation by Cytokines and activation of monocytes by the ligand for 
CD40. J. Exp. Med.178: 669. 
• Allan RS, Waithman J, Bedoui S et al. (2006): Migratory dendritic cells transfer 
antigen to a lymph node-resident dendritic cell population for efficient CTL priming. 
Immunity. 25: 153–162. 
• Amigorena S (1998): Anti-tumour immunotherapy using dendritic cell derived 
exosomes. Research in Immunology. 149(7-8): 661-2. 
• Anderson KV (2000): Toll signaling pathways in the innate immune response Curr 
Opin. Immunol. 12: 13-19. 
• Andrieu JM and Lu W (2007): A dendritic cell –based vaccine for treating HIV 
infection: background and preliminary results. J. Int. Med. 261: 123-131.  
• Arai K, Lee F, Miyajima A et al. (1990): Cytokines co-ordinators of immune and 
inflammatory response. Annu. Rev. Biochem.59: 783 -836. 
• Ardavin C, Martinez del Hoyo G, Martin P et al. (2001): Origin and differentiation of 
dendritic cells. Trends Immunol. 22: 691- 700.  
• Ardavin C, Amigorena S and Reis de Sousa C (2004b): Dendritic cells: 
immunobiology and cancer immunotherapy. Immunity 20: 17-23.  
Stellenbosch University  http://scholar.sun.ac.za
  
162 
 
 
 
 
 
• Ashley D, Faiola B, Nair S et al. (1997): Bone marrow-generated dendritic cells pulsed 
with tumor extracts or tumor RNA induces antitumor immunity against central nervous 
system tumor. J. Exp. Med. 186: 1177-1182. 
• Asselin-Paturel C and Trinchieri G (2005): Production of type I interferons: 
plasmacytoid dendritic cells and beyond. J. Exp. Med.202: 461-465. 
• Austyn JM. (1996a): New insights into the mobilization and phagocytic activity of 
dendritic cells. J. Exp. Med. 183: 1287–1292.  
• Austyn JM (2000b): Antigen-presenting cells. Experimental and clinical studies of 
dendritic cells. Am. J. Respir. Crit. Care Med 162: S146-S150. 
• Baggiolini M (1998): Chemokines and leucocyte traffic. Nature 392: 565-568. 
• Bajenoff M, Granjeaud S and Guerder S (2003): The strategy of T cell antigen-
presenting cell encounter in antigen-draining lymph nodes revealed by imaging of 
initial T cell activation. J. Exp. Med.198: 715–724.  
• Bakke AC (2001): The principles of flow cytometry. Lab. Med. 32:207-211. 
• Banchereau J, Breire F, Caux C et al. (2000a): Immunobiology of dendritic cells. 
         Annu. Rev. Immonol. 18: 767-811. 
• Banchereau J and Steinman RM (2001b): Dendritic cells and the control of  
          immunity. Nature. 392: 245– 52. 
• Baron S, Tyring SR, Fleischmann WR  et al. (1991): The interferons: 
         mechanisms of action and clinical applications. JAMA. 266: 1375– 1383. 
• Barron MA, Blyveis N, Palmer BE et al. (2003): Influence of plasma viremia on 
defects in number and innunophenotype of blood dendritic cell subsets in human 
immunodeficiency virus-1 infected individuals. J.Infect.Dis.187: 26-37. 
• Barton BE (1996): The biological effects of IL-6. Med. Res. Rev.16: 87–109. 
Stellenbosch University  http://scholar.sun.ac.za
  
163 
 
 
 
 
 
• Barton GM and Medzhitov R (2002): Control of adaptive immune responses by Toll-
like receptors Curr. Opin. Immunol. Jun 14(3): 380-3. 
• Basu S, Binder R, Suto R et al. (2000): Necrotic but not apoptotic cell death releases 
heat shock proteins, which deliver a partial maturation signal to dendritic cells and 
activate the nf-kappa-β pathway. Int. Immunol. 12(11): 1539–1546. 
• Basu S and Srivastava P (2003b): Fever-like temperature induces maturation of 
        dendritic cells through induction of hsp90. Int. Immunol.15 (9): 1053– 1061. 
• Bayry J, Thirion M, Delignat S et al. (2003): Dendritic cells and autoimmunity. 
        Autoimmunity Reviews. 3: 183–187. 
• Bazzoni F and Beutler B (1995): How do tumor necrosis factors work? 
         J. Inflamm. 45: 221–238. 
• Beatty W and Russel DG (2000): Identification of mycobacterial surface proteins 
         released into subcellular compartments of infected macrophages. Infect. 
         Immun. 68: 6997–7002. 
• Becton Dickinson Biosciences Clinical and Research Catalogue (2006). 
• Bender A, Sapp M, Schuler G et al. (1996): Improved methods for the generation of 
dendritic cells from nonproliferating progenitors in human blood. J Immunol Meth. 
         196: 121 – 135. 
• Berard F, Blanco P, Davoust J et al. (2000): Priming of naive CD8 T-cells against 
melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. 
J. Exp. Med. 192: 1535–1544. 
• Belz, GT, Heath WR  and Carbone FR (2002): The role of dendritic cell 
         subsets in selection between tolerance and immunity. Immunol. Cell Biol. 
        80: 463–468. 
Stellenbosch University  http://scholar.sun.ac.za
  
164 
 
 
 
 
 
• Benvenuti F, Lagaudriere – Gesbert C, Grandjean I et al. (2004): Dendritic cell 
maturation controls adhesion, synapse formation and the duration of the interactions 
with naïve T lymphocytes. J. of Immunol. 172: 292-301. 
• Bickels J, Kollender Y, Merinsky O and  Meller I (2002): Coley’s toxin: historical 
         Perspective. Israel Med. Assoc. J. 4: 471–2. 
• Biron CA and Gazzinelli RT (1995): Effects of IL-12 on immune responses to 
microbial infections: a key mediator in regulating disease outcome. Curr. Opin. 
Immunol.7: 485–496. 
• Bleesing JJ and Fleisher TA (2001): Cell function-based flow cytometry. Semin. 
Hematol. 38: 169-78. 
• Boczkowski D, Nair SK, Nam JH et al. (2000): Induction of tumor immunity and 
cytotoxic T lymphocyte responses using dendritic cells transfected with messenger 
RNA amplified from tumor cells Cancer Res. 60: 1028-1034. 
• Bonasio R and Von Adrian UH (2006): Generation, migration and function of 
circulating dendritic cells. Curr. Opin. Immunol. 18: 503-511. 
• Bonini C, Lee SP, Riddel SR and Greenberg PD (2001): Targeting antigen in mature 
dendritic cells for simultaneous stimulation of CD 4 + and CD8+ T cells.  
J. Immunol. 166: 5250-5257.  
• Bousso P and Robey E (2003): Dynamics of CD8 T cell priming by dendritic cells in 
intact lymph nodes. Nature Immunol. 4: 579–585. 
• Brie`re F, Bendriss-Vermare N, Delale T et al. (2002): Origin and Filiation of Human 
Plasmacytoid Dendritic Cells. Human Immunology. 63: 1081–1093.  
• Brocker T (1999): The role of dendritic cells in T cell selection and survival.  
J. Leukoc. Biol. 66: 331-335. 
Stellenbosch University  http://scholar.sun.ac.za
  
165 
 
 
 
 
 
• Brossart P and Bevan MJ (1997): Presentation of exogenous protein antigens on major 
histocompatibility complex class I molecules by dendritic cells: pathway of 
presentation and regulation by cytokines. Blood. 90: 1594–1599. 
• Bueno C, Almeida J, Alguero MC et al. (2001): Flow Cytometric analysis of cytokine 
production by normal human peripheral blood dendritic cells and monocytes: 
comparative analysis of different stimuli, secretion-blocking agents and incubation 
periods. Cytometry.46: 33-40. 
• Camilla C, Defoort JP, Delaage M et al. (1998): A new flow cytometry-based multi-
assay system. 1. Application to cytokine immunoassays. Cytometry Suppl. 8: 132. 
• Camporeale A, Boni A, Iezzi G et al. (2003): Critical impact of the kinetics of dendritic 
cells activation in the in vivo induction of tumor specific T lymphocytes. Cancer Res 
Jul 1:63(13): 3688-94.  
• Cao W and Liu Y (2007): Innate immune functions of plasmacytoid cells. Curr. Opin. 
Immunol. 9: 24-30. 
• Caux C, Dezutter-Dambuyant C, Schmitt D et al. (1992a): GM-CSF and TNF-α 
cooperate in the generation of dendritic Langerhans cells. Nature 360: 258-261. 
• Caux C, Massacrier C, Vanbervilet B, Dubois B et al. (1994b): Activation of human 
dendritic cells through CD40 cross-linking. J. Exp. Med. 180: 1263. 
• Cella M, Sallusto F and Lanzavechia A (1997a): Origin, maturation and antigen 
presenting function of dendritic cells. Curr. Opin. Immunol. 9:10-16. 
• Cella M, Facchetti F, Pinet V et al. (2000b) Plasmacytoid dendritic cells activated by 
influenza virus and CD40L drive a potent TH1 polarization. Nat. Immunol. 1: 305-310. 
• Celluzzi CM, Mayordoma J, Storkus WJ et al. (1996): Peptide-pulsed dendritic cells 
induce antigen-specific, CTL-mediated protective immunity. J.Exp. Med.                   
Jan 1:183(1): 283-7. 
Stellenbosch University  http://scholar.sun.ac.za
  
166 
 
 
 
 
 
• Cerundolo V, Hermans IF and Salio M (2004): Dendritic cells: a journey from 
laboratory to clinic Nat Immunol. Jan 5(1):7-10. 
• Chapuis F, Rosenzwajg M, Yagello M et al. (1997): Differentiation of human dendritic 
cells from monocytes in vitro. Eur. J. Immunol. 27: 431-41. 
• Chaperot L, Chokri M, Jacob MC et al. (2000): Differentiation of antigen-presenting 
cells (dendritic cells and macrophages) for therapeutic application in patients with 
lymphoma. Leukemia (Baltimore) 14: 1667-1677. 
• Chehimi J, Campbell DE, Azzoni L et al. (2002): Persistent decreases in blood 
plasmacytoid dendritic cell number and function despite effective highly active 
antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected 
individuals. J Immunol 168: 4796. 
• Chen B, Shi Y, Smith JD et al. (1998): The role of tumor necrosis factor alpha in 
modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic 
cells and its role in enhancing the quality of dendritic cell function in presenting 
soluble antigens to CD4+ T cells in vitro. Blood. 91: 4652. 
• Chen R, Low L, Wilson JD et al. (1999): Simultaneous quantification of six human 
cytokines in a single sample using microparticlebased flow cytometric technology. 
Clin. Chem. 9: 1693-1694. 
• Chomarat P, Banchereau J, Davoust J et al. (2000): IL-6 switches the differentiation of 
monocytes from dendritic cells to macrophages. Nat Immunol.  1: 510-514. 
• Chow A , Toomre D, Garrett W et al. (2002): Dendritic cell maturation triggers 
retrograde MHC class II transport from lysosomes to the plasma membrane. 
Nature.418: 988–994. 
• Colaco CA (1999): Why are dendritic cells central to cancer immunotherapy?  
         Review. Molecular Medicine Today. 5(1): 14-7.   
Stellenbosch University  http://scholar.sun.ac.za
  
167 
 
 
 
 
 
• Colonna M, Krug A and Cella M (2002a): Interferon-producing cells: On the 
         front line in immune responses against pathogens. Curr. Opin. Immunol. 
         14: 373–379. 
• Colonna M, Trinchieri G and Liu YJ (2004b): Plasmacytoid dendritic cells in 
         immunity. Nat. Immunol. 5: 1219–1226. 
• Comeau MR, Van der Vuurst de Vries AR, Maliszewski CR et al. (2002): 
CD123bright plasmacytoid predendritic cells: progenitors undergoing cell fate 
conversion? J Immunol 169: 7. 
• Cook E, Stah B, Lowe L et al. (2001): Simultaneous measurement of six cytokines in a 
single sample ofhuman tears using microparticle-based flow cytometry: allergics vs. 
non-allergics. J. Immuno. Methods 254: 109-118. 
• Cyster, JG (1999): Chemokines and the homing of dendritic cells to the T cell areas of 
lymphoid organs. J.Exp. Med.189: 447–450.  
• Dale DC, Liles WC, Summer WR et al. (1995): Review: granulocyte colony-
stimulating factor (G-CSF)—role and relationships in infectious diseases. J. Infect. 
Dis.172: 1061–1075. 
• Dallal RM and Lotze MT (2000): The dendritic cell and human cancer vaccines. 
Curr. Opin. Immunol. 12: 583-588. 
• Dalod M, Salazar-Mather TP, Malmgaard L et al. (2002): Interferon alpha/beta and     
IL-12 responses to viral infections: pathways regulating dendritic cell cytokine 
expression in vivo. J Exp Med 195: 517. 
• D’Andrea AM, .Aste-Amezaga NM, Valiante X et al. (1993): Interleukin-10 (IL-10) 
inhibits human lymphocyte interferon- g-production by suppressing natural killer cell 
stimulatory factor/ IL-12 synthesis in accessory cells. J. Exp. Med. 178: 1041–1048. 
Stellenbosch University  http://scholar.sun.ac.za
  
168 
 
 
 
 
 
• Demangel C, Bean AG, Martin E et al. (1999): Protection against aerosol 
Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette 
Guerin infected dendritic cells. Eur. J. Immunol. 29: 1972-1979. 
• Demangel C, Palendira U, Feng CG et al. (2001): Stimulation of dendritic cells via 
CD40 enhances immune responses to Mycobacterium tuberculosis infection. Infect. 
Immun. 69:2456-2461. 
• De Smedt T, Pajak B, Muraille E et al. (1996): Regulation of dendritic cell numbers 
and maturation by lipopolysaccharide in vivo.J. Exp. Med. 184: 1413–1424. 
• De Vries IJ, Krooshoop DJ, Scharenborg NM et al. (2003): Effective migration of 
antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by 
their maturation state. Cancer Res.63: 12–17. 
• Dezutter-Dambuyant C, Schmitt DA, Dusserre N et al. (1991): Interaction of human     
epidermal Langerhans cells with HIV-1 viral envelope proteins (gp 120 and gp 160s) 
involves a receptor-mediatedendocytosis independent of the CD4 T4A epitope. J. 
Dermatol.18: 377–392. 
• Dhodapkar MV and Steinman RM (1999a): Rapid generation of broad T-cell immunity     
in humans after a single injection of mature dendritic cells. J. Clin. Invest.104: 173–
180 
• Dhodapkar MV and Bhardwaj N (2000b): Active immunization of humans with     
dendritic cells. J. Clin. Immunol. 20: 167–174. 
• Dhodapkar MV, Krasovsky J, Steinman RM et al. (2000c): Mature dendritic cells 
boost functionally superior CD8 (+) T-cell in humans without foreign helper epitopes. 
J. Clin. Invest. 105: R9-R14. 
• Dickson J (1979): Hyperthermia in the treatment of cancer.Lancet 1(8109):202-205. 
Stellenbosch University  http://scholar.sun.ac.za
  
169 
 
 
 
 
 
• Diebold SS, Montoya M, Unger H et al. (2003): Viral infection switches non-
plasmacytoid dendritic cells into high interferon producers. Nature. 424: 324-8. 
• Dieu MC, Vanbervliet B, Vicari A et al. (1998): Selective recruitment of immature and 
mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. 
Exp. Med.188: 373-386. 
• Dieu –Nosjean MC, Massacrier C, Homey B et al. (1999): Regulation of dendritic cell 
trafficking: a process that involves the participation of selective chemokines.  J. 
Leukoc. Biol. 66: 252-262. 
• Donaghy H, Pozniak A, Gazzard B et al. (2001a): Loss of blood CD11c+ myeloid and 
CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with 
HIV-1 RNA virus load. Blood. 98:2574-2576. 
• Donaghy H, Gazzard B, Gotcj F et al. (2003b): Dysfunction and infection of freshly 
isolated blood myeloid and plasmacytoid dendritic cells in patients infected with     
HIV-1. Blood 101: 4505-4511. 
• Donaghy H, Wilkinson J and Cunningham AL (2006c): HIV interactions with dendritic 
cells: has our focus been too narrow?  J. Leukoc. Biol. 80: 1001-1012.  
• Duramad O, Fearon KL., Chan JH et al. (2003): IL-10 regulates plasmacytoid dendritic 
cellresponse to CpG-containing immunostimulatory sequences. Blood 102: 4487–4492. 
• Durie FH, Foy TM, Masters SR et al. (1994): Therole of CD40 in the regulation of 
humoral and cell-mediated immunity. Immunol Today 15: 406. 
• Dzionek A, Fuchs A, Schmidt P et al. (2000): BDCA-2, BDCA-3 and BDCA -4: three 
markers for distinct subsets of dendritic cells in human peripheral blood. J 
         J.of Immunol. 165(11): 6037-6046. 
• Egan MA (2007): Towards the development of a therapeutic vaccine for the treatment 
of HIV-1 infection: are we closer than ever? Expert Rev. Vaccines. 6(3): 289-291. 
Stellenbosch University  http://scholar.sun.ac.za
  
170 
 
 
 
 
 
• Eloranta ML, Sandberg K, Ricciardi-Castagnoli et al. (1997): Production of interferon-
alpha/beta by murine dendritic cell lines stimulated by virus and bacteria. Scand. J. 
Immunol. 46: 235-241. 
• Ensor JE, Wiener SM, McCrea KA et al. (1994): Differential effects of hyperthermia 
on macrophage IL-6 and tumor necrosis factor-α expression, Am. J. Physol. Cell 
Physiol. 266: C967–C974. 
• Esche C, Lokshin A, Shurin GV et al. (1999): Tumor’s other immune targets: dendritic 
cells J. Leukoc. Biol. 66: 336-344. 
• Facchetti F, de Wolf-Peeters C, Mason DY et al. (1988): Plasmacytoid T cells. 
Immunohistochemical evidence for their monocyte/macrophage origin. Am J Pathol 
1988, 133: 15-21. 
• Faith A and Hawrylowicz CM (2005): Targeting the dendritic cell: the key to 
immunotherapy in cancer? Clinical and Experimental Immunology. 
         139 (3): 395-397. 
• Falkenburg.JHF (1994): IL-4 down-regulates IL-2-, IL-3-, and GM-CSF induced 
         cytokine gene expression in peripheral blood monocytes. Ann.Hematol. 68: 293–298. 
• Faratian D, Colvin L, O’Connell PJ et al. (2000): Dendritic Cell Heterogeneity: A 
Complex Picture Emerges. Graft. 3(2): 54-58. 
• Farrar MA and Schreiber.RD (1993): The molecular cell biology of interferon-g and its 
receptor. Annu. Rev. Immunol.11: 571–611. 
• Fehervari Z, Sakaguchi S (2004): Control of Foxp3+ CD25+CD4+ regulatory cell 
         activation and function by dendritic cells. Int Immunol; 16: 1769–80. 
• Feldman S, Stein D, Amrute S et al. (2001): Decreased interferon-alpha production in 
HIV-infected patients correlates with numerical and functional deficiencies in 
circulating type 2 dendritic cell precursors. Clin Immunol. 101: 201-210. 
Stellenbosch University  http://scholar.sun.ac.za
  
171 
 
 
 
 
 
• Ferrero E, Bondanza A, Leone BE et al. (1998): CD14+ CD34+ peripheral blood 
mononuclear cells migrate across endothelium and give rise to immunostimulatory 
dendritic cells. J. Immunol.15. 160 (6): 2675-83. 
• Fiebiger E, Meraner P, Weber E et al. (2001): Cytokines regulate proteolysis in major 
histocompatibility complex class II-dependent antigen presentation by dendritic cells. 
J. Exp.Med.193: 881–892. 
• Figdor CG, de Vries IJM, Lesterhuis WJ and Melief CJM (2004): Dendritic cell 
immunotherapy: mapping the way. Nat. Med.10: 475– 80. 
• Filgueria L, Nestle FO, Rittig M et al. (1996): Human dendritic cells phagocytose and 
process Borrelia burgdorferi. J. Immunol. 157: 2998.  
• Finn O (2003): Cancer vaccines: Between the idea and the reality. Nature reviews: 
Immunology.3: 630-641. 
• Fong L and Engleman EG (2000a): Dendritic cells in cancer immunotherapy 
Ann.Rev.Immunol. 18: 245 – 273. 
• Fong L, Mengozzi M, Abbey NW et al. (2002b): Productive infection of plasmacytoid 
dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 
ligation. J. Virol.76: 11033-11041. 
• Fonteneau JF, Larsson M, Beignon AS (2004): Human immunodeficiency virus type 1 
activates plasmacytoid dendritic cells and concomitantly induces the bystander 
maturation of myeloid dendritic cells. J. Virol. 78 (10): 5223-32. 
• Foti M, Granucci F, Aggujaro D et al. (1999): Upon dendritic cell activation 
chemokines and chemokine receptor expression are rapidly regulated for recruitement 
and maintenance of DC at the inflammatory site. Int. Immunol 11: 979-986. 
 
Stellenbosch University  http://scholar.sun.ac.za
  
172 
 
 
 
 
 
• Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. (2004): The linkage of innate to 
adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in 
addition to antigen presentation and CD80/86 costimulation. J. Exp.Med.                   
Jun 21; 199 (12): 607-18.  
• Fujimoto T, Duda RB, Szilvasi A et al. (1997): Streptococcal preparation OK432 is a 
potent inducer of IL-12 and a T helper cell 1 dominant state. J. Immuno.158: 5619. 
• Fulton R, McDade R  and P Smith (1997): Advanced multiplexed 
         analysis with the FlowMetrix system. Clin. Chem. 43: 1749 -1756. 
• Gabrilovich DI, Ciernik F and Carbone DP (1996): Dendritic cells in antitumor 
immune responses. Defective antigen presentation in tumor-bearing hosts. Cell 
Immunol.      170: 101. 
• Gallagher R (1997): Tagging T cells: TH1 or TH2? Science. Mar 14; 275 (5306):1615. 
• Galibert L, Maliszewski CR and Vandenabeele S (2001): Plasmacytoid  monocytes /T 
cells: a dendritic cell lineage? Semin. Immunol. 13: 283-289. 
• Galluci S, Lolkema M and Matzinger P (1999a): Natural adjuvants :endogenous 
activators of dendritic cells. Nat. Med. 5:1249-1255. 
• Galluci S and Matzinger P (2001b): Danger signals: SOS to the immune system. 
         Curr, Opin. Immunol. 13: 111-119  
• Garcia E, Pion M, Pelchen-Matthews A et al. (2005): HIV-1 trafficking to the dendritic 
cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the 
immunological synapse. Traffic.6:  488-501. 
• Geiger J, Hutchinson R, Hohenkirk L et al. (2000): Treatment of solid tumours in 
children with tumour-lysate-pulsed dendritic cells. Lancet 356, 1163–1165. 
Stellenbosch University  http://scholar.sun.ac.za
  
173 
 
 
 
 
 
• Geijtenbeek TB, Kwon DS, Torensma R et al. (2000): DC-SIGN, a dendritic cell-
specific HIV-1-binding protein that enhances trans-infection of T cells. Cell.            
100: 587-597. 
• Giacomini E, Iona E, Ferroni L et al. (2001): Infection of human macrophages 
         and dendritic cells with Mycobacterium tuberculosis induces a differential 
         cytokine gene expression that modulates T cell response. J. Immunol. 
         166: 7033–41. 
• Gilliet M. and Liu YJ (2002): Generation of human CD8 T regulatory cells by 
   CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med.                              
195: 695–704. 
• Girardi M (2006): Immunosurveillance and immunoregulation by γδ T cells. 
         Invest Dermatol 126 (1): 25-31. 
• Girolomoni G and Ricciardi-Castagnoli P (1997): Dendritic cells hold promise in 
immunotherapy.Immunol Today.18 (3): 102-4. 
• Givan AL (2001): Principles of flow cytometry: an overview. Methods Cell Biol.       
63: 19-50. 
• Gong J, Chen D, Kashiwaba M and Kufe D (1997): Induction of antitumour activity by 
immunization with fusions of dendritic and carcinoma cells. Nature Med.3: 558. 
• Gorak PM, Engwerda CR and Kaye PM (1998): Dendritic cells, but not macrophages, 
produce IL-12 immediately following Leishmania donovani infection. Eur. J. 
Immunol.28: 687-695. 
• Grabbe S, Kämpgen E and Schuler G (2000): Dendritic cells: multi-lineal and multi-
functional. Immunology Today.21: 431-433. 
• Grakoui A, Bromley SK, Sumen C et al. (1999): The immunological synapse: a 
molecular machine T cell activation. Science 285: 221-227.  
Stellenbosch University  http://scholar.sun.ac.za
  
174 
 
 
 
 
 
• Grohmann U, Bianchi R, Belladonna ML et al.(1999) IL-12 acts selectively on CD8 
alpha- dendritic cells to enhance presentation of a tumor peptidein vivo.J. Immunol.  
163: 3100-3105.  
• Grouard G, Rissoan MC, Filgueira L .et al. (1997): The enigmatic plasmacytoid T cells 
develop into dendritic cells with IL-3 and CD40-ligand. J. Exp. Med.185: 1101–1111. 
• Groot F, Geijtenbeek TB, Sanders RW et al. (2005a): Lactoferrin prevents dendritic 
cell-mediated human immunodeficiency virus type 1 transmission by 
          blocking the DC-SIGN—gp120 interaction. J. Virol. 79: 3009-3015. 
• Groot F, van Capel T.M.M, Schuitemaker JHN et al. (2006b): Differential 
susceptibility of naïve, central memory and effector memory T cells to dendritic cell-
mediated HIV-1 transmission Retrovirology (3) 52: 1-10. 
• Groot F, van Capel, TMM, Kapsenberg ML et al. (2006c): Opposing roles of blood 
myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission 
facilitation versus replication inhibition. Blood 108: 1957-1964. 
• Gruber A, Kan-Mitchell J, Kuhen KL et al. (2000): Wong-Staal. Dendritic cells 
transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions 
and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood.               
96: 1327-1333. 
• Guermonprez P, Valladeau J, Zitvogel L et al. (2002): Antigen presentation and T cell 
stimulation by dendritic cells. Annu Rev Immunol. 20: 621-67. 
• Guery J and Adorini L (1995): Dendritic cells are the most efficient in presenting 
endogenous naturally processed self-epitopes to class II-restricted T cells. J 
Immunol.154: 536.  
Stellenbosch University  http://scholar.sun.ac.za
  
175 
 
 
 
 
 
• Gunzer M, Schafer A, Borgmann S et al. (2000): Antigen presentation in extracellular 
matrix: interactions of T cells with dendritic cells are dynamic, short lived, and 
sequential. Immunity 13: 323–332. 
• Harshyne LA, Watkins SC, Gambotto A et al. (2001): Dendritic cells acquire antigens 
from live cells for cross- presentation to CTL. J. Immunol 166: 3717-3727. 
• Hart DNJ (1997): Dendritic cells: unique leukocyte populations which control the 
primary immune response. Blood. 90: 3245-3287. 
• Hayakawa Y, Smyth MJ (2006): Innate immune recognition and suppression of 
tumors. Adv Cancer Res. 95: 293–322. 
• Heath WR and Carbone FR (2001): Cross-presentation, dendritic cells, tolerance and 
immunity. Annu. Rev. Immunol.19: 47–64. 
• Heufler C, Koch F Stanzi U et al. (1996): IL-12 is produced by dendritic cells and 
mediates TH 1 development as well as interferon gamma production by TH1 cells. Eur. 
J. Immunol. 26: 659:668. 
• Hellman P, Eriksson P (2007): Early Activation Markers of Human Peripheral 
Dendritic Cells Human Immunology 68: 324–333. 
• Hemmi H, Kaisho T, Takeuchi O et al. (2001): Toll-like receptors and innate 
immunity.Nature Rev Immunol 1: 135. 
• Henderson RA, Watkins SC and Flynn JL (1997): Activation of human dendritic 
         cells following infection with Mycobacterium tuberculosis. J. Immunol. 
         159: 635–43. 
• Hendrzak JA and Brunda MJ (1995): Biology of disease. IL-12: biologic activity, 
therapeutic utility, and role in disease. Lab. Invest.72: 619–114. 
 
Stellenbosch University  http://scholar.sun.ac.za
  
176 
 
 
 
 
 
• Herrmann TL, Morita CT Lee K et al. (2005): Calmodulin kinase II regulates the 
maturation and antigen presentation of human dendritic cells. 
         J. Leuco.Biology.78: 1397-1407. 
• Hermans IF, Moroni Rawson P, Ronchese F et al. (1998a): The emerging role of    the 
dendritic cell in novel cancer therapies. New Zealand Medical Journal.           
111(1063): 11-113. 
• Hermans IF, Silk JD, Gileadi U et al. (2007b): Dendritic cell function can be 
modulated through cooperative actions of TLR ligands and invariant NKT cells. J 
Immunol. Mar 1; 178(5): 2721-9. 
• Hertz C J., Kiertscher SM, Godowski PJ et al. (2001): Microbial lipopeptides stimulate 
dendritic cell maturation via Toll-like receptor. J. Immunol. 166: 2444. 
• Hochrein H, O’Keeffe M, Luft T et al. (2000): IL-4 is a major regulatory cytokine 
governing bioactive IL-12 prudction by mouse and human dendritic cells. J. Exp. Med. 
Sep 18; 192 (6): 823-33. 
• Holtmeier W, Kabelitz D (2005): γδ T cells link innate and adaptive immune 
responses. Chem. Immunol. Allergy. 86: 151-183. 
• Hommel M (2004): On the dynamics of T cell activation in lymph nodes. Immunol. 
Cell Biol 82: 62-66. 
• Howard CJ, Sopp P, Brownlie J et al. (1997): Identification of two distinct populations 
of dendritic cells in afferent lymph that vary in their ability to stimulate T cells. J. 
Immunol. 159: 5372–5382.  
• Hsu FJ, Benike C, Fagnoni F et al. (1996): Vaccination of patients with B-cell 
lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52–58. 
Stellenbosch University  http://scholar.sun.ac.za
  
177 
 
 
 
 
 
• Huang, FP, Platt N, Wykes M et al. (2000): A discrete subpopulation of dendritic cells 
transports apoptotic intestinalepithelial cells to T cell areas of mesenteric lymph nodes. 
J. Exp. Med. 191: 435–444. 
• Ida JA, Shrestha N, Desai S et al. (2006): A whole blood assay to assess peripheral 
blood dendritic cell function in response to Toll-like receptor stimulation.  
J. Immunol. Meth. 310: 86–99. 
• Inaba K, Metlay JP, Crawley MT and Steinman RM (1990a): Dendritic cells pulsed 
with protein antigens in vitro can prime antigen specific, MHC-restricted T cells in 
situ. J. Exp. Med.172: 631–640. 
• Ingulli E, Mondino A, Khoruts A and Jenkins MK (1997b): In vivo detection of 
dendritic cell antigen presentation to CD4+ T-cells. J. Exp. Med. 185: 2133 – 2141. 
• Iruretagoyena MI, Wiesendanger M and Kalergis AM (2006): The Dendritic Cell-T 
Cell Synapse as a Determinant of Autoimmune Pathogenisis. Current Pharmaceutical 
Design 12: 131-147. 
• Ito T, Amakawa R, Kaisho T et al. (2002): Interferon-alpha and IL-12 are   induced 
differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. 
Exp. Med. 195: 1507. 
• Ito T, Yang M, Wang Y et al. (2007b): Plasmacytoid dendritic cells prime IL-10 
producing T regulatory cells by inducible costimulator ligand. J Exp Med. 22;           
204 (1): 105-15. 
• Iwasaki A and Medzhitov R (2004): Toll-like receptor control of the adaptive immune 
responses. Nat Immunol.5: 987- 995. 
• Janeway CA and Travers P (1996): Immunobiology: The immune system in health and 
disease Garland Publishing Inc.1:1-1:32 ISBN 0-443-05658-7. 
Stellenbosch University  http://scholar.sun.ac.za
  
178 
 
 
 
 
 
• Jarrossay D, Napolitani G, Colonna M et al. (2001): Specialization and 
complementarity in microbial molecule recognition by human myeloid and 
plasmacytoid dendritic cells. Eur. J. Immunol. 31: 3388. 
• Jenne L, Arrighi JF, Jonuleit H et al. (2000): Dendritic cells containing 
apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell 
lysis.Cancer Res.Aug 15; 60 (16): 4446-52. 
• Jiang W, Swiggard WJ, Heufler C et al. (1995): The receptor DEC-205 expressed by 
dendritic cells and thymic epithelial cells is involved in antigen processing. Nature.   
375: 151-155.  
• Joyce DA and Steer JH (1996): IL-4, IL-10 and IFN-γ have distinct, but interacting, 
effects on differentiation-induced changes in TNF-α and TNF receptor release by 
cultured human monocytes. Cytokine 8: 49–57. 
• Kabelitz D and Medzhitov R (2007): Innate immunity - cross-talk with adaptive 
immunity through pattern recognition receptors and cytokines. Curr.Opin. Immunol.   
19: 1–3. 
• Kadowaki N, Ho S, Antonenko S et al. (2001): Subsets of human dendritic cell 
precursors express different Toll-like receptors and respond to different microbial 
antigens. J. Exp. Med. 194: 863-869. 
• Kalinski P, Schuitemaker JH, Hilkens CM et al. (1999a): Final maturation of dendritic 
cells is associated with impaired responsiveness to IFN-γ and to bacterial IL-12 
inducers: decreased ability of mature dendritic cells to produce IL-12 during the 
interaction with TH cells. J. Immunol. 162: 3231–3236.     
• Kalinski  P, Hilkens CM, Wierenga EA et al. (1999b): T-cell priming by type-1 and  
type 2 polarized dendritic cells: the concept of a third signal. Immunol. Today. 
20: 561–567b. 
Stellenbosch University  http://scholar.sun.ac.za
  
179 
 
 
 
 
 
• Karnitz LM and Abraham RT (1995): Cytokine receptor signaling mechanisms. Curr    
Opin Immunol.Jun; 7 (3):320–326. 
• Kapsenberg, ML (2003): Dendritic-cell control of pathogen-driven T cell  polarization. 
Nat. Rev. Immunol. 3: 984–993. 
• Kato T, Morokata T, Igarashi O et al. (1997): Costimulatory effect of IL-12 on the 
activation of naive, memory CD4+ T cells, and Th1 clone. Cell Immunol. Feb 25;     
176 (1):50–58. 
• Kawamura K, Kadowaki N, Kitawaki T et al. (2006): Virus stimulated 
      plasmacytoid dendritic cells induce CD4+ cytotoxic regulatory T cells. Blood.           
107: 1031–1038. 
• Kikuchi K, Yanagawa Y, Aranami T et al. (2003): Tumour necrosis factor-a but not 
lipopolysaccharide enhances preference of murine dendritic cells for TH2 
differentiation. Immunology 108: 42- 49. 
• Kim KD, Lee HG, Kim JK et al. (1999): Enhanced antigen-presenting activity 
      and tumour necrosis factor-alpha–independent activation of dendritic cells following 
treatment with Mycobacterium bovis bacillus Calmette- Gue´rin. Immunology 97: 626–
33. 
• Koch F, Stanzl U, Jennewein P et al. (1996): High level IL-12 production by murine 
dendritic cells: upregulation via MHC class II and CD40 molecules and down 
regulation by IL-4 and IL-10 published erratum appears in J. Exp .Med. 1 ;                   
J. Exp. Med.; 184: 741-6.  
• Kohrgruber N, Halanek N, Groger M et al. (1999): Survival, maturation, and 
      function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially 
      regulated by cytokines. J. Immunol.163: 3250. 
Stellenbosch University  http://scholar.sun.ac.za
  
180 
 
 
 
 
 
• Kronin V, Winkel K, Suss G et al. (1996): A subclass of dendritic cells regulates the 
response of naive CD8 T cells by limiting their IL-2 production. 
      J. Immunol.157:  3819–3827.  
• Kurts C, Cannarile M, Klebba I and Brocker T (2001): Dendritic cells are 
      sufficient to cross-present self-antigens to CD8 T cells in vivo. J. Immunol.              
166: 1439–1442. 
• Kwon DS, Gregorio G, Bitton N et al. (2002): DC-SIGN-mediated internalization of 
HIV is required for trans-enhancement of T cell infection. Immunity.16: 135-144. 
• Lambrecht BN (2001): Allergen uptake and presentation by dendritic cells. Curr. Opin. 
Allergy Clin. Immunol. Feb (1): 51-9. 
• Langenkamp A, Messi M, Lanzavecchia A et al. (2000): Kinetics of dendritic cell 
activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol.    
1: 311. 
• Larsson M, Fonteneau JF, Bhardway N et al. (2001a): Dendritic cells resurrect antigens 
from dead cells Trends in immunology 22: 141-147. 
• Larsson M, Beignon AS and Bhardway N (2004b): DC-virus interplay:a double edged 
sword. Semin. Immunol. 16: 147-161. 
• Lechmann M, Berchtold S, Hauber J et al. (2002): CD83 on dendritic cells: more than 
just a marker for maturation. Trends in immunology 23: 273-275. 
• Lee JD, Rhoades K and  Economou  JS (1995): IL-4 inhibits the expression of tumour 
necrosis factors a and b, IL-1β and -6 and interferon-γ. Immunol. Cell Biol. 73: 57–61. 
• Levine TP, Chain BM (1992): Endocytosis by antigen presenting cells: Dendritic cells 
are as endocytically active as other antigen presenting cells. Proc. Natl. Acad. Sci. 
USA. 89: 8342.  
Stellenbosch University  http://scholar.sun.ac.za
  
181 
 
 
 
 
 
• Liles WC and Van Voorhis WC (1995): Review: nomenclature and biologic 
significance of cytokines involved in inflammation and the host immune response. 
      J. Infect. Dis. Dec; 172 (6): 1573–1580. 
• Lipscomb MF, Masten BJ (2002): Dendritic cells: Immune regulators in health and 
Disease. Physiol.Rev. 82: 97-130. 
• Liu YJ, Kanzler H, Soumelis V and Gilliet M (2001a): Dendritic cell lineage, plasticity 
and cross-regulation. Nat Immunol. 2: 585–9. 
• Liu Y J (2005b): Professional type 1 interferon-producing cells and plasmacytoid 
dendritic cell precursors. Annu. Rev. Immunol.23: 275–306. 
• Lore K, Smed Sorensen A, Vasudevan J et al. (2005): Myeloid and plasmacytoid 
dendritic cells transfer HIV-1 preferentially to antigen specific CD 4+ Cells. J. Exp. 
Med. 201: 2023-2033. 
• Lotze MT, Hellerstedt B and Stolinski L (1997a): The role of IL-1, IL-12 and dendritic 
cells in cancer therapy. Cancer J. Sci. Am. 3: S109-14. 
• Lotze MT and Thomson AW (2001b): Dendritic cells: Biology and Clinical 
Applications, 2nd edn. London:Academic Press 1-794. 
• Lu W, Arreas LC; Ferreira WT et al. (2004):Therapeutic dendritic –cell vaccine for 
chronic HIV-1 infection. Nat. Med. 10(12): 1359-1365.    
• Lucey DR, Clerici M, and Shearer GM (1996): Type 1 and type 2 cytokine 
dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin 
Microbiol Rev. Oct; 9(4): 532–562. 
• Ludewig B, Ehl S, Karrer U et al. (1998a): Dendritic cells efficiently induce protective 
antiviral immunity. J. Virol. 272: 3812 – 3818. 
Stellenbosch University  http://scholar.sun.ac.za
  
182 
 
 
 
 
 
• Ludewig B, Barchiesi F, Pericin M et al. (2000b): In vivo antigen loading and 
activation of dendritic cells via a liposomal peptide vaccine mediates protective 
antiviral and anti-tumor immunity. Vaccine.19: 23–32. 
• Lutz MB and Schuler G (2002): Immature, semi-mature and fully mature dendritic 
      cells: which signals induce tolerance or immunity? Trends Immunol.23: 445–449. 
• Macagno A, Napolitani G, Lanzavecchia A et al. (2007): Duration, 
      combination and timing: the signal integration model of dendritic cell 
      activation. Trends Immunol. May 28(5): 227-33. 
• Macatonia SE, Lau R, Patterson S et al. (1990a): Dendritic cell infection, depletion and 
dysfunction in HIV-infected individuals. Immunology 71: 38–45. 
• Macatonia SE, Hosken NA, Litton M et al (1995b): Dendritic cells produce IL-12 and 
direct the development of Th1 cells from naive CD4+ T cells. J. Immunol. 154: 5071. 
• MacDonald KP, Munster DJ, Clark DJ et al. (2002): Characterization of human blood 
dendritic cell subsets.Blood.100: 4512-4520. 
• Macey MG, McCarthy DA, Vogiatzi D et al. (1998): Rapid flow cytometric 
identification of putative CD14- and CD64- dendritic cells in whole blood. Cytometry 
81: 199-207.  
• MacPherson GG and L. Liu (1993): Dendritic cells “in vivo”: migration and antigen 
handling p. 327–332. In E. W. A. Kamperdijk, P. Nieuwenhuis and E. C. M. Hoefsmit 
(ed.), Dendritic cells in fundamental and clinical immunology. Plenum Press, New 
York. 
• Maldonado-Lopez R and Moser M (2001): Dendritic cell subsets and the regulation of 
TH1/TH2 responses. Semin. Immunol. Oct;13 (5): 275-821. 
Stellenbosch University  http://scholar.sun.ac.za
  
183 
 
 
 
 
 
• Manca F, Li Pira G, Fenoglio D et al. (1994): Dendritic cells are potent antigen-
presenting cells for in vitro induction of primary human CD41 T-cell lines specific for 
HIV gp120. J. Acq. Immune Defic. SynDr 7: 15–23. 
• Markowicz S and Engleman EG (1990): Granulocyte-macrophage colony-stimulating 
factor promotes differentiation and survival of human peripheral blood dendritic cells 
in vitro. J. Clin. Invest.85: 955-961. 
• McCarthy DA, Macey MG, Bedford PA et al. (1997): Adhesion molecules are 
upregulated on dendritic cells isolated from human blood. Immunology.                     
92: 244-251. 
• McDonald D, Wu L, Bohks SM et al. (2003): Recruitment of HIV and its receptors to 
dendritic cell-T cell junctions. Science.300: 1295-1297. 
• McHeyzer-Williams M, McHeyzer-Williams L,Panus J (2003): Helper T cell-regulated 
B cell immunity. Microbes Infect. Mar; 5 (3): 205-12. 
• McHugh TM (1994): Flow microsphere immunoassay for the quantitative and 
simultaneous detection of multiple soluble analytes. Methods in Cell. Biology.           
42: 575-595.   
• McLellan AD and Kampgen E (2000): Functions of myeloid and lymphoid dendritic 
cells. Immunol Lett .May 1; 72 (2): 101-5. 
• McKenna K, bIegnon AS, Bhardwaj N et al. (2005): Plasmacytoid Dendrtitic cells: 
Linking innate and Adaptive immunity. J. Virol. 79 (1):17-27. 
• McLellan AD and Kampgen E (2000): Functions of myeloid and lymphoid dendritic 
cells. Immunol Lett.May 1; 72 (2): 101-5. 
• McWilliam AS, Napoli S, Marsh AM et al. (1996): Dendritic cells are recruited into 
the airway epithelium during the inflammatory response to a broad spectrum of stimuli. 
J. Exp. Med. 184: 2429-2432.  
Stellenbosch University  http://scholar.sun.ac.za
  
184 
 
 
 
 
 
• Mellman I and Steinman RM (2001): Dendritic cells: specialized and regulated antigen 
processing machines. Cell 106: 255–258. 
• Mempel TR, Henrickson, SE and von Andrian, UH (2004): T-cell 
      priming by dendritic cells in lymph nodes occurs in three distinct phases. 
      Nature.427: 154–159. 
• Meyers JH, Justement JS, Hallahan CW et al.(2007): Impact of HIV on Cell Survival 
and Antiviral Activity of Plasmacytoid Dendritic Cells. PLoS ONE. May 23: 2. 
• Miggin  SM and O’Neill LA (2006): New insights into the regulation 
      of TLR signaling. J. Leukoc. Biol. 80:  220–226. 
• Mitchell DA, Nair SK, Gilboa E et al. (1998): Dendritic cell/macrophage precursors 
capture exogenous antigen for MHC class I presentation by dendritic cells Eur. J. 
Immunol. 28: 1923–1933. 
• Mohamdzadeh M and Luftig R (2004): Dendritic cells: In the forefront of 
immunopathogenisis and vaccine development- A Review. Journal of Immune based 
therapies and vaccines 2: 1-11. 
• Montoya  MC, Sancho D, Vicente-Manzanares M and Sanchez- Madrid F (2002): Cell 
adhesion and polarity during immune interactions. Immunol. Rev 186: 68–82. 
• Morgan DJ, Kreuwel HT, Sherman LA et al. (1999) Antigen concentration and 
precursor frequency determine the rate of CD8+ T-cell tolerance to peripherally 
expressed antigens. J. Immunol.163: 723–727. 
• Morse MA, Mosca P, Clay TM, Lyerly HK (2002): Dendritic cell maturation in active 
immunotherapy strategies. Expert Opin. Biol. Ther. 2: 35–43. 
• Moser M, Murphy KM (2000): Dendritic cell regulation of TH1-TH2 development. 
Nat. Immunol.1: 199. 
Stellenbosch University  http://scholar.sun.ac.za
  
185 
 
 
 
 
 
• Nair S, Zhou F, Reddy R, Huang L et al. (1992): Soluble proteins delivered to dendritic 
cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in 
vitro. J. Exp.Med. 175: 609–612. 
• Nakahara S, Tsunoda T, Baba T et al. (2003): Dendritic Cells Stimulated with a 
Bacterial Product, OK-432, Efficiently Induce Cytotoxic T Lymphocytes Specific to 
Tumor Rejection Peptide.Cancer Research. 63:  4112-4118.  
• Nelson CA, Petzold SJ and Unanue ER (1994): Peptides determine the lifespan of 
MHC class II molecules in the antigen-presenting cell. Nature. 371: 250–252.  
• Nelson EL, Strobl S, Sobleski J et al. (1999): Cycling of human dendritic cell effector 
phenotypes in response to TNF- α: modification of the current “maturation” paradigm 
and implications for in vivo immunoregulation. The FASEB journal.13: 2021-2030. 
• Nestle FO, Alijagic S, Gilliet M et al. (1998): Vaccination of melanoma patients with 
peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328– 32. 
• Netea MG, van der Graaf C, Van der Meer JW, Kullberg BJ (2004): Toll-like receptors 
and the host defense against microbial pathogens: bringing specificity to the innate-
immune system. J. Leukoc. Bio. l75: 749- 755. 
• Nguyen LT, Radhakrishnan S, Ciric B et al. (2002): Cross-linking the B7 family 
      molecule B7-DC directly activates immune functions of dendritic cells. J. Exp. 
Med.196: 1393-1398. 
• Nouri-Shirazi M, Banchereau J, Bell D et al. (2000): Dendritic cells capture killed 
tumor cells and present their antigens to elicit tumor-specific immune responses.J 
Immunol 165: 3797-3803. 
• O’Doherty U, Peng M, Gezelter S et al. (1994): Human blood contains two subsets of 
dendritic cells, one immunologically mature and the other immature. Immunology.    
82: 487. 
Stellenbosch University  http://scholar.sun.ac.za
  
186 
 
 
 
 
 
• O’Gorman MRG (2001): Clinically relevant functional flow cytometry assays. Clin. 
Lab. Med.21: 779-794. 
• O’Garra A (1998): Cytokines induce the development of functionally heterogeneous T 
helper cell subsets. Immunity. 8:  275–283. 
• Oliver KG, Kettman JR and Fulton RJ (1998): Multiplexed analysis of human 
cytokines by use of the FlowMetrix system. Clin. Chem.44: 2057-60. 
• Olweus J, BitMansour A, Warnke R et al. (1997): Dendritic cell ontogeny: a human 
dendritic cell lineage of myeloid origin. Proc. Natl. Acad .Sci .USA 94: 12551-12556. 
• O’Neil D, Adams S and Bhardwaj N (2004): Manipulating dendritic cell biology for 
the active immunotherapy of cancer. Blood.104: 2235-2246. 
• O'Sullivan B and Thomas R (2003): CD40 and dendritic cell function. Crit Rev 
Immunol. 23 (1-2): 83-107.  
• Ossevoort MA, Kleijmeer MJ, Nijman HW et al. (1995): Functional and ultrastructural 
aspects of antigen processing by dendritic cells. p. 227–231. In J. Banchereau and D. 
Schmitt, Dendritic cells in fundamental and clinical immunology, vol. 2 Plenum Press, 
New York. 
• Pacanowski J, Kahi S, Bailllet M et al. (2001): Reduced blood lymphoid and myeloid 
dendritic cell numbers in primary HIV-1 infection. Blood. 98: 3016-3021. 
• Paczesny S, Ueno H, Fay J et al. (2003): Dendritic cells as vectors for immunotherapy 
of cancer. Seminars Cancer Biol. 13: 439-47. 
• Palucka K and Banchereau J. (2002): How dendritic cells and microbes interact to elicit 
or subvert protective immune responses. Curr. Opin. Immunol.14: 420-431. 
• Pan J, Zhang M, Wang J et al.(2004): Interferon-γ is an autocrine mediator for 
     dendritic cell maturation. Immunol. Lett. 94: 141–151. 
Stellenbosch University  http://scholar.sun.ac.za
  
187 
 
 
 
 
 
• Patterson S, Robinson SP, English NR et al. (1999a): Subpopulations of peripheral 
blood endritic cells show differential susceptibility to infection with a lymphotropic 
strain of HIV-1. Immunol Lett. Mar, 66(1-3):111-6. 
• Patterson S (2000b): Flexibility and cooperation among dendritic cells. Nat. Immunol.    
1: 273-274. 
• Patterson S, Rae A, Hockey N et al. (2001c): Plasmacytoid dendritic cells are highly 
susceptible to human immunodeficiency virus type 1 infection and release infectious 
virus. J. Virol. 75: 6710-6713. 
• Penna G, Vulcano M., Roncari A.et al. (2002): Cutting edge: Differential chemokine 
production by myeloid and plasmacytoid dendritic cells. J. Immunol.169: 6673-6676. 
• Piguet V and Steinman RM (2007): The interaction of HIV with dendritic cells: 
outcomes and pathways. TRENDS in Immunology.Vol.28 (11): 503-510. 
• Piqueras B, Connolly O, Frietas H et al. (2006): Upon viral exposure, myeloid and 
plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruite 
immune effectors.Blood.107: 2613-2618. 
• Prechtel AT and Steinkasserer A (2007): CD83: an update on functions and prospects 
of the maturation marker of dendritic cells.Arch. Dermatol. Res. 299: 59–69. 
• Prussin, C. and D. Metcalfe.(1995): Detection of intracytoplasmic cytokine using flow 
cytometry and directly conjugated anti-cytokine antibodies. J. Immunol. Meth.           
188: 117 – 128. 
• Pulendran B, Smit JL, Caspary G et al. (1999a): Distinct dendritic cell subsets 
differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. USA 
96: 1036-41. 
• Pulendram B, Banchereau J, Maraskovsky E et al. (2001b): Modulating the immune 
response with dendritic cells and their growth factors. Trends Immunol. 22: 41-47.  
Stellenbosch University  http://scholar.sun.ac.za
  
188 
 
 
 
 
 
• Reis e Sousa C, Diebold SD, Edwards AD et al. (2003a): Regulation of dendritic cell 
function by microbial stimuli. Pathol. Biol.51: 67–68. 
• Reis e Sousa, C (2004b): Activation of dendritic cells: translating innate into adaptive 
immunity. Curr. Opin. Immunol.16: 21-15. 
• Rescigno M, Martino M, Sutherland CL et al. (1998a): Dendritic cell survival and 
maturation are regulated by different signaling pathways. J. Exp. Med. 188: 2175- 
2180. 
• Rescigno M, Granucci F, Citterio S et al. (1999): Coordinated events during bacteria-
induced DC maturation. Immunol. Today. 20(5): 200-203 
• Ricciardi-Castagnoli P (1997): Dendritic cell maturation is required for initiation 
     of the immune response. J. Leukocyte Biol. 61:  415–421. 
• Richter G, Hayden-Ledbetter M, Irgang M et al. (2001):Tumor necrosis factor α 
regulates the expression of inducible costimulator receptor ligand on CD 34+ 
Progenitor Cells during differentiation into antigen presenting cells. J. Biol. Chem.             
49:45686 – 45693. 
• Ridge JP, Di Rosa F and Matzinger P (1998): A conditioned dendritic cell can be a 
temporal bridge between a CD4+ T- helper and a T-killer cell. Nature. 393: 474–478. 
• Rissoan MC, Soumelis V, Kadowaki N et al. (1999): Reciprocal control of T helper 
cell and dendritic cell differentiation. Science 283: 1183–6. 
• Robinson SP, Patterson S, Englis N et al. (1999): Human peripheral blood contains two 
distinct lineages of dendritic cells. Eur. J. Immunol. 29: 2769-78. 
• Rodriguez A., Regnault A, Kleijmeer M et al. (1999): Selective transport of 
internalized antigens to the cytosol for MHC class I presentationin dendritic cells. Nat. 
Cell. Biol.  1: 362–368. 
Stellenbosch University  http://scholar.sun.ac.za
  
189 
 
 
 
 
 
• Romani N, Gruner S, Brang D et al. (1994a) Proliferating dendritic cell progenitors in 
human blood. J Exp Med.180: 83– 93. 
• Romani N, Reider D, Heuer M et al. (1996b) Generation of mature dendritic cells from 
human blood: An improved method with special regard to clinical applicability. J. 
Immunol. Meth. 196: 137–151. 
• Rovere P, Vallinoto C, Bondanza A et al. (1998): Bystander apoptosis triggers 
dendritic cell maturation and antigenpresenting function. J. Immunol. 161: 4467–4471. 
• Rowland-Jones SL (1999): HIV: the deadly passenger in dendritic cells. Curr Biol.      
9: R248-R250. 
• Sallusto, F, Cella  S, Danieli C  et al. (1995a): Dendritic cells use macropinocytosis 
and the mannose receptor to concentrate macromolecules in the major 
histocompatibility complex class II compartment: down-regulation by cytokines and 
bacterial products.  
      J. Exp. Med.182: 389–400. 
• Sallusto F, Schaerli P, Loetscher P et al. (1998b): Rapid and coordinated switch in 
chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol.      
28:  2760–2769. 
• Sallusto F, Palermo B, Lenig D et al. (1999c): Distinct patterns and kinetics of 
chemokine production regulate dendritic function. Eur. J. Immunol. 29: 1617-1625 
• Sallusto F and Lanzavecchia A (2000d): Understanding dendritixc cell and lymphocyte 
traffic through the analysis of chemokine receptor expression. Immunol. Rev.    
177:134-140. 
• Sallusto F (2002e): T cell priming by dendritic cells: thresholds for proliferation, 
      differentiation and death and intraclonal functional diversification. Eur. J. Immuno. 
l.32: 2046–2054. 
Stellenbosch University  http://scholar.sun.ac.za
  
190 
 
 
 
 
 
• Sallusto F and Lanzavecchia A (2002f): The instructive role of dendritic cells on T cell 
responses Arthritis Res. 4 Suppl 3: S127-32. 
• Sanders RW, de Jong EC, Baldwin CE et al. (2002): Differential transmission of 
human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. 
J.Virol. 76: 7812-7821. 
• Savary CA, Grazziutti ML, Melichar B et al. (1998): Multidimensional flow-
cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer 
patients. Cancer Immunol Immunother 45: 234-240. 
• Scheeren RA, Koopman G, Van der BS, et al. (1991): Adhesion receptors involved in 
clustering of blood dendritic cells and T lymphocytes. Eur. J. Immunol. 21: 1101-1105. 
• Schmidt B, Ashlock B, Foster H et al. (2005a): HIV- infected cells are major inducers 
of plasmacytoid dendritic cell interferon production, maturation and migration. Virol. 
343(2): 256-266. 
• Schmidt B, Fujimura S, Martin J et al. (2006b): Variations in plasmacytoid (pDC) and 
myeloid dendritic cell (mDC) levels in HIV-infected subjects on and off antretoviral 
therapy. J.Clin. Immunol. 26: 55-64. 
• Schoenberger SP, Toes RE, van der Voort EI et al. (1998): T-cell help for cytotoxic T 
lymphocytes is mediated by CD40- CD40L interactions. Nature 393:  480–483. 
• Scholler N, Hayden-Ledbetter M, Dahlin A et al. (2002): Cutting Edge: CD83 
Regulates the Development of Cellular Immunity The Journal of Immunology          
168: 2599-2602. 
• Schuler G, and Steinman RM.(1997): Dendritic cells as adjuvants for immunemediated 
      resistance to tumours. J. Exp. Med 186: 1183 – 1187. 
Stellenbosch University  http://scholar.sun.ac.za
  
191 
 
 
 
 
 
• Schuurhuis DH, Laban S, Toes RE et al. (2002a):  Immature dendritic cells acquire 
CD8 (+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-
independent or -dependent stimuli. J. Exp. Med.192: 145- 150. 
• Schuurhuis DH, Fu N, Ossendorp F et al. (2006b): Ins and outs of dendritic cells. Int 
Arch Allergy Immunol. 140(1): 53-72. 
• Scott P (1993): IL-12: initiation cytokine for cell-mediated immunity. Science.  
       260: 496- 497. 
• Sevko AL, Barysik N, Perez L et al. (2007): Differences in Dendritic cell activation 
and distribution after intravenous, intraperitoneal and subcutaneous Injection of 
Lymphoma Cells in mice. Immun. Med. Diseases 6: 257-264.  
• Shen L, Sigal LJ, Boes M  et al. (2004): Important role of cathepsin S in generating 
peptides for TAP independent MHC class I crosspresentation in vivo. Immunity         
21: 155-165. 
• Shortman, K, Wu L, Suss G et al. (1997a): Dendritic cells and T lymphocytes: 
developmental and functional interactions. Ciba Found Symp 204: 130-8; discussion 
138-141. 
• Shortman K and Liu YJ (2002b): Mouse and human dendritic cell subtypes. Nat. Rev. 
Immunol.2: 151-161. 
• Siegal FP, Kadowaki N, Shodell M et al. (1999): The nature of the principal type 1 
      interferon-producing cells in human blood. Science 284: 1835–1837. 
• Smed-Sorensen A, Lore K, Vasudevan J et al. (2005): Differential susceptibility to 
human immunodeficiency virus type 1 infection of myeloid and plasmacytoid 
      dendritic cells. J.Virol. 79: 8861-8869. 
• Smyth MJ, Godfrey DI and Trapani JA (2001): A fresh look at tumor 
      immunosurveillance and immunotherapy Nat. Immunol .2: 293-299. 
Stellenbosch University  http://scholar.sun.ac.za
  
192 
 
 
 
 
 
• Sol-Foulon N, Moris A, Nobile C et al. (2002): HIV-1 Nef-induced upregulation of 
DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. 
Immunity.16: 145-155. 
• Sozanni S, Allavena P, D’Amico G et al. (1998a): Differential regulation of chemokine 
receptors during dendritic cell maturation: a model for their trafficking properties. J. 
Immunol.161: 1083-1086. 
• Sozzani S, Allavena P, Vecchi A et al. (2000b): Chemokines and dendritic cell traffic.  
J. Clin. Immunol. 20:151–160. 
• Spight D, Zhao B, Haas M et al. (2004): Immunoregulatory effects of regulated, lung 
targeted expression if IL-10 in vivo. Am. J. Physiol. Lung. Cell. Mol. Physiol.          
288: L251-L265. 
• Spits H, Couwenberg F, Bakker AQ et al. (2000): Id2 and Id3 inhibit development of 
CD34(+) stem cells into predendritic cell pre(DC)2 but not into pre-DC1. Evidence for 
a lymphoid origin in pre DC2. J. Exp. Med.192: 1775-1784. 
• Stebbing J and Bower M (2006): Opposing roles of dendritic cell subsets in HIV-1 
infection Blood Vol. 108, No. 6, pp. 1785-1786. 
• Steinman RM (2001a): Dendritic cells and the control of immunity: Enhancing the 
efficiency of antigen presentation.The Mount Sinal Journal of Medicine                 
68(3): 160-166. 
• Steinman RM and Nussenzweig MC (2002b): Avoiding horror autotoxicus: the 
importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S 
A.99: 351-358. 
• Steinman RM and Banchereau J (2007c): Taking dendritic cells into medicine. Nature 
449: 419-426. 
Stellenbosch University  http://scholar.sun.ac.za
  
193 
 
 
 
 
 
• Stern AS, Magram J and Presky DH (1996): IL-12 an integral cytokine in the immune 
response. Life Sci. 58(8): 639–654. 
• Syme R and Gluck S (2001): Generation of dendritic cells: role of cytokines and 
potential clinical applications. Transfusion and Apheresis Science.24: 117 – 124. 
• Tang HL and Cyster JG (1999): Chemokine up-regulation and activated T cell 
attraction by maturing dendritic cells. Science 284: 819–822.  
• Tailleux L, Schwartz O, Herrmann JL et al. (2003): DC-SIGN is the major 
      Mycobacterium tuberculosis receptor on human dendritic cells. J. Exp. 
       Med 197: 121–7. 
• Thomas R, Davis LS and Lipsky PE (1993a): Isolation and characterization of human 
peripheral blood dendritic cells. J. Immunol.150: 821. 
• Thomas R and Lipsky PE (1994b): Human peripheral blood dendritic cell 
subsets. Isolation and characterization of precursor and mature antigenpresenting 
cells. J. Immunol. 153: 4016–4028. 
• Thomas R and Lipsky PE (1994c): Human peripheral blood dendritic cell subsets. 
Isolation and characterization of precursor and mature antigen-presenting cells. 
J. Immunol.153: 4016-28. 
• Timmerman JM and Levy R (1999): Dendritic cell vaccines for cancer  
immunotherapy.Annu Rev Med 50: 507-529. 
• Tkachenko N, Wojas K, Tabarkiewicz J et al. (2005): Generation of dendritic cells 
from human peripheral blood monocytes-comparison of different culture medium. 
Folia Histochemica et Cytobiologica.Vol 43(1): 25-30.   
• Tortorella D, Gewurz BE, Furman MH, Schust DJ and Ploegh HL (2000): Viral 
subversion of the immune system. Annu. Rev. Immunol.18: 861-926. 
Stellenbosch University  http://scholar.sun.ac.za
  
194 
 
 
 
 
 
• Trieb K, Sztankay A, Amberger A et al. (1994): Hyperthermia inhibits proliferation 
and stimulates the expression of differentiation markers in cultured thyroid carcinoma 
cells. CancerLett .87(1): 65– 71. 
• Trinchieri G (1995): IL-12: a proinflammatory cytokine with immunoregulatory 
functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. 
Rev. Immunol. 13: 251- 276.  
• Trombetta ES, Ebersold M, Garrett W et al. (2003): Activation of lysosomal function 
during dendritic cell maturation Science 299: 1400–1403. 
• Turley SJ, Inaba K, Garrett WS et al. (2000): Transport of peptide- MHC class II 
complexes in developing dendritic cells. Science 288: 522 – 527. 
• Turley SJ (2000): Dendritic cells: inciting and inhibiting autoimmunity. Curr. Opin. 
Immunol. 14: 765–770. 
• Turville SG, Cameron PU, Handley A et al. (2002a): Diversity of receptors binding 
HIV on dendritic cell subsets Nat Immunol.3: 975-983. 
• Turville SG, Santos JJ, Frank I et al. (2003b): Immunodeficiency virus uptake, 
turnover, and two-phase transfer in human dendritic cells Blood.103: 2170-2179. 
• van Oss CJ., Absolom DR, Moore LL et al. (1980): Effect of temperature on the 
chemotaxis, phagocytic engulfment, digestion and O2 consumption of human 
polymorphonuclear leukocytes, J. Reticuloendothel. Soc. 27: 561–565. 
• Van Voorhuis WC, Hair LS, Steinman RM et al. (1982): Human dendritic cells. 
Enrichment and characterisation from peripheral blood. J. Exp. Med.155: 1172. 
• Veckman V, Miettinen M, Phirhonen J et al. (2004): Streptococcus pyogenes and 
Lactobacillus rhamnosus differentially induce maturation and production of Th1-type 
cytokines and chemokines in human monocyte-derived dendritic cells. J Leukoc Biol. 
75(5): 764-71. 
Stellenbosch University  http://scholar.sun.ac.za
  
195 
 
 
 
 
 
• Veeraswamy RK, Cella M, Colonna M et al. (2003): Dendritic cells process and 
present antigens across a range of maturation states. J. Immunol.170: 5367-5372. 
• Verhasselt V, Buelens C, Willems F et al. (1997): Bacterial lipopolysaccharide 
stimulates the production of cytokines and the expression ofcostimulatory molecules by 
human peripheral blood dendritic cells: evidence for a soluble CD14-dependent 
pathway J. Immunol. 158: 2919. 
• Vicari AP, Vanberyleit B, Massacrier C et al. (2004): In vivo manipulation of dendritic 
cells migration and activation to elicit anti-tumor immunity. Novartis Found Symp. 
256: 241-54.  
• Vieira PL, de Jong EC, Wierenga EA et al (2000): Development of TH1-inducing 
capacity in myeloid dendritic cells requires environmental instruction J. Immunol.  
164: 4507–4512. 
• Vignali D (1999): Simultaneous quantitation of fifteen cytokines using a multiplexed 
flow cytometric assay J. Immunol. Methods 227: 41-52. 
• Villadangos JA, Cardoso M, Steptoe RJ et al. (2001): MHC class II expression is 
regulated in dendritic cells independently of invariant chain degradation. Immunity 14: 
739- 749. 
• Viney JL (1999): Dendritic cell subsets: the ultimate T cell differentiation decision 
makers? GUT. 45: 640-641.  
• Watts C (1997a): Capture and processing of exogenous antigens for presentation on 
MHC molecules. Ann. Rev. Immunol 15: 821-850.  
• Watts C and Amigorena S (2000b): Antigen traffic pathways in dendritic cells. Traffic 
2000. 1:312–317. 
Stellenbosch University  http://scholar.sun.ac.za
  
196 
 
 
 
 
 
• Weissman D, Li Y, Ananworanich J et al. (1995): Three populations of cells with 
dendritic morphology exist in peripheral blood, only one of which is infectable with 
human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92: 826-830.  
• Wentworth PA, Celis E, Crimi C et al. (1997): In vitro induction of primary, antigen-
specific CTL from human peripheral blood mononuclear cells stimulated with synthetic 
peptides Mol. Immunol. 32: 603.  
• Wesa AK and Galy A (2001): Regulation of T cell cytokine production by dendritic 
cells generated in vitro from hematopoietic progenitor cells. Cell Immunol.        
15:208(2): 115-24. 
• Wiemann B and Starnes CO (1994): Coley’s Toxins, tumor necrosis factor and cancer 
      research: a historical perspective Pharmacology &Therapeutics 64: 529–64. 
• Yonezawa A, Morita R, Takaori-Kondo A et al. (2003): Natural alpha interferon-
producing cells respond to human immunodeficiency virus type 1 with alpha 
      interferon production and maturation into dendritic cells J. Virol.                                 
77: 3777-3784. 
• Yu Q, Gu JX, Kovacs C et al. (2003): Cooperation of TNF family members CD40 
ligand, receptor activator of NF-kappa B ligand, and TNF-α in the activation of 
dendritic cells and the expansion of viral specific CD8+ T cell memory responses in 
HIV-1-infected and HIV-1-uninfected individuals. J Immunol. 170(4): 1797-805. 
• Zhou LJ and Tedder TF (1995): Human blood dendritic cells selectively 
express CD83, a member of the immunoglobulin superfamily  J. Immunol. 
154: 3821–3835. 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  
197 
 
 
 
 
 
Websites: 
1.  www.csa.com 
2.   http://inet.uni2.dk/~iirrh/IIR/03Th/Th.htm 
3.    www.zoo.zool.kyoto-u.ac.jp/imm/lab/lab-e.html 
4   .www.home.comcast.net/.../C/ClassIIpath.gif 
5.   www.nwbio.com 
6.   www.scq.ubc.ca 
7.   www.medinfo.ufl.edu/.../bms5300/bugs/stapaure.html  
8.   www.bact.wisc.edu/.../S.pneumoniae.html 
9.   www.vietsciences.free.fr/khaocuu/nguyenlandung/ca... 
10. www.mf.uni-lj.si/.../index.php?id=bakteriologija  
11  www.stud.uni-leipzig.de/.../einfuerung.htm 
12. www.medinfo.ufl.edu/.../bms5300/bugs/corydiap.html 
13. commons.wikimedia.org/wiki/Image:Streptococcu... 
14. news.bbc.co.uk/2/hi/health/2246287.stm 
15. faculty.plattsburgh.edu/.../Prokaryotes.htm  
16. www.primer.ru/std/gallery_std2/proteus.htm 
17. botit.botany.wisc.edu/toms_fungi/feb2006.html 
18. www.doctorfungus.org/.../Candida_albicans.htm 
19. student.ccbcmd.edu/.../unit2/bacpath/gpsp.html 
20. www.bact.wisc.edu/Microtextbook/index.php?mod... 
21. www.student.biology.arizona.edu 
22. http://bloodjournal.hematologylibrary.org/cgi/content/full/108/6/1785/FIG1, 
 
Stellenbosch University  http://scholar.sun.ac.za
  
198 
 
 
 
 
 
Glossary 
Adaptive immunity: response of antigen specific lymphocytes to antigen, including the 
development of immunological memory. 
Agglutination: The aggregation of particulate antigen by antibodies. Agglutination applies 
to red blood cells as well as to bacteria and inert particles coated with antigen.  
Allergen: An antigen responsible for producing allergic reactions by inducing IgE 
formation.  
Allergy: A term covering immune reactions to non-pathogenic antigens, which lead to 
inflammation and deleterious effects in the host.  
Anergy: The condition of exhibiting no response to an antigen or antibody. 
Antibody: Plasma proteins that bind specifically to antigens. Serum protein formed in 
response to immunization; antibodies are generally defined in terms of their specific 
binding to the immunizing antigen, serum protein made in response to antigen; also called 
immunoglobulin (Ig)Specific molecules of the humoral immune response that bind to and 
neutralize pathogens or prepare them for uptake and destruction by paghocytes.  
  
Antigen binding: physical association of antigen with antibody, TCR, or MHC. 
 
Antigen processing: Large molecules are broken down (processed) within macrophages 
into peptides and presented within the groove of MHC molecules, enzymatic digestion of 
antigen and association with MHC for presentation to T cells. 
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Antigen receptor: The specific antigen-binding receptor on T or B lymphocytes; these 
receptors are transcribed and translated from rearrangements of V genes.  
Antigen: molecule that react with antibodies. Any foreign material that is specifically 
bound by specific antibody or specific lymphocytes; also used loosely to describe materials 
used for immunization. Antigens may also be immunogens if they are able to trigger an 
immune response, or haptens if not.  
Antigen-binding site: The part of an immunoglobulin molecule that binds antigen 
specifically.  
Antigen-presenting cell (APC): A specialized type of cell, bearing cell surface class II 
MHC (major histocompatibility complex) molecules, involved in processing and 
presentation of antigen to inducer, or helper, T cells. Examples: macrophage, dendritic 
cells.  
Autoimmunity (autoallergy): An immune response to "self" tissues or components. Such 
an immune response may have pathological consequences leading to autoimmune diseases.  
 
Active immunity: immunity acquired through exposure to antigen and response of one's 
own immune system. 
 
B lymphocyte (B cell): The precursors of antibody-forming plasma cells; these cells carry 
immunoglobulin and class II MHC (major histocompatibility complex) antigens on their 
surfaces, lymphocyte which develops in the bone marrow and binds antigen with 
membrane antibody (immunoglobulin). 
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Basophil: A polymorphonuclear leukocyte, whose basophils granules contain heparin, 
histamine and other vasoactive amines. Within tissues, these cells are known as mast cells 
q.v.  
Bone marrow: The site of hematopoiesis, the generation of the cellular elements of blood, 
including red blood cells, polymorphonuclear leukocytes, platelets and monocytes.Also the 
site of B cell development and the source of stem cells that give rise to T cells upon 
migration to the thymus  
CD: Cluster of Differentiation; membrane proteins on immune system cells that allow for 
their identification and isolation. Groups of monoclonal antibodies that identify the same 
cell surface molecule. The cell surface molecule is designated CD followed by a number 
The designation CD stands for "cluster of differentiation", a historical term that was coined 
to define cell-surface molecules that are recognized by a given set of monoclonal 
antibodies. This cluster of differentiation then received a number, for example CD1, CD2 
etc., which stands only for the order of discovery. In general, each CD is associated with 
one or more functions, which were discovered through the effects on cell or tissue function 
of the antibodies that define it. 
CD3: part of the T cell (antigen) receptor complex. CD3 transduces the antigen binding 
signal outside the plasma membrane into chemical signals (phosphorylation) in the 
cytoplasm. 
 
CD4:co-receptor on helper T cells that binds Class II MHC and participates in T cell 
activation by antigen. 
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CD8: co-receptor on cytotoxic T cells that binds Class I MHC and participates in T cell 
activation by antigen. 
Cell-mediated cytotoxicity (CMC): Killing (lysis) of a target cell by an effector 
lymphocyte.  
Cell-mediated immunity (CMI): Immune reaction mediated by T cells; in contrast to 
humoral immunity, which is antibody mediated. Also referred to as delayed-type 
hypersensitivity. Describes any adaptive immune response in which antigen specific T 
cells play the main role. 
Cellular immunity : immunity which can be transferred between individuals with the 
transfer of T cells. 
 
Chemokine: small molecule secreted by white blood cells that attracts leukocytes. Small 
cytokines that are involved in the migration and activation of cells, especially phagocytic 
cells and lymphocytes. They play a centre part in inflammatory responses. 
Chemotaxis: The characteristic movement or orientation of an organism or cell along a 
chemical concentration gradient either toward or away from the chemical stimulus. 
Class I, II and III MHC molecules: Proteins encoded by genes in the major 
histocompatibility complex (q.v.). Class I molecules are designated HLA-A, B, or C. Class 
II molecules are designated DP, DQ or DR  
Cluster determinant (CD): Cluster of antigens with which antibodies react that 
characterize a cell surface marker.  
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Complement components: An enzymatic system of serum proteins triggered by the 
classical and alternative pathways, and resulting in target cell lysis, phagocytosis, 
opsonization and chemotaxis.  
Complement receptor: A structure found on erythrocytes, lymphocytes, neutrophils, 
monocytes and macrophages that binds C3 fragments.  
Complement: A series of serum proteins involved in the mediation of immune reactions. 
The complement cascade is triggered classically by the interaction of antibody with 
specific antigen. Collection of plasma proteins that can be activated to promote 
inflammation and antigen elimination. They complement (work with) antibody.  
Co-receptor: A cell surface protein that increases the sensitivity of the antigen receptor to 
antigen by binding to associated ligands and participating in signaling for activation 
 
CTLA-4.: expressed on the surface of T cells after T cell activation - it competes with 
CD28 for binding to CD80 and CD86 on the surface of antigen-presenting cells (APCs). 
The CTLA-4-Ig attempt to suppress T cell activation uses a manufactured free-floating 
version of CTLA-4 that binds to CD80/86 and so prevents their signalling to CD28 and the 
ensuing costimulation of T cells, thus blocking the development of an effective T cell 
response. 
 
Cytokine: small molecule secreted from one cell that signals another cell by binding to its 
specific receptor. Cytokines are proteins made by cells that affect the behavior of other 
cells. Cytokines produced by lymphocytes are called lymphokines or interleukins. 
Cytokines act on specific cytokine receptors on the cells they affect. 
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Cytokine receptor: Cellular receptor for cytokines. Binding of the cytokine to the 
cytokine receptor induces new activities in the cell, such as growth, differentiation or 
death. 
 
Cytotoxic (Cytolytic) T cell: Cell that kills target cells bearing appropriate antigen within 
the groove of an MHC class I molecule that is identical to that of the T cell. T cell which 
kills virus-infected cells and tumor cells. 
DC-SIGN or CD209 is a C-type lectin receptor present mainly on myeloid and pre-
plasmacytoid dendritic cells that mediates dendritic cell rolling interactions with blood 
endothelium and activation of CD4+ T cells, as well as recognition of pathogen haptens. 
This molecule is involved in the initial stages of the Human Immunodeficiency Virus 
infection, as the HIV gp120 molecule causes co-internalization of the DC-SIGN molecule 
and HIV virion. The dendritic cell then migrates to the cognate lymphoid organ, 
whereupon recycling of the DC-SIGN/HIV virion complex to the cell periphery facilitates 
HIV infection of T cells by interaction between DC-SIGN and ICAM-3. 
Dendritic cell: cell with long processes (dendrites) that presents antigen. These cells are 
found in T-cell areas of lymphoid tissues. They are the most potent stimulators of T cell 
responses. The dendritic cell derives from bone marrow precursors. 
Determinant: Part of the antigen molecule which binds to an antibody-combining site or 
to a receptor on T cells (see hapten and epitope).  
Diapedesis: The blood vessels are lined with the endothelium, a layer of cells that tends to 
protect blood cell migration outside of the cells. However, injury or trauma can cause 
white blood cells to migrate across the endothelium. This process is called diapedesis.  
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Domain: A compact segment of an immunoglobulin molecule, made up of about 110 
amino acids around an S-S bond, and encoded by a unique segment of DNA, surrounded 
by nontranslated sequences.  
DR antigens: MHC class II molecules found on B cells and antigen-presenting cells of 
humans.  
Enzyme: organic reaction catalyst, which facilitates a chemical reaction without being 
used up. Most enzymes are proteins, but some RNA has catalytic activity for processing 
mRNA.  
Enzyme-linked immunosorbent assay (ELISA): An assay in which an enzyme is linked 
to an antibody and a coloured substrate is used to measure the activity of bound enzyme 
and, hence, the amount of bound antibody.  
Eosinophil: A polymorphonuclear leukocyte with large eosinophilic (i.e. red) cytoplasmic 
granules.  
Epitope: An alternative term for antigenic determinant.  
Fab: Fragment of antibody containing the antigen-binding site, generated by cleavage of 
the antibody with the enzyme papain, which cuts at the hinge region N-terminally to the 
inter-H-chain disulphide bond and generates two Fab fragments from one antibody 
molecule.  
FACS : Fluorescence-Activated Cell Sorter; equipment used to count and separate 
leukocytes labeled with fluorescent-tagged antibodies to cell surface molecules. 
Stellenbosch University  http://scholar.sun.ac.za
  
205 
 
 
 
 
 
Fc receptor (FcR): A receptor on a cell surface with specific binding affinity for the Fc 
portion of an antibody molecule. Fc receptors are found on many types of cells.  
Fc: Fragment of antibody without antigen-binding sites, generated by cleavage with 
papain; the Fc fragment contains the C-terminal domains of the heavy immunoglobulin 
chains.  
FDC: Follicular Dendritic Cell. Found in the B cell areas of secondary lymphoid  
 
Ficoll Histopaque: material used to separate leukocytes by their density, especially 
lymphocytes from other white blood cells and erythrocytes. 
 
Flow cytometry :process used to detect and quantify fluorescent antibody bound to 
leukocytes. 
Fluorescent antibody: An antibody coupled with a fluorescent dye, used with a 
fluorescence microscope to detect antigen on cells, tissues, or microorganisms.  
GM-CSF : A cytokine involved in the growth and differentiation of myeloid and 
monocytic lineage cells, including dendritic cells , monocytes and tissue macrophages. 
 
Helper T cells: A class of T cells which help trigger B cells to make antibody against 
thymus-dependent antigens. Helper T cells also help generate cytotoxic T cells. Regulatory 
T cell which used cytokines to stimulate B cells to produce antibodies, macrophages to 
become activated, or cytotoxic T cells to become effector CTL. 
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Histocompatibility: Literally, the ability of tissues to get along; in immunology, it means 
identity in all transplantation antigens. These antigens, in turn, are collectively referred to 
as histocompatibility antigens.  
HIV : Human Immunodeficiency Virus, the virus that causes AIDS. 
 
HLA: The acronym for Human Leukocyte Antigen, human MHC contains an MHC Class 
II that encode HLA –DM that is involved in the loading of peptides onto MHC Class II 
molecules. 
Humoral immunity: Any immune reaction that can be transferred with immune serum is 
termed humoral immunity (as opposed to cell-mediated immunity). In general, this term 
refers to a resistance that results from the presence of specific antibody.  
Hypersensitivity: State of reactivity to antigen that is greater than normal for the antigenic 
challenge; hypersensitivity is the same as allergy and denotes a deleterious outcome rather 
than a protective one.  
ICOS(CD278): is a CD28-superfamily costimulatory molecule that is expressed on 
activated T cells. It is thought to be important for Th2 cells in particular. 
IFN-α : alpha interferon; cytokine produced in response to virus infection that interferes 
with virus replication. 
 
IFN-β : beta interferon; cytokine produced in response to virus infection that interferes 
with virus replication. 
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IFN-γ:  gamma interferon; cytokine produced by T cells that signals APC to express more 
membrane MHC. 
Immune complex: Antigen bound to antibody.  
Immunofluorescence: A technique used for detecting molecules using antibodies labeled 
with fluorescent dye. The bound fluorescent antibody can be detected by microscopy, flow 
cytometry or by fluorimetry, depending on the application being used. 
Immunoglobulin (Ig): A general term for all antibody molecules. Each Ig unit is made up 
of two heavy chains and two light chains and has two antigen- binding sites.  
Innate immunity: immunity present from birth and not dependent on prior antigen 
exposure. Innate immunity includes physical and chemical barriers to infection, 
phagocytes, complement, and Natural Killer cells. 
 
Interdigitating dendritic cells: leukocytes with long processes (dendrites) that present 
antigen to T cells. 
Interferon: A group of proteins having antiviral activity and capable of enhancing and 
modifying the immune response.  
Interleukins: Glycoproteins secreted by a variety of leukocytes which have effects on 
other leukocytes.  
Killer T cell: A T cell with a particular immune specificity and an endogenously produced 
receptor for antigen, capable of specifically killing its target cell after attachment to the 
target cell by this receptor. Also called cytotoxic T cell.  
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Leukocyte: white blood cell: neutrophil, basophil, eosinophil, or lymphocyte. 
 
Ligand: molecule which specifically binds a receptor and triggers a response from the cell. 
Antigen is the ligand for the memory Ig on B lymphocytes and triggers B cell immune 
responses; insulin is the ligand for insulin receptor and triggers glucose uptake. 
  
LPS: LipoPolySaccharide; endotoxin. Present in the outer membrane of Gram negative 
bacteria. 
 
Lymphatic: vessel which transports lymph and leukocytes into and out of the lymph nodes 
and back into the circulatory system at the vena cava. 
Light chain (L chain): The light chain of immunoglobulin is a structural feature that 
occurs in two forms: kappa and lambda.  
Lymphocyte: Small cell with virtually no cytoplasm, found in blood, in all tissue, and in 
lymphoid organs, such as lymph nodes, spleen, and Peyer's patches, and bears antigen-
specific receptors.  
Lymphokines: Soluble substances secreted by lymphocytes, which have a variety of 
effects on lymphocytes and other cell types. MIIC vesicle:cytoplasmic vesicle in antigen-
presenting cells where class II MHC binds processed exogenous antigen.  
 
Macrophage: phagocytic white blood cell found in the tissues; the circulating form of the 
cell is called a monocyte. Acts as an antigen-presenting cell. 
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Macrophage-activating factor (MAF): Actually several lymphokines, including 
interferon, released by activated T cells, which together induce activation of macrophages, 
making them more efficient in phagocytosis and cytotoxicity. 
Mannose receptor: The mannose receptor (MR) is an endocytic receptor  and is expressed 
by immature cultured dendritic cells (DC), where it mediates high efficiency uptake of 
glycosylated 
Major histocompatibility complex (MHC): A cluster of genes on chromosome 6 in 
humans, encoding cell surface molecules that are polymorphic and that code for antigens 
which lead to rapid graft rejection between members of a single species which differ at 
these loci. Several classes of protein such as MHC class I and II proteins are encoded in 
this region. These in humans, are known as 'Human leukocyte antigens' (HLA).  
Memory: In the immune system, memory denotes an active state of immunity to a specific 
antigen, such that a second encounter with that antigen leads to a larger and more rapid 
response.  
MHC class I molecule: A molecule encoded to genes of the MHC which participates in 
antigen presentation to cytotoxic T (CD8+) cells.  
MHC class II molecule: A molecule encoded by genes of the MHC which participates in 
antigen presentation to helper T (CD4+) cells.  
MHC: Major Histocompatibility Complex; refers to the proteins used to present antigen to 
T cells or the genes which encode them. MHC proteins on body tissues must be matched 
between organ donor and recipient for an organ transplant to avoid rejection. 
Stellenbosch University  http://scholar.sun.ac.za
  
210 
 
 
 
 
 
monoclonal antibody: antibody that is homogenous, every molecule identical to the next 
in physical structure and antigen binding; produced by a hybridoma.  
Monoclonal: Literally, coming from a single clone. A clone is the progeny of a single cell. 
In immunology, monoclonal generally describes a preparation of antibody that is 
monogenous, or cells of a single specificity.  
Monocyte: Large circulating white cell, 2-10% of total white cells, phagocytic, indented 
nucleus. Migrates to tissues, where it is known as a macrophage.  
Myeloma: A tumor of plasma cells, generally secreting a single species of 
immunoglobulin.  
NK cell: Naturally occurring, large, granular, lymphocyte-like killer cells that kill various 
tumor cells; they may play a role in resistance to tumors. Also, they participate in ADCC. 
They do not exhibit antigenic specificity, and their number does not increase by 
immunization.  
Opsonin: A substance, usually antibody or complement component, which coats a particle 
such as a bacterium and enhances phagocytosis by phagocytic cells.  
Opsonization: Literally means "preparation for eating". The coating of a bacterium with 
antibody and/or complement that leads to enhanced phagocytosis of the bacterium by 
phagocytic cells. 
OX 40(CD134): is a member of the TNFR-superfamily of receptors which is not 
constitutively expressed on resting naïve T cells, unlike CD28. OX40 is a secondary 
costimulatory molecule, expressed after 24 to 72 hours following activation; its ligand, 
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OX40L, is also not expressed on resting antigen presenting cells, but is following their 
activation. Expression of OX40 is dependent on full activation of the T cell 
Passive immunization: Immunization by the administration of preformed antibody into a 
non-immune individual.  
Pathogen: disease-causing organism.  
PBMC: Peripheral Blood Mononuclear Cell .Lymphocytes and monocytes isolated fro 
peripheral blood, usually by Ficoll Histopaque density centrifugation. 
Phagocytosis: The engulfment of a particle or a microorganism by leukocytes. The 
ingested material is contained in a vesicle called a phagosome, which then fuses with one 
or more lysosomes to form a phagolysosome. The lysosomal enzymes play an important 
role in pathogen destruction and degradation  
Phagosome: cytoplasmic vesicle containing the engulfed particle. 
Phenotype: The physical expression of an individual's genotype.  
Pinocytosis: Ingestion of liquid or very small particles by vesicle formation in a cell.  
Plasma cell: End-stage differentiation of a B cell to an antibody-producing cell. Plasma 
cells are the main antibody secreting cells of the body. They are found in the medulla of 
the lymph nodes and in the bone marrow.   
Polyclonal activator: A substance that induces activation of many individual clones of 
either T or B cells. See Mitogen.  
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Polymorphism: Literally, "having many shapes"; in genetics polymorphism means 
occurring in more than one form within a species; the existence of multiple alleles at a 
particular genetic locus. 
Polymorphonuclear leukocyte:  White blood cells with multi lobed nuclei and 
cytoplasmic granules. There are three types: neutrophils with granules that stain with 
neutral dyes - most frequent, Eosinophils with granules that stain with eosin and basophils 
with granules that stain with basic dyes 
Primary lymphoid organs: Organs in which the maturation of T and B lymphocytes take 
place and antigen-specific receptors are first acquired.  
Primary responses: The immune response to a first encounter with antigen. The primary 
response is generally small,  has a long induction phase or lag period, consists primarily of 
IgM antibodies, and generates immunologic memory.  
Receptor: molecule which specifically binds a ligand; ligand binding triggers a specific 
response from the cell. Most receptors are on the cell's plasma membrane, but some can be 
cytoplasmic. Antigen is the ligand for the mIg on B lymphocytes and triggers B cell 
immune responses; insulin is the ligand for insulin receptor and triggers glucose uptake. 
 
Secondary lymphoid organ: lymphoid organ in which lymphocytes are activated by 
antigen and accessory cells and become effector cells and memory cells. Includes the 
lymph nodes, spleen, mucosal lymphoid tissue and bone marrow. 
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Secondary response: repeat immune response to an antigen; memory response. This 
response starts sooner and is of higher affinity than the primary response. This response is 
dominated by IgG antibodies.  
 
Stem cell: cell which can develop into more mature functional cells. 
 
Suppressor T cell: T cell which inhibits the function of B cells or other T cells. 
 
T cell: lymphocyte which has developed in the thymus and has membrane TCR that binds 
antigen plus self MHC. T cells are either helper (CD4) or cytotoxic (CD8) phenotype. 
 
T cell activation: biochemical process of stimulating a resting T cell to become an effector 
cell. 
 
T cell education: selection of T cells which can bind self MHC with appropriate affinity to 
be MHC-restricted. 
 
TCR: T cell (antigen) receptor, membrane molecule that binds antigen peptide. 
 
TH1 cell: helper T cell that activates macrophages and cytotoxic T cells. 
 
TH2 cell: helper T cell that activates B cells 
. 
TNF-α: Tumor-Necrosis Factor alpha, a cytokine produced by macrophages, mast cells 
and NK cells. 
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Vaccination: Originally referred to immunization against smallpox with the less virulent 
cowpox (vaccinia) virus; more loosely used for any immunization against a pathogen.  
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